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Abstract 
The study of protein/peptide folding, misfolding, structure, and interactions are 
vital to understanding complex biological problems. The work presented in this 
thesis describes the development and application of mass spectrometry -based 
techniques to investigate protein structure, aggregation and interference with 
aggregation, providing insights into the self-assembly and inhibition of several 
disease-related peptides. 
Mass spectrometry has evolved significantly over the past decade, its applications 
varying from small molecules to macromolecules. Travelling wave ion mobility 
spectrometry (TWIMS), when combined with mass spectrometry (MS), has the 
unique and unrivalled capability of separating molecular ions based on their 
collision cross-sectional area in addition to their mass-to-charge ratio, thus 
facilitating structural studies of co-populated protein conformations and structural 
isomers of protein complexes that cannot be separated by molecular weight alone. 
One biological system that has benefitted enormously from such advances is the 
study of in vitro amyloid formation. 
The ability of amyloidogenic protein/peptides to assemble into insoluble fibrils is 
the basis of a vast array of human disorders. Human islet amyloid polypeptide 
(hIAPP) is one such peptide able to readily assemble into amyloid fibrils in vitro at 
neutral pH, despite being intrinsically disordered. Identifying oligomeric states 
occupied between monomer and final fibrils creates an enormous challenge, given 
that few techniques are able to separate and characterise such lowly-populated 
and transient species. In addition to characterisation of fibril precursors, recent 
research has focussed on the identification of small molecule inhibitors of the 
amyloid cascade and understanding their mechanism of action is of great interest 
to this field. 
In the work presented here, the power of TWIMS-MS has been harnessed to 
achieve the separation and characterisation of oligomeric precursors of the type-2 
diabetes-related peptide hIAPP along with IAPP mutants and peptides 
corresponding to its core sequence. In addition, the effects of small molecule 
inhibitors on oligomer population and fibril formation have been studied and 
 xx 
 
described in detail. Further, an experimentally simple, in vitro MS-based screen has 
been developed and implemented that provides rapid and accurate analysis of 
protein aggregation and its inhibition. All of the results highlight the powers of MS 
to provide important insights into the mechanism of amyloid formation and 
demonstrate the potential of this approach for screening for novel inhibitors of 
disease-related amyloid assembly. 
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Aims 
The propensity of proteins to aggregate into amyloid has severe consequences in 
human disease. Little is known about the nature of these toxic amyloid states and 
current screening techniques used in the search for potential inhibitors are 
expensive, time consuming and require large quantities of protein. 
There is an urgent need for detailed analysis of all potentially toxic amyloid 
intermediates and the generation of a high-throughput, highly sensitive, and cost-
effective assay for inhibitors of amyloid formation. Therefore, the aim of this thesis 
is the observation and characterisation of oligomeric states of amyloid systems 
followed by the development of an in vitro, automated, MS-based screen for 
inhibitors of aggregation that could be applied to multiple aggregating systems. 
The screen should; enable the selection of small molecule inhibitors of protein 
aggregation of various sequences, have a low false positive and false negative rate, 
have the ability to rule out self-aggregating small molecules and allow 
determination of the usefulness of inhibitory compounds based upon spectral 
fingerprints. 
 
These above requirements are all been achieved using the MS-based screen for 
identifying amyloid inhibitors. Chapter 3 and Chapter 4 detail the initial 
characterisation of the peptide that was chosen for use in proof-of-principle 
screening. Chapter 5 describes the development of the screen and its capacity to 
differentiate between inhibitors and non-inhibitors of amyloid assembly, with a 
classification system for compounds based on spectral fingerprints being 
demonstrated. The high-throughput potential and diversity of the screen is 
demonstrated by the use of automation and a second peptide system, respectively. 
Finally, Chapter 6 demonstrates the application of the MS-based screen to other, 
disease related aggregating proteins.  
 
1 
 
1 Introduction 
1.1 History of mass spectrometry 
 
Mass spectrometry (MS) is an analytical technique used to measure the 
mass/charge ratio (m/z) of ions in the gas phase within a mass spectrometer. It is a 
technique used for determining mass, composition and structures of samples. The 
sample is first ionised by a choice of methods, its ions are separated in an analyser 
according to m/z and their relative abundances are recorded by a detector, see 
Figure 1-1.  
 
 
 
Figure 1-1. Schematic of a mass spectrometer. The sample is introduced, ionised in  
the ion source, and the ions separated according to m/z. The detector measures ion 
count detected at each m/z. A computer system converts information from the 
detector into a mass spectrum.  
 
MS has been a widely accepted tool utilised in the analysis of biological systems for 
more than twenty years, since the pioneering development of electrospray 
ionisation (ESI)(1, 2). ESI, along with other soft ionisation techniques, for example 
matrix assisted laser desorption ionisation (MALDI)(3), have been revolutionary in 
their ability to reveal new insights into protein structure and macromolecular 
assemblies using MS. Not only can ESI-MS experiments of biological 
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macromolecules provide accurate molecular mass measurements (2), the 
technique enables structural information about proteins and their biomolecular 
complexes to be acquired. Recent advances have meant that information about 
protein/ligand binding, structure, stability, dynamics and post-translational 
modifications can be obtained (4-6). 
 
1.2 Synapt HDMS 
 
The work presented in this thesis was carried out using a Synapt HDMS mass 
spectrometer (Waters UK Ltd)(Figure 1-2). Samples are introduced using nano-
electrospray ionisation (ESI) (Section 1.3) and guided into the instrument which 
incorporates travelling wave ion mobility spectrometry (IMS) (Section 1.4) with 
Time of flight (ToF) mass spectrometry (Section 1.5) (7). Within this device, three 
travelling wave ion guides (TWIGs) are situated between a quadrupole (Q) mass 
analyser and a ToF analyser. The first TWIG is known as the trap region, the 
second as the mobility cell and the third as the transfer region. The final electrode 
of the trap TWIG is direct current (DC) only and its voltage is adjusted in order for 
it to act as a gate through which ion packets move into the IMS cell to be separated. 
In the mobility cell, a wave voltage is applied to the 1st and 7th pair of electrodes 
followed by the 2nd and 8th pair and so on. The transfer region has a constant 
travelling wave voltage applied to it to maintain temporal separation between the 
mobility cell and the ToF analyser. The ToF pusher is synchronised with the gate of 
the trap region and for each gate pulse, 200 pushes of the ToF analyser are 
recorded for every IMS experiment. Additionally, the trap and transfer regions can 
function as MS/MS collision cells for fragmentation experiments (Section 1.6).  
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Figure 1-2. Schematic showing the layout of the Synapt G1 HDMS Figure adapted 
from (7). 
 
1.3 Ionisation of biological molecules 
 
Ions can be generated by a number of methods for use in MS. In the past, electron 
impact and chemical ionisation were most commonly used to generate ions from a 
sample. These methods require the sample to be in the gas phase, and thus were 
only suitable for the mass determination of small volatile organic molecules. More 
modern, ‘soft ionisation’ methods, MALDI (3) and ESI (2), developed ~27 years 
ago, have allowed mass analysis of polar and thermally labile biomolecules without 
prior derivatisation (8). MALDI ionisation can be used for biological samples, 
however, it results in the formation of predominantly singly charged ions (9), 
meaning that valuable information about the native protein conformation is lost. 
ESI results in the formation of non-fragmented, multiply charged gas phase ions.  
ESI, a very gentle ionisation technique, is performed at atmospheric pressure and 
is suitable for the analysis of polar molecules with a mass range of 100 Da to >1 
MDa. First, the sample is dissolved in the appropriate solvent, depending on the 
sample’s features, which also determine the ionisation mode (positive or negative) 
of the MS.  Next, the sample is sprayed through a narrow stainless steel capillary 
needle into a heated evaporation chamber. The needle is held at a high potential, 
with a voltage of 3-4 kV being applied to its tip. The analyte emerges from the 
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capillary in the form of an aerosol of highly charged droplets. Nebulising gas, 
usually nitrogen, flows around the outside of the capillary and aids formation of 
such droplets. The charged droplets are attracted by a voltage to a sampling cone 
at the opposite end of the desolvation chamber and move towards it. Warm 
nitrogen gas, used as a drying gas, passes orthogonally across the front of the 
ionisation source and aids solvent evaporation leading to decreased size of 
charged droplets as they move across the chamber. When the size of the droplet 
has diminished below a certain threshold for a given charge, a ‘Coulombic 
explosion’ occurs. The charge repulsion at a certain radius exceeds the surface 
tension and droplets split into smaller droplets, each carrying a proportion of the 
charge.  This cycle continues, leading to the formation of a fine spray of analyte ion-
containing samples (Figure 1-3). Eventually, charged sample ions are free of 
solvent and pass through the sampling cone into the vacuum chamber. Two 
opposing models exist for the formation of gas phase ions: the ‘Ion Evaporation 
Model’ (IEM) states that when a droplet reaches a certain radius the field strength 
at the surface of the droplet becomes large enough to cause direct emission of ions 
into the gas phase (10). The ‘Charge Residue Model’ (CRM) states that electrospray 
droplets undergo cycles of evaporation and fission until no more solvent remains 
and droplets contain, on average, one analyte ion or less (1). Despite these two 
proposals, the precise mechanism of ion liberation is unknown and neither model 
is able to explain all observations. It is probable that the proposed mechanisms 
may operate individually or in tandem, depending on the analyte, to invoke ion 
formation (11). It is thought that the IEM model may apply to ions originating from 
relatively small molecules, while ions with multiple charges are likely to be formed 
via the CRM model.  A third, alternative mechanism for unfolded proteins has been 
proposed recently by Konermann et al. (12). This chain ejection model (CEM) 
states that proteins are expelled from the droplet long before complete solvent 
evaporation has taken place (12). 
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Figure 1-3. The mechanism of electrospray ionisation. 
The efficiency of ESI has been improved by use of volatile buffers in the presence of 
acids, which increase the ionic strength of the solution, therefore enhancing 
droplet formation. The sensitivity of ESI can be improved by decreasing the flow 
rate, which causes smaller droplets to be formed usually with few salt adducts on 
the sample ions.  Nano-ESI is a low flow rate version of ESI (13),  in which ions are 
formed and desolvated using electrostatic charging. A small amount of sample is 
added to an appropriate volatile solvent (concentration 1-10 pmol/µL). A high 
voltage (ca. 1000 V) is applied to a gold plated narrow, borosilicate vial which 
initiates a low flow rate of 30-1000 nL/min. This means that far less sample is 
consumed with respect to ESI and therefore multiple experiments can be 
performed on very small volumes of sample. In 2002 John Fenn, who developed 
ESI, received the Nobel Prize (14) together with Koichi Tanaka, who developed 
Laser Desorption Ionisation. The greatest application of ESI is the study of proteins 
and protein complexes whose functions are vitally dependant on non-covalent 
interactions that can be maintained in the gas phase using ESI.  When performing 
ESI, peptides of molecular mass <1200 Da usually give rise to singly charged, 
protonated species, whereas a polypeptide of molecular mass >1200 Da is likely to 
acquire multiple charges. The number of charges that a protein picks up during the 
electrospray process is thought to be directly related to its solvent-exposed surface 
area. Basic residues are most likely to become protonated however protons are 
able to migrate to other sites of high gas-phase bascicity within the mass 
spectrometer. The mass of multiply-charged protonated ions can be determined 
using the equation: m/z = (M + nH+)/n. Nano-ESI has the ability to provide 
effective desolvation to high mass samples of low concentrations, in the nanomolar 
to picomolar range. Consequently, samples in highly aqueous solvents containing a 
low salt concentration can be effectively introduced into the mass spectrometer. A 
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novel method of ionisation is the Advion TriVersa Nanomate (Advion Biosciences 
Inc., Ithaca, NY USA)(15). This is an automated chip-based nano-ESI device, which 
uses a chip consisting of an array of 400 nanospray needles, or nozzles. The analyte 
solution is sprayed from a conducting pipette tip aligned against the rear of the 
chip and a small gas pressure is then used to aspirate the sample. A new nozzle is 
used for each sample.  
 
 
1.4 Ion mobility spectrometry-MS  
 
One key technical advance, the pairing of MS to ion mobility spectrometry (IMS), 
has seen MS emerge as a central component of the structural biology tool kit (16-
18). MS coupled to IMS allows detailed analysis of complex systems via 
determination not only of their masses, but also their rotationally-averaged 
collision cross-sectional areas (CCS). IMS is an analytical technique that separates 
gas phase ions on the basis of their mobility through a carrier buffer gas under the 
influence of an electric field. Separation of ions depends on two fundamental 
principles: the CCS of the ion and the charge of the ion (as well as gas temperature 
and pressure) (19). Larger, more extended ions will experience a greater number 
of collisions with the buffer molecules gas and, as a result, will take longer to 
traverse through the drift tube. Conversely, smaller, more compact ions of the 
same m/z will undergo fewer collisions with the buffer gas molecules and hence 
have a higher mobility and therefore a shorter drift time. Separation depends also 
on charge, with more highly charged ions being accelerated through the drift cell 
and therefore having higher mobility than ions of the same m/z but carrying fewer 
charges. The many applications of IMS-MS include: separating isomers, separating 
protein monomer conformations, separating protein oligomers and calculating ion 
CCS (19). 
When using conventional IMS in determination of drift time (tD), the equation 
below is used to calculate an ion’s CCS (Ω)  (Equation 1.1): (20, 21). 
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Equation 1.1:  Calculation of cross sectional area in conventional IMS 
 
 
 
Where z is the charge of the ion, e is the charge of an electron (1.602×10-19 C), Kb is 
Boltzmann’s constant (1.381×10-23 m2 kgs-2 K-1), T is temperature in K, tD is the 
drift time of the ion, N is the number density of the buffer gas, P is pressure, mI and 
mN are the molecular masses of the ion and the buffer gas respectively.  A ratio of 
actual pressure (P) and temperature (T) are taken against standard temperature 
and pressure values (273.2 K and 760 torr).  The electric field is denoted by E, and 
L is the length of the drift tube in meters (20, 21). Equation 1.1 allows the collision 
cross-sectional area of any species to be determined providing temperature and 
pressure and the drift time (tD) can be measured accurately. 
 
The term below (Equation 1.2) is the reciprocal for reduced mass between the 
analyte ion and the buffer gas.  Reduced mass is the effective inertial mass of a 
molecule, also described as the mass of an object measured by its resistance to 
acceleration. 
Equation 1.2: Calculation of  Reduced mass 
Reduced mass  = 






NI mm
11
 
The major drawback of conventional IMS-MS is its poor sensitivity, with 
approximately just 1 % of ions produced being transmitted through the IMS-MS to 
the detector (22). The major cause of this insensitivity is the length of the drift tube 
and the fact while a particular packet of ions is being separated, no other ions can 
enter the drift cell. 
Over the past decade, much effort has been directed at producing commercially 
viable instrumentation. This has led to the development of ion mobility separation 
based on a travelling-wave IMS system (22) (Figure 1-4). Travelling-wave ion 
mobility spectrometry mass spectrometry (TWIMS-MS) uses the same basic 
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principles as conventional IMS-MS except that ions are trapped until they can all be 
pushed into the drift cell together, giving much higher sensitivity, with >80 % ions 
being transmitted (22). TWIMS-MS has been shown to be promising for protein 
analysis, being highly sensitive and having good separative power for analysis of 
multiply-charged ions, and it can be used to calculate CCS values for each 
component in a sample. Unlike conventional IMS experiments, drift time values are 
not linearly related to Ω in the TWIMS-MS system, therefore cross-sectional area 
must be defined by a calibration approach. The determination of peptide cross-
sectional areas can be achieved due to the abundance of known IMS-MS cross-
sectional areas available within the literature (these can be found on Professor 
David Clemmer’s website: www.indiana.edu/~clemmer) (23). For peptide 
analysis, the TWIMS-MS device can be calibrated by measuring drift times of 
peptides derived from commercially available proteins following tryptic digest. 
Readily available proteins such as cytochrome c and alcohol dehydrogenase (ADH) 
can be used and IMS-MS data for the calibrant protein are acquired under exactly 
the same instrument conditions that will be used for the target protein (24). 
Tryptic digests of such proteins result in a wide range of peptide sizes that are 
observed as singly and doubly charged ions and a wide range of cross-sectional 
areas is covered by the calibration (23).  
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Figure 1-4. Schematic of separation of ions in a TWIMS-MS device. Ions of a low 
mobility fall off the top of the travelling wave and therefore have a longer drift time. 
Figure adapted from (Giles et al., 2004)(22). 
 
 
Because the electric field (E) is not uniform in a TWIMS cell, the conventional IMS 
equation does not apply. The equation for calculating Ω must take into account the 
wave functions of the TWIMS-MS system.  This TWIMS-MS equation contains 
constants A and B that describe TWIMS-MS characteristics rather than electric 
field density. A is the correction factor for the electric field parameters and B is to 
compensate for the non-linear effect of the TWIMS cell, shown in Equation 1.3:  
Equation 1.3: Calculation of Ω when using TWIMS 
 
 
 
The collision cross-sections can also be stated as a charge and mass independent 
value. Equation 1.3 is divided throughout by absolute charge (ze) and reduced 
mass giving rise to  Equation 1.4, shown below: (20) 
 Equation 1.4: Calculation of reduced cross section, Ω’ 
 
 
 
The calculation can be further simplified when the correction for pressure, 
temperature, electric field and other constants are transformed into a single value, 
A’, resulting in Equation 1.5, shown below: (20) 
Equation 1.5: Use of single constant for the correction of temperature, 
pressure and electric field 
’ = A’tDB 
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Equation 1.3 can be then be simplified greatly by the incorporation of reduced 
cross-section, Ω’, giving Equation 1.6, shown below; (20) 
Equation 1.6: Use of reduced cross section for the calculation of cross-
sectional area 
 
 
 
 
For calibrant peptides, Ω and drift times are known and can be used to determine 
values for constants A and B under defined instrument conditions. A plot of 
reduced Ω, (Ω’) against tD fitted allometrically will give A and B values and enable 
determination of unknown peptide Ωs.  The calculations from Equation 1.6 can be 
input into an Excel spreadsheet for rapid determination of unknown peptide Ωs 
from experimental drift times (20). Once the CCS of an ion is known, then 
additional modelling tools can be used to predict its structure. For example, 
modelling of protein structures can be achieved using MOBCAL (25, 26) and/or the 
more recently developed Leeds (20) and PSA methods (27) to calculate theoretical 
cross sections from PDB files. These CCS values can then be compared with those 
obtained experimentally. From this, it can be deduced whether a protein is in a 
native-like compact state, or if a different conformer is observed. 
 
1.5 Mass analysers used in a Synapt HDMS 
 
A mass analyser separates ions according to their m/z after the ionisation step. The 
most commonly used analysers for biomolecular studies are the quadrupole (Q) 
and time-of-flight (ToF) analysers, or combinations of the two. The Q analyser 
detects ions of each m/z sequentially by scanning the m/z range (Figure 1-5), 
while the ToF mass analyser detects all ions simultaneously (Figure 1-6). Mass 
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analysis aims to achieve high resolution, accuracy and a wide mass range and 
sensitivity.  
Quadrupole mass analysers are composed of four rods in parallel to one another in 
a circular arrangement (Figure 1-5). The four rods are arranged as two pairs that 
are connected electrically. The electric field between the pairs consists of a static 
DC potential and an oscillating radio frequency (RF).  Ions travel between the rods 
through the centre of the quadrupole and as they travel through the mass analyser 
they undergo a complex oscillating motion. This motion is a result of the oscillating 
component of the electric field causing the polarity of the rods to change with time, 
the ions being attracted to rods of opposite polarity. Unlike ToF analysers, where 
all ions are analysed simultaneously, Q mass analysers allow ions of a particular 
m/z to be detected for a given ratio of RF and DC voltages. Ions with a certain m/z 
will have a stable trajectory at a given ratio of voltages and will reach the detector. 
All other ions will have unstable trajectories and either collide with the rods or 
become lost in the walls of the analyser (Figure 1-5). Continually varying the 
voltages applied to the rods allows ions with a range of m/z values to be analysed 
and detected.  A Q can be operated as a selection device for a particular ion(s) so 
that tandem MS (MS/MS) can be carried out. Also, a Q can be used as an ion guide 
to transmit all ions (above a lower mass cut-off) by operating in RF mode only. 
 
 
Figure 1-5. Schematic representation of a quadrupole mass analyser. Ions with a 
specific m/z (purple) will traverse through the quadrupole and reach the detector 
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whilst all other ions with unstable trajectories (orange) will be deflected into the 
rods. Voltages can be adjusted to transmit different m/z values. 
 
ToF mass analysers measure the time taken for an ion to traverse a field-free 
region and reach a detector, this time is then converted to m/z (28, 29).  The time 
taken (t) for an ion to travel a given distance, d, can be defined as t=d/v where v is 
the average velocity of the ion. All ions are given a fixed kinetic energy (Ke) when 
they exit the ionisation source but have different velocities (v) corresponding to 
their different masses (m) (Ke=1/2mv2).  ToF analysers have a theoretically 
unlimited m/z range, making them suitable for use in the analysis of large 
biomolecules such as proteins. These analysers also have high sensitivity due to 
the parallel detection of ions, i.e. all of the time is spent looking at all of the ions. A 
pulsed ion beam is used in combination with an orthogonal series of ion filters that 
couple ion flow from the ESI source to the high vacuum analyser. Historically, the 
major disadvantage of ToF analysers was their poor mass resolution, occurring as 
a result of the range of kinetic energies produced by the source for ions of the same 
m/z. However, this drawback has been overcome by several improvements 
including orthogonal geometry, two-stage acceleration, delayed pulsed extraction 
and the use of reflectron lenses. Delayed extraction is achieved by allowing ions to 
initially move in the field-free region with velocities determined by their kinetic 
energy.  An extraction pulse, applied at an optimised delay time, then provides ions 
with low initial kinetic energy with more kinetic energy hence decreasing the 
kinetic energy spread and peak width (30). The reflectron lens system, is a feature 
of modern ToF mass analysers which also enhances resolution (31). The reflectron 
consists of a series of ring electrodes stacked on top of one another in the path of 
the ion (Figure 1-6). It acts as a mirror and doubles the flight distance by 
reflecting ions back through the flight tube towards the detector and focuses ions 
of the same m/z that have slightly different kinetic energies. The reflectron 
circumvents the need for extra lab space or more vacuum pumps, by doubling the 
ion path length, whilst keeping the TOF dimensions (hence pumping/vacuum 
system) the same. Certain analysers with dual reflectrons can be set to operate in V 
or W mode, which represent ions being reflected once or twice by the reflectron 
respectively. V mode allows enhanced sensitivity with respect to W mode which 
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becomes important for the detection of minor species with high resolution within 
co-populated ensembles.  
 
 
 
Figure 1-6. Schematic representation of a TOF mass analyser. Ions represented in 
red and blue have the same m/z value, but slightly different kinetic energies. The 
presence of the reflectron compensates for this, as higher energy ions penetrate the 
reflectron deeper and have a longer flight path. 
 
 
1.6 MS/MS in a Synapt HDMS 
 
The use of hybrid instruments, such as the Synapt HDMS, allows additional 
characterisation of protein or peptide samples using tandem mass spectrometry 
(MS/MS). Here, MS/MS can occur most commonly via a collisional induced 
dissociation (CID) mechanism (32, 33). During CID-MS/MS experiments, precursor 
ions of a specific m/z are selected in the first mass analyser before being 
accelerated into a region filled with an inert gas, commonly argon. The accelerated 
ions collide with the buffer gas molecules, during which the kinetic energy of the 
ion is converted into vibrational energy. If the vibrational energy is sufficient, the 
ion will fragment. Fragmentation yields a charged and neutral ion, of which only 
the charged ion is detected. In the Synapt HDMS, both the Trap and Transfer 
regions can act as collision cells, with parent ions of a specific m/z isolated on the Q 
mass analyser and subsequent daughter fragment ions being detected on the ToF 
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mass analyser. CID-MS/MS can be applied to the study of protein/ligand and 
protein/protein complexes (34, 35). Fragmentation of peptides or proteins 
typically occurs via the cleavage of the peptide amide bonds, (predictably yielding 
b- and y- type ions) (8, 36), where the charge can reside on either ion type 
depending on the exact sequence of the peptide. The sequence of the peptide or 
protein can be identified when fragmentation occurs at adjacent amide bonds 
along the peptide backbone, allowing determination of the mass, and therefore 
identity, of adjacent amino acids. Only one isobaric pair of amino acids exist :- 
Leu/Ile, with Gln/Lys also being very close in mass. 
 
1.7 Mass spectrometry for protein structure elucidation 
 
Early ESI-MS studies of proteins revealed that the extent of ionisation was related 
to structure (37). More compact protein structures, such as those containing 
multiple disulphide bonds, acquired fewer charges during ESI with respect to more 
expanded proteins (37). When a folded protein is in its native state, it has a smaller 
solvent-accessible surface area therefore few sites are accessible to protonation, 
therefore the ESI mass spectrum will show a narrow charge state distribution that 
appears at a relatively high m/z value. On the contrary, when proteins are 
denatured under acidic conditions, they have a larger solvent-accessible surface 
area therefore they acquire higher charge states. This occurs because as a protein 
unfolds, it becomes more accessible to the protonated solvent therefore will have a 
higher charge and therefore a lower m/z.  Additionally, the mass spectrum of an 
unfolded protein will show a wider charge state distribution due to the increased 
variety of charge states that can occur. The number of experimentally determined 
charges on a native protein can therefore help to give an estimate of its surface 
area and can help towards the structural characterisation of protein complexes 
(38). Although protein structure estimates are possible, they are not conclusive 
given the elusive nature of the relationship between structure and charge (5, 38).  
Relatively few techniques are available that allow elucidation of residue-specific 
information about the structure of proteins. NMR and X-ray crystallography have 
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proved useful in providing atomic resolution structures of many protein systems, 
that have been deposited in the PDB. However, such techniques are not applicable 
to all protein systems i.e. NMR is restricted to proteins <~40 kDa in size for full 
structural determination whilst dynamic samples usually elude crystallisation. 
Both NMR and X-ray crystallography require mg quantities of pure protein 
samples for analysis. NMR of intrinsically disordered, dynamic protein assemblies 
leads to challenging data interpretation as a result of signal averaging. MS 
overcomes the caveat of requiring pure protein samples required for NMR or X-ray 
crystallography by ‘purifying’ samples as they are separated by their m/z, allowing 
characterisation of whole species distributions, providing information relating to 
both conformation and equilibria. Monomeric protein can be distinguished easily 
from oligomeric species given that the charge allows determination of the mass of 
each species thus defining oligomer order. Non-covalent assemblies, such as virus 
capsid assembly (39-43) and amyloid intermediates (6, 44-49), that function as 
complexes rather than monomeric protein can be studied in detail using MS. 
Complementary techniques such as covalent labelling (50, 51) and hydrogen-
deuterium exchange (HDX) (52, 53) can be used in combination with MS. By 
combining MS with these methods, high-resolution information on the structure of 
protein assemblies can be gained. Of particular interest is the study of transient, 
lowly populated, heterogeneous amyloid intermediates, discussed below. 
1.8 Protein Folding, Misfolding and Aggregation 
 
The protein folding process is, for the most part, spontaneous and therefore 
determined by the protein’s primary structure (54). However, the exact 
mechanism by which the final folded conformation of a protein is encoded in the 
amino acid sequence, and how the folding process is achieved, remains elusive. 
Funnel-shaped energy landscapes can be used to describe the transition from high 
energy unfolded structures towards functional native states, at local minima of 
folding profiles (Figure 1-7) (55-57).  
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Figure 1-7. The energy landscape of both protein folding (purple) and aggregation 
(pink). The purple surface shows that many intermediate conformations can lead to 
to the native state (which is in a local energy minimum) by the formation of 
intramolecular contacts. The pink surface shows the conformations that can lead to 
amorphous aggregation or amyloid fibril formation through intermolecular contacts. 
Figure adapted from references (57). 
 
Most peptides and small proteins (<100 residues) achieve their native structure 
via a one-step folding process, with only the unfolded and native state being 
populated significantly (57). On the contrary, folding of large multi-domain 
proteins (>100 residues) is achieved via an array of intermediate non-native states 
(57, 58). Such intermediate structures may be on-pathway i.e. towards the native 
state, or alternatively may be stable, misfolded conformations that are trapped in 
local energy minima that have to be reorganised before the native state can be 
revealed (Figure 1-7).  
Aggregation is the association of two or more non-native protein molecules that 
can occur due to exposure of hydrophobic amino acid residues that are buried in 
the native state (56, 59). Misfolding can occur during or after folding, as a result of 
cellular stress conditions (55, 59-61). Proteins can leave the folding pathway and 
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enter alternative aggregation pathways, driven by hydrophobic interactions 
between folding intermediates (Figure 1-7). Off-folding pathways include both the 
amorphous aggregation pathway leading to the formation of disordered 
aggregates and the fibril forming pathway resulting in formation of highly ordered, 
thermostable assemblies (55, 57, 59). Amorphous aggregates are non-toxic and 
can be cleared by the proteasome (57), however oligomeric species formed on the 
fibril forming pathway are considered to be highly toxic and are associated with 
the aetiology of numerous devastating pathologies (Table 1.1). 
 
 
 
 
 
 
 
 
 
1.9 Amyloid formation and the study of amyloid 
intermediates 
 
Aberrant aggregation of proteins and peptides into amyloid fibrils contributes to 
more than 50 human disorders (62). Amyloid diseases can be divided into three 
broad classes: neurodegenerative diseases, where amyloids are deposited in the 
brain and spinal cord (this class includes Alzheimer’s disease (AD), Parkinson’s 
disease (PD) and Huntington’s disease (HD)); non-neuropathic localised 
amyloidosis, where aggregation occurs in a single tissue (not the brain); or 
systemic amyloidoses where aggregation occurs in multiple tissues (Table 1.1). 
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Some of these conditions arise in individuals with a genetic predisposition, or 
alternatively can occur sporadically. The location of protein aggregates varies 
between disease states and the proteins contained within such plaques share no 
obvious sequence, function, or structural similarity and result in a wide variety of 
symptoms (56, 63, 64). In each case, normally soluble proteins that may be folded, 
partially folded or intrinsically disordered embark on alternative aggregation 
energy landscapes (65) (Figure 1-7) leading to the formation of β-sheet rich, 
fibrillar assemblies. The association between amyloid formation and disease 
pathogenesis is common for all amyloidoses and the cytotoxic properties of 
amyloidogenic peptides may also be similar (66). Identifying and characterising 
the structures and dynamics of prefibrillar oligomers is vital to understanding the 
mechanism of protein aggregation in amyloid diseases, identifying the specific 
culprits of toxicity and designing therapeutics to prevent aggregation. 
 
 
 
 
Disease 
class 
Disease 
Protein 
involved 
Location of aggregates Clinical features Ref. 
Neuro-
degenerative 
Transmissible 
spongiform 
encephalopathies 
Prion 
protein 
Extracellular amyloid 
fibrils in CNS 
Dementia, ataxia, 
psychiatric problems 
(67) 
Alzheimer’s (AD) 
Amyloid-β 
and tau 
Extracellular amyloid 
plaques, cytoplasmic 
neurofibrillar tangles 
Progressive dementia (68) 
Parkinson’s (PD) α-synuclein 
Cytoplasmic 
Lewy bodies 
Movement disorder (69) 
Amyotrophic 
lateral sclerosis 
(ALS) 
Superoxide 
dismutase 
Cytoplasmic and axon 
inclusions 
Movement disorder (70) 
Huntington’s (HD) Huntingtin Intranuclear neuron Dementia, motor and (71) 
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inclusions psychiatric problems 
Non-
neuropathic 
localised 
amyloidoses 
Type II diabetes 
mellitus (T2DM) 
hIAPP 
(amylin) 
Pancreatic amyloid 
plaques 
Hyperglycaemia, 
insulin deficiency and 
resistance 
(72) 
Injection-localised 
amyloidosis 
Insulin 
Injection localised 
plaques 
Sub-therapeutic levels 
of insulin 
(73) 
Apolipoprotein A1 
amyloidosis 
Apo A-1 
fragments 
Renal, hepatic, cardiac, 
laryngeal or cutaneous 
fibrillar deposits 
Progressive renal 
and/or hepatic disease 
(74) 
Non-
neuropathic 
systemic 
amyloidosis 
Amyloid light 
chain amyloidosis 
Immuno-
globulin 
light chain 
fragments 
Fibrillar deposits in 
various organs, most 
commonly kidneys 
Renal failure (75) 
Amyloid A 
amyloidosis 
Serum 
amyloid A1 
protein 
fragments 
Kidney, liver and spleen Renal failure (76) 
Dialysis-related 
amyloidosis (DRA) 
β2-micro-
globulin 
Amyloid plaques in 
joints 
Paraplegia (77) 
Lysozyme 
amyloidosis 
Lysozyme 
Fibrillar deposits in 
leukocytes and 
macrophages 
Renal failure (78) 
Table 1.1. Amyloid diseases (56, 79). Table courtesy of Dr. Janet Saunders. 
 
Several in vitro techniques have been implemented successfully in order to gain 
molecular and mechanistic insights into amyloid formation. Imaging techniques 
such as electron microscopy (EM) (Figure 1-8a) and atomic force microscopy 
(AFM) are used routinely to confirm the presence of amyloid (80, 81). Additionally, 
X-ray fibre diffraction enables detection of the cross-β structure, common to 
amyloid fibrils  (Figure 1-8b)(56). Small molecules such as Congo red (Figure 
1-8c) and thioflavin T (ThT) (Figure 1-8d), known to bind to amyloid fibrils, are 
used commonly to detect the presence of fibrils both in vitro (82, 83) and in vivo 
(84, 85). Congo red exhibits apple-green birefringence upon excitation with plane-
polarised light when bound to the regular array of β -strands within the cross-β 
structure of amyloid. Binding of ThT to amyloid fibrils can be monitored by 
excitation of the dye with light at 444 nm, upon which fluorescence emission can 
be measured at 480 nm (86). Although little is known about the specificity of this 
interaction, it is thought that the ThT binds with its long axis parallel to the 
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hydrogen bonded network within fibrils (86). In vitro, ThT fluorescence can be 
monitored in real-time and is therefore routinely used in determination of fibril 
formation kinetics. Typically, ordered amyloid assembly proceeds via a nucleated 
assembly mechanism (87). Such an assembly mechanism begins with a lag-phase 
in which a critical nucleus forms, followed by an elongation phase and ending with 
a stationary phase (Figure 1-8d). Identification of species in each of these phases 
is crucial for understanding the mechanism(s) of amyloid formation and for 
identifying all potentially toxic species as targets for inhibition by ligand binding. 
The latter could pave the way for the development of therapeutics to circumvent 
amyloid-associated toxicity in numerous pathologies (Table 1.1).  
 
Figure 1-8. Techniques for characterisation of in vitro amyloid formation. (a) 
Negative Stain EM image of long, straight hIAPP  fibrils (scale bar = 100 nm); (b) X-
ray fibre diffraction of long, straight hIAPP (20-29) fibrils (88) showing the hallmark 
amyloid pattern; (c) Congo red staining of hIAPP amyloid from a diabetic subject 
(89) (scale bar: 50 μm); (d) Schematic representation of amyloid fibril formation 
starting from monomer (pink circles) and proceeding via oligomers (pink squares) 
along seeded (dotted line) and unseeded (solid line) assembly pathways to produce 
fibrils of different morphologies.  
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Protein aggregation is thought to be initiated by a misfolding or unfolding event 
that allows oligomerisation to proceed followed by either structural 
rearrangement or assembly directly into amyloid fibrils (90). Identifying 
oligomeric species both on- and off-pathway to the final fibrillar structure creates 
an enormous challenge, yet is crucial to understanding the molecular mechanisms 
of amyloid assembly. Whilst much attention has focussed on blocking fibril 
formation using small molecules that target on-pathway oligomers, recent studies 
have suggested that off-pathway oligomers are equally as interesting and exhibit 
toxicity against numerous cell-lines (91, 92). Therefore, it is essential to identify 
and characterise all species present within these heterogeneous ensembles. In 
order to identify such species, techniques are urgently required that enable the 
interrogation of different amyloid systems in great detail. To this end, systems 
including beta-2 microglobulin (β2m) (44, 93, 94), α-synuclein (49, 95-97), Aβ (45, 
98-100) and IAPP (47, 48, 101, 102) have been studied using a range of biophysical 
approaches including IMS-MS (Table 1.2). 
Amyloid System References 
IAPP (47, 48, 101, 102) 
A40 and A42 (45, 98-100) 
-synuclein (49, 95-97) 
2-microgloblin (44, 93, 94) 
Transthyretin (103) 
Insulin (104, 105) 
NNQQNY, VEALYL and SSTNVG peptides (46) 
Prion protein fragment PrP106-126 (106) 
Table 1.2. Amyloid systems studied by IMS 
1.10 hIAPP amyloid assembly in vivo  
 
IAPP is a highly amyloidogenic 37 residue peptide hormone synthesised by beta 
cells of the pancreas as an 89 residue pre-prohormone. Removal of the 22 residue 
signal sequence leads to the 67 residue pro-IAPP, which is further processed in the 
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Golgi and in the insulin secretory granule to produce the 37 residue mature 
hormone (107) (Figure 1-9). Additional post-translational modifications include 
formation of an intramolecular disulfide bridge between cysteine residues at 
positions 2 and 7, and amidation of the C-terminus (Figure 1-9). The mature, 37 
residue peptide is stored in the insulin secretory granule at a ratio of 1:50 -1:100 
relative to insulin and is co-secreted with insulin. The physiological roles of IAPP 
are not completely understood in humans, however rodent models have suggested 
that the peptide plays a part in the inhibition of insulin secretion, glucose 
homeostasis and calcium metabolism and also affects feeding behaviour (89, 108, 
109).   
 
Figure 1-9. Comparison of human IAPP (hIAPP) and rat IAPP (rIAPP) sequences. 
Both peptides have a disulfide bridge between Cys-2 and Cys-7 and have an amidated 
C-terminus. Residues that differ from those of the human peptide are coloured pink in 
the rat sequence. 
 
IAPP was discovered during post mortems of patients with T2DM due to its 
aggregation into insoluble amyloid deposits in pancreatic islets (109). IAPP 
amyloid deposits have been reported to occur in up to 95 % of Type 2 Diabetes 
Mellitus (T2DM) patients compared with less than 15 % of non-diabetic 
individuals (89). T2DM is characterised by insulin resistance and beta cell failure. 
Insulin resistance leads to increased insulin production by beta cells, and when 
these cells fail to produce sufficient insulin, then T2DM develops (110). Elevated 
glucose levels in T2DM cause increased amounts of IAPP to be secreted, 
concomitant with increased insulin secretion, eventually resulting in the formation 
of large extracellular beta sheet-rich aggregates. IAPP’s exact role in T2DM 
remains elusive but its misfolding is thought be a pathogenic factor in the disease 
as there is strong correlation between the degree of amyloid present and disease 
severity (109). Amyloid formation by IAPP is thought likely to induce apoptotic cell 
death of pancreatic islets (110) thus leading to the observed decrease in beta cell 
hIAPP 
rIAPP 
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mass and function (111). Such proteinaceous deposits are restricted to the islet 
area, not spread throughout the pancreas (109).  
IAPP amyloid forms via a nucleation-dependent mechanism possibly via binding to 
beta cell membranes (112). IAPP amyloidosis is thought to begin intracellularly; 
however, deposits are extracellular leading to the following hypothesis for IAPP 
amyloid: amyloid first forms intracellularly and causes cell death leaving a small 
amount of extracellular amyloid to act as a seed for progressive amyloid formation 
leading to development of the proteinaceous plaques observed in T2DM patients, 
shown in Figure 1-10 (109).  
 
 
Figure 1-10. Hypothesis of IAPP fibril formation during the progression of T2DM. 
Figure adapted from (109). 
 
1.11 Sequence dependence of IAPP amyloid formation 
 
Amyloid formation by IAPP is highly sequence specific (113). Mice and rats do not 
develop islet amyloid, but cats, non-human primates and humans do. Whilst the 
human polypeptide is extremely amyloidogenic, rat IAPP does not form amyloid in 
vivo or in vitro, despite differing in sequence at only six amino acid positions (three 
being Pro residues in rat IAPP, leading to disruption of secondary structure 
formation) (Figure 1-9) (114). Much attention has been focused on the sequence 
within the 20–29 region and the role it plays in controlling amyloid formation. This 
region (SNNFGAILSS) forms amyloid-like fibrils readily in isolation in vitro (101, 
115) and is considered to be one of the major determinants of the ability of IAPP 
variants to form amyloid. The shortest IAPP sequence capable of forming fibrils is 
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NFGAIL, whereas FGAIL forms short ribbon-like structures and GAIL is not capable 
of fibril formation (115). The characterisation of designed variants of IAPP support 
the significance of residues 20-29; analogs of IAPP which contain prolines or N-
methylated residues within this portion of the polypeptide are considerably less 
amyloidogenic than wild type IAPP (116, 117). Although there is a strong 
correlation between the primary sequence of the 20–29 segment and rate of in 
vitro amyloid formation (118), mutations outside of this region significantly impact 
amyloid formation, indicating other factors are involved in controlling IAPP’s 
amyloid propensity.  
 
A variety of single point mutants and a free C-terminal mutant exhibit altered rates 
of amyloid formation with respect to the wild-type peptide sequence (119). The 
missense S20G mutation of the human IAPP gene, known to occur in vivo, is 
associated with a history of an early onset, more severe type of T2DM (120). This 
substitution also enhances amyloid formation in vitro (120). A H18L mutant, in 
which His-18 is replaced by Leu, a neutral residue of a similar volume, has a 
significantly increased rate of amyloid formation with respect to wild-type human 
IAPP (121). On the contrary, an IAPP variant with a free acid at its C-terminus 
forms amyloid much more slowly (121) and the ‘non-amyloid’, single-point mutant 
I26P has been shown previously to be a moderately effective inhibitor of amyloid 
formation by wild-type human IAPP (116). Studies of the monomeric and 
oligomeric species populated by mutant IAPP sequences over time would give key 
insights into the amyloid competence and possible toxicity of distinct states. 
 
1.12 Inhibitors of amyloid formation 
 
Given the multifaceted nature of the mechanisms involved in amyloid diseases, 
alarmingly few therapies are available currently (122-126). The toxic species in 
many of these disorders remains elusive, therefore any available therapies target 
the symptoms rather than culprits of the disease (127). The use of small molecule 
inhibitors (low molecular weight organic compounds) to bind to amyloid species 
and block and/or re-direct amyloid assembly is one promising therapeutic avenue 
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(125, 126). This inhibition approach was first introduced upon observations that 
aromatic compounds such as ThT and Congo red could bind to and inhibit the 
formation of amyloid structures, for example formed from the Aβ peptide, when 
present at high enough concentrations (122, 128-130). Small molecule inhibitors 
have numerous advantages over peptide inhibitors; they are able to cross the 
blood-brain barrier, avoid an immunological response, and are more stable in 
biological fluids and tissues (131). A vast arrays of compounds have since been 
demonstrated to interfere with the aggregation pathways of many proteins 
associated with amyloid disease. Table 1.3 contains examples selected to highlight 
the structural and chemical diversity of small molecules that bind to amyloid 
suggesting that they may be binding to different sites and/or have different 
binding modes to the proteins of interest. 
 
 
Small Molecule Structure Protein Target 
Congo red 
 
 
 
 
Aβ (129, 132), insulin 
(133), Ig domain (134) 
EGCG 
(epigallocatechin-3-
gallate) 
 
 
 
 
 
Aβ (135), hIAPP (136-
138), TTR (139), κ-
casein (140), α-syn 
(141) 
Tramiprosate 
 
 
Aβ (142) 
Hemin 
 
Aβ (143, 144) 
Curcumin 
 
Aβ (145, 146), hIAPP 
(147, 148), α-syn 
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(149), lysozyme (150) 
Aspirin 
 
 
Aβ (151) 
Tafamadis 
 
TTR (126) 
Table 1.3 Select examples of small molecule inhibitors of protein aggregation.  Table 
courtesy of Dr. Janet Saunders.  
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The most common family of small-molecule inhibitors of aggregation are 
polyphenol compounds (139, 152-155) found naturally at high concentrations in 
wine, tea and many plants. The compounds play protective roles including disease 
prevention and protection from ultraviolet radiation damage and their human 
consumption has been proposed to have potential antibacterial, antiviral, 
anticancer and neuroprotective benefits (155). 
Polyphenols are believed to interact with amyloid and interfere with aggregation 
by means of competitive interactions with key aromatic residues within the 
peptides and proteins (156-158). Aromatic rings of polyphenols can compete and 
prevent stacking of aromatic residues (‘π-stacking’), believed to be pivotal for 
formation of amyloid fibrils (156-158). The prevention of π-π interactions 
subsequently blocks further self-assembly (155, 159, 160). This has been 
demonstrated by structural analysis of the interaction between Congo red and the 
aromatic moieties of insulin, an interaction which subsequently abolishes fibril 
formation by insulin (133). Aromatic stacking is, however, not the sole 
determinant of aggregation, as demonstrated recently with the Aβ peptide in 
which replacement of aromatic side chains with leucine or isoleucine enhances 
amyloid formation (161).  
One of the most intensively studied small molecules, is the tea-derived flavanol (-)-
epigallocatechin-3-gallate (EGCG) (Figure 1-11). EGCG has been shown to interact 
with multiple amyloid systems and is capable of preventing oligomerisation and 
fibrillation as well as disaggregating preformed fibrils both in vivo and in vitro 
(102, 128, 135, 136, 138, 140, 141, 162-164). The numerous phenolic hydroxyl 
groups, as well as the aromatic rings, of EGCG (Figure 1-11) are believed to play a 
central role in aggregation inhibition, potentially via hydrogen bonding to the 
peptide backbone of the amyloidogenic protein (135, 137). When these hydroxyl 
groups are removed sequentially, the ability of the molecule to inhibit aggregation 
decreases sequentially (137).  
Upon incubation with EGCG, fibril formation from α-synuclein and Aβ40 is ablated 
and small spherical species result in the place of fibrils (141, 156). 
Characterisation of the spherical off-pathway species formed when EGCG is 
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incubated with α-synuclein or Aβ40 has shown that the species formed reduce 
cellular toxicity when compared with fibrillar species (162). However, the point at 
which the assembly pathways switch from fibril formation to off-pathway oligomer 
formation and the mechanism by which such spherical aggregates form remains to 
be deduced.  
 
 
Figure 1-11. Chemical structure of the polyphenol (-)-epigallocatechin-3-gallate 
(EGCG). The high number of phenolic hydroxyl groups is pivotal to its broad anti-
amyloidogenic properties (135, 137) 
One possible disadvantage of polyphenol compounds as aggregation inhibitors is 
their lack of specificity. The generic structure of the final amyloid fibril formed by a 
wide variety of protein sequences enables polyphenol compounds to interact with 
a vast array of systems.  This could be disadvantageous given that not all amyloid 
sytems are disease-related. Interference with functional amyloid (56, 165, 166), 
such as the fibrils formed by PMel17 in mammalian melanocytes that assist in 
melanin deposition (167), would be of great detriment. Additionally, the lack of 
understanding of the nature of the toxic species makes inhibitors of fibril 
formation and/or fibril disaggregates potentially harmful. Each non-native species 
on the aggregation pathway could potentially contribute towards the toxicity 
therefore molecules that bind to monomers and prevent all stages of misfolding 
and aggregation are desirable as therapeutics. Techniques for determining the 
mode of action of potential inhibitors and the exact species with which they 
interact is of great interest and importance to this field. 
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1.13 IMS-MS for studying amyloid assembly  
 
IMS-MS is ideally suited to the study of amyloid formation (6, 97). It allows 
separation of multiple conformations of the same protein monomer with the same 
m/z ratio that differ in size and/or shape, thus enabling all of the non-native states 
occupied en route to fibril formation to be identified and characterised in detail. 
Several studies have shown that the ESI process is capable of conserving a 
protein’s solution-phase characteristics in the gas-phase and that by performing 
ESI-MS alone, observation and characterisation of the different conformational 
states of folded proteins is possible (95, 168). A protein’s charge state distribution 
alone can provide useful information on the protein’s conformation, given that 
unfolded conformations expose more ionisable sites than the more folded/ 
compact conformations (95, 168). This means that unfolded conformers of the 
same protein will exhibit higher charge states than their folded counterparts 
during the ESI process (Section 1.7). For protein systems that exhibit multiple 
conformations, Gaussian distributions can be fitted to charge state envelopes to 
estimate the number of conformers present (95, 168). Although fitting charge state 
distributions to ESI-MS m/z spectra helps in determining the number of 
conformations present, and their relative abundances, it does not allow separation 
and/or detailed interrogation of these species. By contrast, using IMS-MS, 
conformers of distinct CCS are separated and characterised individually. These 
approaches have been demonstrated for both α-synuclein (α-syn), an intrinsically 
disordered amyloidogenic protein associated with Parkinson’s disease (169) and 
β2-microglobulin (β2m), a protein with an immunoglobulin fold that forms amyloid 
fibrils associated with DRA (170), a debilitating osteoarticular complication of 
long-term hemodialysis. In the case of α-syn, Gaussian fitting allowed identification 
of four distinct conformational states, ranging from a highly structured one to a 
random coil (95). The use of IMS-MS later allowed a highly amyloidogenic 
fragment of α-syn (residues 72–140) to be separated from the intact protein 
according to its CCS and subsequently individually characterised (171). In the case 
of β2m, under low pH conditions (pH 2.5) three different conformeric families 
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(compact, partially compact and expanded) of the protein monomer were first 
identified by fitting the charge state distributions (168) and later separated using 
IMS-MS (172). A variety of proteins and peptides that assemble into amyloid have 
been studied using IMS and are listed in Table 1.2. 
After IMS-MS separation and subsequent CCS determination, it is possible to use 
molecular dynamics simulations and/or coarse-grain modelling to reveal potential 
structures of protein conformers observed using IMS-MS and to understand the 
mechanism of oligomer growth. Molecular dynamics (MD) simulations have been 
utilised in conjunction with IMS-MS in the analysis of several amyloid systems 
including IAPP (47), α-syn (49) and a short prion fragment (residues 106-126) 
(106). In the case of IAPP (discussed in detail in Section 1.11), a distinct change in 
monomer conformation associated with amyloid propensity was identified using 
IMS-MS. IMS-MS revealed that human IAPP populates a more expanded 
conformation than its non-amyloidogenic rat counterpart (48). MD simulations 
confirmed that the expanded conformation identified in the IMS-MS analyses was 
likely populated by a β-hairpin structure. Similarly, NMR data suggested that fibril 
formation of hIAPP is initiated through a β-hairpin intermediate (173), validating 
the use of IMS-MS in combination with MD for study of early amyloid 
intermediates. In a similar study, Dupuis et al.  suggested a β-hairpin human IAPP 
dimer structure with CCS values consistent with this species containing two β-
hairpin IAPP monomers bound side-to-side (47) (Figure 1-12).  
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Figure 1-12. Mechanism of dimer formation by hIAPP: dimers have β-strand 
monomer-monomer interfaces. IMS-MS and simulation data support  a route to the 
fibril state through an “early conformational transition” to a β-stranded conformer. 
Figure take from (47). 
 
Using the same approach, a mechanism of the prion fragment 106-126  oligomer 
formation was proposed (106). An expanded conformer observed using IMS-MS 
was shown likely to have a β-hairpin-like structure according to MD simulations. 
This β-hairpin-like conformation decreased in relative intensity over time, 
concomitant with an increased intensity of a peak in the IMS spectra 
corresponding to oligomeric species (Figure 1-13). Increased β-sheet content over 
time, measured using CD (106), was additional evidence for this conformational 
change. 
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Figure 1-13. Ion mobility spectrometry-mass spectrometry of the assembly pathway 
of the prion protein fragment 106-126. a) Ion mobility traces for the +2 charge state 
monomeric ions of the prion fragment 106-126 showing the presence of Species A 
(CCS = 371 Å2) together with Species B, an expanded β-sheet conformation with a CCS 
of 466 Å2, at early time-points. Species B is absent in the “Control” sample, a non-
amyloidogenic peptide of the same amino acid composition but with a scrambled 
sequence (CCS = 391 Å2). The population of expanded conformers in the “Normal” 
prion protein fragment 106-126 decreases over time as species with drift times of 390 
µs and 425 µs appear. These peaks are presumed to be oligomeric as the CCS values 
are too small to belong to a monomeric conformer with +2 charges. b) Schematic 
showing the proposed mechanism of PrP106-126 oligomer formation involving the 
assembly of Species A and Species B into ordered small aggregates. Figure taken from 
(106). 
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Although IMS-MS is a relatively new addition to the structural biology tool kit, it  is 
now accepted as a powerful method for the interrogation of the conformational 
properties of proteins which may be folded, partially folded or intrinsically 
unfolded (6, 97). Given that amyloid fibril formation can be initiated via the 
formation of lowly populated and highly dynamic, transient species, this is 
especially useful. 
1.14 Studying oligomeric intermediates using IMS-MS 
 
A significant challenge in the study of amyloid assembly is the identification and 
characterisation of oligomeric intermediates. In the early stages of amyloid 
assembly multiple, rapidly-converting, transient and lowly-populated species are 
co-populated in solution, so the detection and characterisation of individual 
species is extremely difficult. In contrast to rival biophysical techniques, such as 
light-scattering or fluorescence, IMS-MS can individually identify and characterise 
oligomers that are present, rather than simply providing information on the 
average properties of the species populated. ESI-IMS-MS lends itself to the study of 
amyloid systems for a number of reasons. Firstly, MS enables the detection of 
multiple ions within the same sample at femtomolar concentrations, and their 
identification, based on their m/z. Secondly, nESI-MS allows preservation of large, 
non-covalently bound biomolecular species in the gas phase that are reflective of 
species populated in solution (174-177). Thirdly, IMS-MS allows ion species of the 
same m/z but different CCSs to be separated, enabling different protein 
conformational states and oligomeric species to be distinguished confidently (178, 
179), all within a single experiment. Amyloid formation can be followed over time 
and any changes in oligomer distribution and/or protein conformation can be 
monitored (180). 
In the past, using ESI-MS without IMS, high order oligomers occupied during fibril 
formation of proteins including β2m and insulin have been identified based upon 
m/z alone (94, 105). Using this approach, oligomer charge states were identified 
based on the observed 13C isotope spacing or through the identification of unique, 
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odd numbered charge states (94, 105).  More recently, using IMS-MS, it has been 
possible to establish unequivocally which species are present in solution, given 
that at a particular m/z different oligomeric ions may contribute to the peak in the 
ESI-MS spectrum. Oligomeric states that have coincident m/z, but different 
size/shapes can be separated based on their mobility through an inert gas under 
the influence of a weak electric field, as they travel through the IMS drift cell. 
Multiple amyloid systems have been interrogated by IMS-MS (Table 1.2) including 
the Aβ40 (98, 100) and Aβ42 (45) peptides that form extracellular plaques in AD 
and contribute to cell death associated with memory loss (123). Both peptides are 
aggregation prone, however Aβ42 is more highly amyloidogenic and considered to 
be significantly more neurotoxic (123). The discrepancy in amyloid propensity of 
the two peptides has been proposed to be in part due to a difference in the 
oligomeric states occupied during fibril formation. Bernstein et al. (98) employed 
negative mode ESI-IMS-MS in order to show significant differences in the 
oligomeric states populated by Aβ40 and Aβ42 (Figure 1-14). IMS-MS data 
revealed that the key structure in the aggregation pathway of Aβ40 is a ‘closed’ 
tetramer that is not amenable to further oligomerisation by monomer or dimer 
addition. In contrast, Aβ42 occupies ‘open’ tetramers en route to a planar hexamer 
which stacks to form a dodecamer, proposed to be a potential candidate for the 
primary toxic species in AD (Figure 1-14).  
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Figure 1-14. Differences in Aβ40 /Aβ42 fibril formation determined by ESI-IMS-MS. 
For Aβ40 the key structure is the tetramer that does not undergo further monomer or 
dimer addition. For Aβ42 an 'open' tetramer promotes the formation of the planar 
hexamer (paranucleus) and the stacked dodecamer. The Aβ40 tetramer is suggested 
to go on to forms fibrils, but these were not observed in this study. For Aβ42 a rate-
limiting slow α- to β-sheet transformation was suggested for the dodecamer, but this 
was not explicitly demonstrated. Fibril formation was indirectly detected through 
macroscopic clogging of the spray tips used for Aβ42. Figure taken from reference 
(98). 
 
Using positive mode ESI with travelling wave IMS-MS and improved m/z 
resolution, however, Kłoniecki et al. observed higher order species (monomer to 
13-mer) formed by the Aβ40 peptide (100) demonstrating the possible instrument 
and settings dependence of data produced. 
Comparison of IMS-MS-derived CCS values with coarse grain modelled oligomer 
structures enables estimations of the mechanism by which protein monomers 
assemble into fibrils.  For example, theoretical isotropic and linear growth models 
can be estimated by the use of equations and compared with measured CCS values. 
In an isotropic growth model, σn = σmonomer*n2/3, where n = oligomer number, σn is 
the CCS of the oligomer number n and σmonomer is the monomer CCS (98). Similarly, 
linear growth in one direction (fibril growth) can be estimated by σn=a*n + k, 
where a describes the CCS of a monomer within a fibril and k is the size of the fibril 
cap. Such modelling has been employed in the study of oligomers formed during 
the assembly of the small highly amyloidogenic peptides sequences NNQQNY, 
VEALYL and SSTNVG (46) derived from the yeast prion protein Sup 35, human 
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insulin and IAPP, respectively. Self-assembly of these amyloid fragments proceeds 
rapidly in vitro. Comparisons with modelled structures reveal that fibrillation 
proceeds via stacking of extended, fibril-like conformers. For each peptide 
sequence, a transition of soluble oligomers from globular conformations into β-
strand structures occurs at different points in the aggregation pathway, as early as 
dimer (Figure 1-15). In contrast, a non-amyloidgenic control sequence leucine 
enkephalin (YGGFL) forms an isotropic distribution of compact oligomers and does 
not transition toward β-strand structures as aggregation proceeds (46). 
 
Figure 1-15. The in vitro self-assembly of peptide monomers into mature, insoluble 
β-sheet fibrils. A distinct transition of IMS-detectable oligomeric states (horizontal 
axis) from globular conformations into β-strand structures occurs during the lag 
phase of fibril formation. Self-assembly begins with a folded monomer (n=1) and 
proceeds to soluble oligomers of increasing size (n=2, 4, 7, and 10, right). Soluble 
peptide oligomers with identical mass (i.e. the same n) can occupy different 
conformations such as globular (blue structures) or β-strand conformations (flat 
yellow arrows) with different CCS. CCS determination of the oligomeric states reveals 
the nature of the self-assembly pathway that is taking place in solution (large, pale 
blue arrow). The oligomer size at which the divergence from compact to extended 
conformers occurs differs for peptides of different sequences. Figure taken from (46). 
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1.15 IMS-MS can be used to unravel the mechanism of 
inhibition of fibril assembly by small molecules 
 
Over the past decade IMS-MS has been utilised successfully to gain information on 
the inhibition of amyloid assembly by small molecules. The first example of a study 
of this kind was performed by Robinson et al., who used ESI-MS to identify 
inhibitors of transthyretin (TTR) amyloidosis (103). TTR, a native homotetramer, 
is active in the serum and cerebroserum wherein it functions to transport vitamin 
A and the hormone thyroxine, respectively. Upon dissociation from its tetrameric 
state, however, TTR mis-folds and aggregates into amyloid fibrils (103). 
Stabilisation of the native tetramer by ligand binding and therefore prevention of 
the initiation of amyloid assembly is a possible therapeutic strategy. The ESI-MS-
based study demonstrated the stabilisation of the native state via binding of small 
molecule ligands (103). These ligands have subsequently been evolved leading to 
production of tafamadis,  the first small molecule therapeutic for an amyloid 
disease (126). 
More recently, by combining IMS separation with ESI-MS analysis, the detection of 
ligand binding to specific monomeric conformations and oligomeric species has 
been shown to be possible. Several amyloid-small molecule interactions have been 
probed to this extent, including Aβ42, IAPP, α-synuclein and β2m (44, 96, 181). 
Bowers and co-workers, for example, studied the changes in the well-characterised 
oligomerisation pathway of Aβ42 (98) in the presence of a known inhibitor, Z-Phe-
Ala-diazomethylketone (PADK) (99). ESI-IMS-MS data demonstrated the binding of 
PADK to monomeric and oligomeric forms of Aβ42 resulting in both the inhibition 
of assembly from monomer and the dissociation of potentially toxic high order 
oligomers. The same group revealed that insulin, a potent inhibitor of  hIAPP self-
assembly, interacts with the compact hIAPP monomer conformation and shifts the 
equilibrium away from the extended, aggregation-prone conformation (48), thus 
preventing initiation of β-sheet formation and subsequent amyloid assembly 
(182). 
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The changes in the conformational properties of monomeric α-synuclein in the 
presence of the known amyloid inhibitor EGCG (141, 162) have also been probed 
using ESI-IMS-MS (183). The results revealed that addition of EGCG to the disease 
related A53T α -synuclein variant results in the formation of a ligand-bound off-
pathway conformer as opposed to a compact conformer previously described and 
attributed to an amyloid competent state. The reverse effect can be observed in the 
presence of spermine, an amyloid accelerator, that initiates the formation of a 
compact state of α-synuclein (184) thereby increasing the rate of fibrillation. 
The conformer-specific mechanism of inhibition of β2m fibrillation by the 
antibiotic rifamycin SV was demonstrated by Woods et al. using ESI-IMS-MS. At pH 
2.5, β2m occupies several monomeric conformations, i.e. compact (thought to be 
native like) partially compact, and extended (20, 93). Rifamycin SV was observed 
to bind all three monomeric conformers and inhibit amyloid assembly by β2m (44). 
By contrast, other antibiotics from the rifamycin family with very similar 
structures, for example rifaximin, bind only to the most compact conformations 
and fail to inhibit amyloid formation. The data suggested that the unfolded and 
partially folded conformers are amyloid competent, thus revealing key insights 
into the self-assembly mechanism of β2m. 
Identifying amyloid inhibitors is difficult given that many protein precursors of 
aggregation are partially folded or intrinsically disordered. The level of disorder of 
such systems means that they are not amenable to structure-based design. 
Together, the studies reviewed above clearly demonstrate the power of IMS-MS to 
identify binding of ligands to specific amyloid species and to reveal the mechanism 
of action of small molecules that interfere with the amyloid cascade. Furthermore, 
the role of different conformers in the amyloid assembly route can be determined. 
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2 Materials and methods 
 
2.1 Materials  
 Technical equipment 2.1.1
 
Equipment     Manufacturer 
Microplate readers 
FLUOstar OPTIMA plate reader   BMG Labtech, Aylesbury, Bucks, UK 
NEPHELOstar Galaxy laser-based  BMG Labtech, Aylesbury, Bucks, UK 
 nephelometer   
 
 
Electron microscope 
JEOL JEM-1400 transmission   JEOL Ltd., Tokyo, Japan 
electron microscope   
 
Other equipment 
Grant JB1 Unstirred Waterbath  Grant Instruments, Shepreth, UK 
Jenway 3020 Bench pH Meter  Bibby Scientific, Stone, UK 
 
 
Mass spectrometer 
Synapt High Definition Mass Spectrometry (HDMS) quadrupole-time-of-flight mass 
spectrometer (Micromass UK Ltd., Waters Corpn., Manchester, UK), equipped with 
a Triversa automated nano-electrospray ionisation (ESI) interface (Advion 
Biosciences, Ithaca, NY, USA). 
MATERIALS AND METHODS 
41 
 
 Chemicals 2.1.2
 
A  
Acetic acid, glacial     Fisher Scientific, Loughborough, UK 
Acetonitrile      J.T.Baker, Deventer, The Netherlands 
Acid fuchsin       Fisher Scientific, Loughborough, UK 
Acridine orange     Fisher Scientific, Loughborough, UK 
Alcohol dehydrogenase    Sigma Life Sciences, St. Louis, USA 
Ammonium Acetate     Sigma Life Sciences, St. Louis, USA 
Ammonium bicarbonate    Sigma Life Sciences, St. Louis, USA 
Aspirin       Sigma Life Sciences, St. Louis, USA 
Azure A      Sigma Life Sciences, St. Louis, USA 
Azure C      Alfa Aesar, Heysham, UK 
 
B  
1H benzimidazole-2-sulfonic acid   Sigma Life Sciences, St. Louis, USA 
Benzimidazole      Sigma Life Sciences, St. Louis, USA 
Bromophenol blue     Sigma Life Sciences, St. Louis, USA 
 
C  
Caffeic acid      Sigma Life Sciences, St. Louis, USA 
Caesium iodide     Sigma Life Sciences, St. Louis, USA 
Congo red      Sigma Life Sciences, St. Louis, USA 
Curcumin      Sigma Life Sciences, St. Louis, USA 
Cytochrome c      Sigma Life Sciences, St. Louis, 
USA 
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D  
Dimethyl sulphoxide, DMSO    Sigma Life Sciences, St. Louis, USA 
 
E  
(-)-Epigallocatechin-3-gallate (EGCG)   Sigma Life Sciences, St. Louis, USA 
Ethanol      Fisher Scientific, Loughborough, UK 
 
F 
Fast Green FCF      Fisher Scientific, Loughborough, UK 
 
H  
Hemin       Sigma Life Sciences, St. Louis, USA 
Hexafluoroisopropanol    Sigma Life Sciences, St. Louis, USA 
Hydrochloric acid, HCl     Fisher Scientific, Loughborough, UK 
 
L 
Lysozyme (hen egg)     Sigma Life Sciences, St. Louis, USA 
 
M  
Morin hydrate      Sigma Life Sciences, St. Louis, USA 
Myoglobin (horse heart)    Sigma Life Sciences, St. Louis, USA 
Myricetin      Sigma Life Sciences, St. Louis, 
USA 
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O 
Orange G      Sigma Life Sciences, St. Louis, USA 
Orcein       Sigma Life Sciences, St. Louis, USA 
 
 
P  
Phenol red      Fisher Scientific, Loughborough, UK 
 
R 
Resveratrol      Santa Cruz Biotech, Middlesex, UK 
 
S  
Silibinin      Sigma Life Sciences, St. Louis, USA 
 
T  
Thiabenzadole      Sigma Life Sciences, St. Louis, USA 
Thioflavin T      Santa Cruz Biotech, Middlesex, UK 
Tramiprosate      Santa Cruz Biotech, Middlesex, UK 
 
 
U 
Uranyl acetate     Sigma Life Sciences, St. Louis, USA 
Ubiquitin (bovine)     Sigma Life Sciences, St. Louis, USA 
 
W 
Water       J.T.Baker, Deventer, The Netherland 
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 Acquisition of IAPP fragment peptides 2.1.3
 
Human IAPP fragment peptides H2N-24GAIL27-CO2H (372.2 Da), H2N-
22NFGAIL27-CO2H (633.4 Da), H2N-20SNNFGAIL27-CO2H (834.4 Da), and H2N-
20SNNFGAILSS29-CO2H (1008.5 Da) were purchased from Protein Peptide 
Research (Cambridge, UK). 
 
 Acquisition and Synthesis of IAPP 2.1.4
 
Human and rat IAPP were synthesised, purified and kindly provided by Ping Cao, 
Cynthia Tu and Professor Daniel Raleigh (Stony Brook University, New York, USA) 
according to the following procedure :   
IAPP sequences were synthesised on a 0.1 mmol or 0.25 mmol scale using a CEM 
Liberty peptide syntheiser, and 9-fluorenylmethoxycarbonyl (Fmoc) chemistry. 
Fmoc protected pseudoproline dipeptide derivatives were incorporated to 
facilitate the synthesis. 5-(4'- Fmoc-aminomethyl-3', 5-dimethoxyphenol) valeric 
acid (PAL-PEG) resin was used to generate an amidated C-terminus. Double 
couplings were performed for the first residue attached to the resin, 
pseudoprolines, all β-branched residues and all residues directly following a β-
branched residue. Peptides were cleaved from the resin through the use of 
standard trifluoroacetic acid (TFA) methods. Crude peptides were dissolved in 
20% acetic acid (v/v), frozen in liquid nitrogen and lyophilized. The disulphide 
bond was formed via oxidation by use of DMSO. Peptides were purified by reverse-
phase HPLC using a Vydac C18 preparative column (10 mm x 250 mm) with buffer 
A, consisting of 100% H2O and 0.045% HCl (v/v) and buffer B, composed of 80% 
acetonitrile, 20% H2O and 0.045% HCl. HCl was used as the ion-pairing agent since 
residual TFA can cause problems with cell toxicity assays and can influence the 
aggregation kinetics of some amyloidogenic peptides. The identity of the pure 
products was confirmed by mass spectrometry using a Bruker MALDI-TOF MS. 
Analytical HPLC was used to confirm the purity of the peptides before each 
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experiment. This is an important control because deamidation alters the 
aggregation of hIAPP (185, 186).  
 
 Purification of Aβ40 2.1.5
 
The Aβ40 purification protocol was developed and performed by Rachel A. 
Mahood (The Astbury Centre for Structural Molecular Biology, Faculty of Biological 
Sciences, University of Leeds, UK), as follows. 
Recombinant expression of Aβ40 results in an additional N-terminal methionine 
(Aβ(M40), refered to as Aβ40 throughout the thesis)  (187). Aβ40 was expressed in 
BL21 [DE3] pLysS cells (Agilent) from a PetSac vector, kindly provided by Dominic 
Walsh (Brigham & Women's Hospital, Boston, USA) and Sara Linse (Lund 
University, Sweden) (187). Cells were grown at 37 °C in LB media, containing 
ampicillin (100 μg/mL) and chloramphenicol (25 μg/mL). Expression of Aβ40 was 
induced by the addition of 0.5 mM isopropyl-β-D-thiogalacto-pyranoside at an 
OD600 of 0.5, followed by a 3 h incubation at 37 °C. Cells were collected by 
centrifugation (Beckman-Coulter JLA 8.1, 6000 g, 15 min, 4 ˚C) and purified using a 
modified protocol provided by Walsh et al. (187). Briefly, cells were disrupted in 
10 mM Tris-HCl, 1 mM EDTA, pH 8.5, containing 20 μg/mL DNase, 1 mM 
phenylmethanesulfonyl fluoride and 2 mM benzamidine. The suspension was 
stirred at 4 °C for 1 h before homogenization and sonication (30 s, 4 W). The 
extract was then centrifuged (Beckman-Coulter JA 25.5, 20,000 g, 15 min, 4 ˚C). 
The pellet was resuspended in 10 mM Tris-HCl, pH 8.5, containing 8 M urea and 
sonicated to dissolve the inclusion bodies. The suspension was centrifuged again 
and the supernatant collected, diluted 1:4 in 10 mM Tris-HCl buffer and agitated 
gently with Q Sepharose Fast Flow resin (GE Healthcare, Amersham, Bucks, UK.) 
for 30 min. After washing the resin with buffer containing 0 mM NaCl and then 25 
mM NaCl, peptide-enriched fractions were eluted with buffer containing 125 mM 
NaCl, dialysed into 50 mM ammonium bicarbonate, pH 8.0 and lyophilized. Semi-
purified Aβ(M1-40) was resolubilized in 50 mM Tris-HCl containing 7 M GuHCl, pH 
8.5 at a concentration of approximately 10 mg/mL and purified by size exclusion 
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chromatography (HiLoad Superdex 75 26/60 column, GE Healthcare, Amersham, 
Bucks, UK) in 50 mM ammonium bicarbonate, pH 8.0, before finally lyophilizing 
and storing at -20 °C.  
 
2.2 Mass spectrometry  
 
All analyses were performed on a Synapt HDMS quadrupole time-of-flight mass 
spectrometer (Micromass UK Ltd., Waters Corpn., Manchester, U.K.), equipped 
with a Triversa (Advion Biosciences, Ithaca, NY, U.S.) automated nano-ESI 
interface. All samples were analysed by positive ionisation nanoESI (nESI). Data 
were processed by use of MassLynx v4.1 and Driftscope software supplied with the 
mass spectrometer. The m/z scale was calibrated with aq. CsI clusters (1 mg/ml, 
m/z range 200-10000). CCSs were estimated following IMS-MS calibration using 
the denatured proteins equine cytochrome c, hen egg lysozyme (disulphide bridge-
reduced), horse heart myoglobin and bovine ubiquitin (10 μM in 50:40:10, v/v/v, 
acetonitrile, water, acetic acid), in addition to a range of peptides generated by 
trypsin proteolysis of equine cytochrome c and alcohol dehydrogenase, as 
described previously (20, 188). 
 
 ESI-MS to detect oligomers of hIAPP peptide fragments 2.2.1
 
2.2.1.1 Sample preparation 
 
Lyophilized peptides H2N-24GAIL27-CO2H (372.2 Da), H2N-22NFGAIL27-CO2H 
(633.4 Da), H2N-20SNNFGAIL27-CO2H (834.4 Da), and H2N-20SNNFGAILSS29-CO2H 
(1008.5 Da) were dissolved in DMSO at concentrations of 5 mM. After 24 h 
incubation at 25 °C, stock solutions were diluted into 20 mM ammonium acetate, 
pH 6.8, to a final concentration of 100 μM for MS analysis. 
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2.2.1.2 ESI-MS analysis 
 
A capillary voltage of 1.7 kV and a nitrogen nebulizing gas pressure of 0.8 psi. The 
following instrument parameters were used: cone voltage 170 V; source 
temperature 60 °C; backing pressure 4.2 mBar; ramped travelling wave height 4–
20 V; travelling wave speed 400 m/s; IMS nitrogen gas flow 20 mL/min; IMS cell 
pressure 0.55 mBar. The cone voltage was optimized to transmit the higher order 
peptide oligomers; the CCS of the oligomers did not alter over the range 30–170 V.  
 
 ESI-MS to detect oligomers of hIAPP, rIAPP and Aβ40 2.2.2
 
2.2.2.1 Sample preparation 
 
Lyophilised hIAPP and rIAPP samples were dissolved in DMSO to a concentration 
of 3.2 or 5 mM. After 24 h incubation at 25 °C, stock solutions were diluted in 200 
mM ammonium acetate, pH 6.8, to give a final peptide concentration of 32/50 μM 
for mass spectrometry analysis. The final concentration of DMSO was 1 % (v/v). 
Lyophilised Aβ40 was dissolved at 32 µM in 200 mM ammonium acetate, pH 6.8, 1 
% DMSO (v/v). The Aβ40 peptide samples were centrifuged at 13,000 rpm, 4 °C for 
10 min before analysis. All samples were incubated at 25 or 37 °C in 96-well plates 
(Corning Costar 3915, Corning Life Sciences, Amsterdam, The Netherlands) with or 
without agitation (600 rpm).  
 
2.2.2.2 ESI-MS analysis 
 
A capillary voltage of 1.7 kV and a nitrogen nebulizing gas pressure of 0.8 psi were 
used. The following instrumental parameters were used: cone voltage 30−100 V; 
source temperature 60 °C; backing pressure 4.0 mBar; ramped traveling wave 
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height 7−20 V; traveling wave speed 400 m/s; IMS nitrogen gas flow 20 mL/min; 
IMS cell pressure 0.55 mBar. The cone voltage was optimized to transmit the 
higher order peptide oligomers; the CCS of the oligomers did not alter over the 
range 30−100 V. For ESI-IMS-MS time course experiments, 50 µM peptide samples 
were incubated in 20/100/200/500 mM ammonium acetate buffer, pH 6.8, 1 % 
DMSO) for 24 h. 10 µL volumes were removed from each solution and infused into 
the mass spectrometer for analysis via a Triversa automated nano-ESI interface 
(Advion Biosciences, Ithaca, NY, USA). 
 
 ESI-MS to detect ligand binding to hIAPP, rIAPP and Aβ40 2.2.3
 
hIAPP, rIAPP or Aβ40 (32/50 μM) were dissolved in 20 or 200 mM ammonium 
acetate (pH 6.8) containing 32/50 μM (1:1 molar ratio small molecule:peptide) or 
320/500 μM (10:1 molar ratio small molecule:peptide) of small molecule. For 
analysis of these samples by nESI-MS, a sampling cone voltage of 30 V was used to 
preserve protein-ligand interactions, and a backing pressure of 1.6 mbar was 
applied.  
Please note 32 and 320 μM are used in Chapter 4 and 50 and 500 μM are used in 
Chapter 5 and Chapter 6. 
 
 MS/MS 2.2.4
 
2.2.4.1 Collision induced unfolding (CIU) MS/MS of hIAPP and 
rIAPP monomers 
 
CIU-MS/MS experiments were performed using the quadrupole analyser to select 
monomeric ions of hIAPP or rIAPP.  Increasing collision energy was applied to the 
trap collision cell in 10 V increments from 10 to 100 V until the ions unfold, 
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observed in extracted ion mobility plots. The dependence of the ion arrival time 
distribution (ATD) versus increasing the trap energy (used to affect CIU) was 
examined. 
2.2.4.2 Collision induced dissociation (CID) MS/MS of hIAPP and 
rIAPP oligomers 
 
CID-MS/MS experiments were performed using the quadrupole analyser to select 
isobaric m/z ions representing the dimer and tetramer, separating these ions in 
the IMS device and performing CID in the transfer collision cell prior to the ToF 
analyser (the pressure in the collision cell was kept constant). Increasing collision 
energy was applied to the transfer collision cell in 10 V increments from 10 to 100 
V until the oligomers ions were completely dissociated into monomer ions. 
 
2.2.4.3 Collision induced dissociation (CID) MS/MS of hIAPP and 
Aβ40 dimers 
 
CID-MS/MS experiments were performed using the quadrupole analyzer to select 
isobaric m/z ions representing the dimer 5+ ions and performing CID in the trap 
collision cell prior to the IMS device and ToF analyser. Increasing collision energy 
was applied to the trap collision cell in 10 V increments from 10-100 V until the 
oligomer ions were completely dissociated into monomer ions. 
 
2.2.4.4 Collision induced dissociation (CID) MS/MS of ligand-
bound hIAPP  
 
CID-MS/MS was carried out in the trap collision cell of the mass spectrometer. The 
quadrupole analyser was used to select ions that represented ligand-bound 
monomer complexes and increasing collision energy was applied to the trap 
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collision cell in 10 V increments from 10 to 100 V until the ligands were completely 
dissociated from the monomer ions. Quantification of precursor ion intensity 
relative to total ion intensity was calculated using area under peaks. 
2.3 Molecular modelling of peptide oligomers 
 
The molecular modelling detailed in this section was performed by Hlengisizwe 
Ndlovu (School of Physics & Astronomy, University of Leeds). 
The different sized models were built from the PDB coordinates of a model of the 
structure of SNNFGAILSS fibrils generated using ssNMR constraints (88). In this 
structure, SNNFGAILSS forms fibrils in which constituent β-sheets are organised in 
a parallel structure of protofibrils consisting of a pair of two peptide-long β-sheets 
(88). The parallel model was chosen arbitrarily as the difference in CCS between 
parallel and anti-parallel aggregates would be too small to be distinguishable by 
ESI-IMS-MS. The Nucleic Acid Builder (NAB) software package (189) was used to 
extend the length and width of the fibril by translating and joining copies of the 
template, allowing a variety of models with distinct dimensions to be built. The 
models were comprised of single β-sheets with a range of 1 to 30 peptides, double 
β-sheets with a range of 2 to 30 peptides, triple β-sheets with 3 to 30 peptides and 
finally quadruple β-sheets ranging from 4 to 28 peptides. In all cases the 4.7 Å 
inter-peptide β-strand distance was maintained. Missing hydrogen atoms, 
unresolved in the ssNMR derived coordinates, were added automatically via the 
LEAP module of the AMBER11 package (190). The models were then refined to 
remove steric clashes by multi-step energy minimization in the NAMD2.7b1 
software package utilising the Amberff99sb forcefield (191, 192). CCSs were 
calculated on the energy minimized structures using an in-house projection 
approximation method (20), with the default parameters for the number of 
projection angles and the gas radius used. 
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2.4 In vitro techniques 
 
 Transmission electron microscopy 2.4.1
 
Transmission electron microscope images were acquired on a JEOL JEM-1400 
transmission electron microscope (JEOL Ltd., Tokyo, Japan) after incubating 32/50 
µM protein (rIAPP, hIAPP and Aβ40) solutions in the presence or absence of 320 or 
500 µM small molecules for 5 days at 25/37 °C. Carbon grids were prepared by 
irradiating under UV light for 30 min and staining with 4 % (w/v) uranyl acetate 
solution.  
 
 Thioflavin T fluorometry 2.4.2
 
100 µL samples containing 100 µM thioflavin T and 32/50 µM protein in 20/200 
mM ammonium acetate, pH 6.8 and a 1 % (v/v) final concentration of DMSO were 
prepared in a 96-well plate and sealed with clear sealing film (Corning Costar 
3915, Corning Life Sciences, Amsterdam, The Netherlands). Plates were incubated 
in a FLUOstar OPTIMA plate reader for 5 days at 25/37 °C with or without 
agitation (600 rpm), as indicated in each figure. Fluorescence was excited using a 
440 ± 5 nm filter, and emission intensity was measured using a 485 ± 5 nm filter.  
 
 Nephelometry 2.4.3
 
Nephelometry was used to determine the extent of aggregation in rat and human 
IAPP peptide samples. For these experiments, the samples were prepared as 
described above (Section 2.4.2), except that ThT was not included. In each 
experiment readings were taken every 5 min, from 2 min to 50 h. 100 µL of 50 µM 
peptide samples were added to the wells of a flat-bottomed 96-well plate (CoStar, 
UK). To avoid evaporation and condensation, the plates were sealed with 
transparent, hydrophobic and gas permeable plastic films (Breathe Easy, Sigma 
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Aldrich) during incubation and measurement. A NEPHELOstar Galaxy laser-based 
microplate nephelometer (BMG LABTECH, Germany) was used to monitoring the 
turbidity of the samples over time. 
 
 Fibril Depolymerisation 2.4.4
 
Mixed samples containing a 1:1 molar ratio of hIAPP:rIAPP  or hIAPP:Aβ40 were 
prepared by diluting 3.2 or 5 mM stock solutions of each peptide in DMSO 100-fold 
into 20 or 200 mM ammonium acetate, pH 6.8, to a final concentration of each 
peptide of 32 or 50 μM in 1% (v/v) DMSO for MS analysis. After 7.5 hours or 5 days 
of incubation at 25 or 37 °C and 600 rpm, mixed samples were centrifuged in a 
Beckman ultracentrifuge at 300,000 g for 45 min. Fibrillar samples in the pellet 
were depolymerised by incubation in 100 % (v/v) HFIP for 24 h at 25 °C, 200 rpm 
in 200 μL Eppendorf tubes. Samples were air-dried with nitrogen gas and then re-
dissolved in 50:40:10 (v/v/v) acetonitrile/water/acetic acid, and fibril constituent 
peptides were identified by ESI-MS (Section 2.2). 
 
 Selecting novel small molecules for analysis of fibrillation 2.4.5
inhibition 
 
 
Compounds were selected for analysis by Charlotte H. Revill and Dr. Richard J. 
Foster (University of Leeds). The structure of each of the five query molecules 
(vanillin, resveratrol, curcumin, chloronaphthoquinine-tryptophan and 
epigallocatechin-3-gallate (EGCG)) was minimised to the lowest energy conformer 
using LigPrep (193).  The minimised conformers were used as the query scaffold 
for virtual screening of an in-house library of 50,000 structurally diverse, novel 
small molecules using Rapid Overlay of Chemical Structures (ROCS) (194). ROCS is 
a 3D method that matches the shape of a molecule to the shape of the query 
molecule. ROCS also incorporates pharmacophoric features in assessing overlays 
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such that the ROCS Combiscore in ROCS measures the similarity of the matched 
shapes as well as the matched pharmacophoric features. Virtual hits were pooled 
and ranked according to the ROCS Combiscore parameter and 20 of the top 100 
compounds selected for screening based on a qualitative assessment of structural 
diversity. This subset of 20 compounds chosen (Chapter 5  Table 5.2, referred to 
as molecules 11-30) were then screened against hIAPP (and later Aβ40), along 
with a further 10 compounds (molecules 31-40) which have been reported 
previously to inhibit aggregation by other amyloidogenic polypeptides (Chapter 5  
Table 5.2). 
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3 Monitoring oligomer formation from self-aggregating 
amylin peptides using ESI-IMS-MS   
 
3.1 Introduction  
 
The work described in this Chapter has been published in reference (101). 
The structure of small peptide systems has been studied extensively by IMS-MS, 
facilitated by both their commercial availability (3, 23, 46, 101, 106, 188, 195) and 
the rapid and efficient nature of modern peptide synthesis methods (196). Small 
peptides often serve as model systems for the interactions that occur in larger 
proteins and protein complexes (197, 198) and enable the structural impact of 
alterations in protein primary sequence to be investigated (188, 196-198). In-
depth IMS and modelling studies have led to the understanding of the structures 
adopted by peptides in the gas-phase, thus enabling comparisons to be drawn 
between gas- and solution-phase structures. The application of IMS methods to 
peptide systems is not limited to monomeric species. Indeed, many peptide 
sequences, particularly those implicated in amyloid disease, form large oligomeric 
aggregates, via self‐assembly of secondary structure elements, that are amenable 
to study using ESI-IMS-MS (Chapter 1 Section 1.14). β-sheet peptide systems 
have been reported frequently as models for amyloid proteins, often constituting 
core amyloidogenic sequences from longer proteins and polypeptides (37, 199). 
One advantage of studying smaller peptide fragments of larger amyloid proteins by 
IMS is that it enables higher order oligomers to be observed, which is often not the 
case for the corresponding proteins from which they are derived (106). Oligomers 
of fibril-competent peptide fragments can be observed and monitored over time 
under fibril-forming conditions and their estimated CCSs compared with modelled 
structures to provide insights into the assembly pathways of these sequences (46, 
106). 
Here ESI-IMS-MS analyses of oligomers populated during the assembly of peptides 
from the amyloidogenic core of the human IAPP sequence are described (Figure 3-
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1). Intact hIAPP contains several functional regions: residues 1-19 comprise the N-
terminal region that is involved in membrane binding, residues 20-29 are essential 
for amyloidosis (200), and residues 30-37 form the C-terminal region that aids 
amyloid formation (109, 201) (Chapter 1 Section 1.10).   The ability of the full-
length IAPP to form amyloid fibrils in different species has been linked directly to 
the sequence variability of residues 20-29 (20SNNFGAILSS29 in hIAPP), suggesting 
that this region of the peptide is in part responsible for the self-aggregating 
properties of the polypeptide (200). This is supported by the observation that the 
peptide fragment 20-29 (SNNFGAILSS) is highly amyloidogenic in vitro and forms 
amyloid-like fibrils readily in isolation that have a β-sheet morphology typical of 
amyloid (118, 199). The shortest IAPP sequence capable of forming amyloid-like 
fibrils is 22NFGAIL27, whereas the sequence 23FGAIL27 forms short, ribbon-like 
structures, and the four-amino acid peptide 24GAIL27 is not capable of fibril or 
higher-order aggregate formation, even at a monomer concentration of 25 mM 
(199).  
 
 
Figure 3-1. Human islet amyloid polypeptide (hIAPP) sequence and the associated 
peptide fragments used in this study. Residues 20–29 (SNNFGAILSS) comprise the 
amyloidogenic core (200) . 
 
The interesting sequence and length dependency of amyloid fibril formation 
observed for IAPP and its fragments provides an ideal model system for studying 
the mechanism by which amyloid fibrils are formed from soluble monomers. MS-
based techniques are ideally suited to separating mixtures of heterogeneous non-
covalent oligomeric species in the early stages of fibril formation (6, 94) and 
furthermore, individual structural analysis of these oligomers is enabled using 
IMS-MS. Recent studies have shown that both drift tube IMS and TWIMS have the 
capability to evaluate the shapes of oligomeric states in amyloid proteins and 
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polypeptides (48, 93, 98).  The shortest region of hIAPP that has been shown to 
form fibrils, 22NFGAIL27, was chosen for study alongside two other amyloid 
competent sequences, the entire amyloid core, 20SNNFGAILSS29 and a peptide 
intermediate in size, 20SNNFGAIL27. Additionally, the tetrapeptide that is incapable 
of fibril formation, 24GAIL27 was chosen as a control (Figure 3-1). 
Characterisation of the structures of early oligomers may provide potential 
therapeutic targets for inhibiting the formation of amyloid fibrils in diseases such 
as T2DM.  In this chapter, ESI-IMS-MS experiments are performed alongside 
conventional techniques for studying amyloid including the measurement of fibril 
formation kinetics using ThT fluorescence and determination of the final fibril 
morphology using negative stain TEM. These data combine to provide a model for 
the assembly mechanism of amyloid structures formed from the hIAPP core region. 
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3.2 Results 
 Fibril formation from IAPP peptide fragments 3.2.1
 
Four peptides from the amyloidogenic core region of hIAPP were used in this 
study: H2N-24GAIL27-CO2H (372.2 Da), H2N-22NFGAIL27-CO2H (633.4 Da), H2N-
20SNNFGAIL27-CO2H (834.4 Da), and H2N-20SNNFGAILSS29-CO2H (1008.5 Da), 
purchased from Protein Peptide Research (Cambridge, UK). Self-assembly of 
20SNNFGAILSS29, 20SNNFGAIL27 and 22NFGAIL27, all known to aggregate into 
amyloid fibrils, was studied alongside the non-assembling tetrapeptide fragment 
24GAIL27 which was used as a control (Figure 3-1).  
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Figure 3-2. ESI-mass  spectra for (a) 20SNNFGAILSS29, (b) 20SNNFGAIL27, (c) 
22NFGAIL27 and (d) 24GAIL27 demonstrating the purity of the peptides and showing 
the singly charged monomer (and oligomers) observed 2 min after dilution of each 
peptide (100 μM) into 20 mM ammonium acetate (pH 6.8, 25 °C). Oligomers are 
denoted as ‘2’ for dimer, ‘3’ for trimer and so on. All ions annotated are singly 
charged. Peaks are broad due to presence of sodium and potassium adducts. 
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After confirming the molecular mass and purity of each of the peptides ( 
 
 
 
 
 
 
 
 
 
Figure 3-2) the generation of fibrils from solutions of the peptides in volatile, mass 
spectrometry-compatible solvents and buffers was verified. For this procedure, 
lyophilised peptides were dissolved in dimethyl sulphoxide (DMSO), used as a 
disaggregating solvent to avoid the presence of pre-aggregated peptide seeds 
(202). After 24h, the peptide solutions were diluted 50-fold with ammonium 
acetate (20 mM, pH 6.8) for fibril growth analyses. ThT fluorescence was used to 
monitor fibril growth over a 5 day period from samples contained in 96-well plates 
at 25 °C with agitation (600 rpm) (Chapter 2 Section 2.4.2), and ESI-MS spectra 
were acquired for each peptide during this time. After 5 days, an aliquot of each 
sample was removed to confirm the presence of fibrils using negative stain TEM. 
Figure 3-3a shows the time course of fibril formation for 20SNNFGAILSS29, 
20SNNFGAIL27 and 22NFGAIL27, monitored by the increase in the fluorescence of 
ThT over time. The ThT data demonstrated rapid fibril formation kinetics for each 
of the three IAPP peptide fragments 20SNNFGAILSS29, 20SNNFGAIL27 and 
22NFGAIL27 within 1-2 hours without an obvious lag-time, whilst no amyloid 
formation was detected for the control peptide 24GAIL27. These results are 
consistent with earlier studies by Kapurniotu and co-workers (199) who reported 
the kinetic profiles of aggregation for these small, highly amyloidogenic peptides to 
proceed with negligible lag-times. Similar, rapid aggregation kinetics have been 
observed by others monitoring fibril growth from an hIAPP 8-37 construct (203). 
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Electron micrographs taken after five days of incubation confirmed the presence of 
polymorphic fibrillar aggregates for each of the three amyloidogenic peptides 
under the conditions employed (Figure 3-3b i-iii), and the absence of aggregated 
material for the control peptide, 24GAIL27 (Figure 3-3b iv). 
 
 
Figure 3-3. Fibril formation from hIAPP peptide fragments. a) Monitoring amyloid 
fibril formation using the fluorescence of thioflavin T (ThT) for 20SNNFGAILSS29 
(blue), 20SNNFGAIL27 (pink) and 22NFGAIL27 (green), three self-aggregating peptide 
fragments from the hIAPP peptide sequence. Under the conditions used (100 μM 
peptide, 20 mM ammonium acetate, pH 6.8, 25 °C, 600 rpm) fibril formation reaches 
a maximum fluorescence in 1–2 h. The non-assembling tetrapeptide fragment 
24GAIL27 (yellow) does not form fibrils under the same conditions. The data illustrated 
are one representative experiment from a minimum of three independent replicates, 
performed in triplicate. b) Negative stain transmission electron microscopy (TEM) 
images of i) 20SNNFGAILSS29 (blue), ii) 20SNNFGAIL27 (pink) and iii) 22NFGAIL27 
(green) after 5 days under the above conditions, showing the presence of fibrillar 
aggregates, and of iv) 24GAIL27 (yellow) which does not form fibrils. The scale 
bar=100 nm. 
 
 
 TWIMS‐MS cross‐section calibration for peptide systems 3.2.2
 
As discussed in Section 1.4, TWIMS-MS yields ATD information, but in order to 
obtain CCS values, calibration of the measured ATD data using standards of known 
CCSs is required. The IMS-MS spectra of these calibrants must be recorded with the 
 AGGREGATION OF AMYLIN PEPTIDE FRAGMENTS 
61 
 
same IMS parameters as the analyte (such as the height and velocity of the voltage 
waves), as these influence the arrival time and hence the obtained CCS (16). 
Determination of small peptide cross-sections by TWIMS‐MS is enabled by the 
availability of drift tube IMS peptide CCS values obtained from tryptic digests of 
protein standards e.g. equine cytochrome c, which can be found in Clemmer’s 
cross- section library (www.indiana.edu/~clemmer/Research). 
Figure 3-4 shows a three dimensional Driftscope plot (m/z vs. drift time vs. 
intensity) of ions from equine cytochrome c following digestion with trypsin. Many 
tryptic peptides are detected and measured from a single digest thus enabling a 
peptide calibration to be achieved rapidly following analysis of a single ESI-IMS 
mass spectrum. Tryptic peptides are observed as singly and doubly‐charged ions 
with a wide range of peptide sizes and yield many calibration data points that 
cover a wide range of reduced CCS (CCS’) values (Figure 3-4). 
 
 
Figure 3-4. Calibration of TWIMS-MS device three dimensional Driftscope plot (m/z 
vs. drift time) of ions produced from a tryptic digest of equine cytochrome c (2 hours 
at 37 °C using 1:50 (w/w) enzyme:substrate). The m/z spectrum is shown along the y 
axis, and TWIMS chromatogram along the x axis.   
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The cytochrome c calibration shown in Figure 3-5 covers a relatively wide range 
of CCS’ values observed in tryptic peptides, particularly at low mobilities, 
subsequently facilitating the analysis of larger peptide oligomers, such as those 
observed during the process of amyloid fibril formation.      
 
 
 
Figure 3-5. ESI-TWIMS‐MS drift time calibration curve. ESI-TWIMS‐MS drift time 
calibration using tryptic peptides derived from equine cytochrome c, analysed using a 
7-20V travelling wave ramp. An allometric (y=A’xB) fit is applied to the data to yield 
reduced cross-sections from drift time measurements.  
 
 ESI-IMS-MS analysis of pre-fibrillar oligomers of IAPP 3.2.3
peptides 
 
Having confirmed that the three self-aggregating IAPP peptide fragments could 
form fibrils reliably under ESI-MS-compatible solution conditions, the next step 
was to identify and characterise the oligomers formed during the early stages of 
aggregation using ESI-IMS-MS. As discussed in Chapter 1 Section 1.14, ESI-IMS-
MS is ideally suited to the characterisation of heterogeneous, lowly-populated 
amyloid intermediates that are intractable by most conventional biophysical 
methods. Figure 3-6 presents the ESI-IMS-MS 3D Driftscope plot (m/z vs. Drift 
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time vs. Intensity) for 20SNNFGAILSS29, showing the oligomers observed 2 mins 
after dilution of the 10-residue peptide into 20 mM ammonium acetate (pH 6.8). 
ESI-IMS-MS enables separation of all the oligomers present in solution, including 
isobaric species which give rise to ions of the same m/z in the ESI-MS spectrum. As 
discussed in Chapter 1 Section 1.4, protein conformers of the same mass and the 
same charge that have different shapes (e.g. extended vs. compact conformations), 
will have different IMS mobility and hence different drift times. More expanded 
structures will experience a greater number of collisions with buffer gas molecules 
and therefore will have longer drift times than their more compact counterparts. In 
the case of oligomers with the same m/z ratio, but different mass and different 
charge, the most highly charged species usually has the highest mobility and hence 
the shorter drift time. An example of this is illustrated in Figure 3-6 for the 
separation of the singly charged trimer ions, the doubly charged hexamer ions and 
the triply charged nonamer ions originating from 20SNNFGAILSS29, highlighted 
with a yellow box. These isobaric monomeric and oligomeric ions will contribute 
to coincident peaks on a 2-dimensional ESI-MS spectrum ( 
 
 
 
 
 
 
 
 
 
Figure 3-2a) however, when separated by IMS and visualised on a 3-dimensional 
Driftscope plot (Figure 3-6a), they each have separate peaks that are easily 
distinguishable. Once separated, the oligomers can be identified by the isotopic 
distributions of their charge states; in this case, the nonamer, with the highest 
number of charges, had the shortest IMS drift time (Figure 3-6b). 
 AGGREGATION OF AMYLIN PEPTIDE FRAGMENTS 
 
64 
 
 
Figure 3-6. 20SNNFGAILSS29 forms monomer through 22-mers. a)  ESI-IMS-MS 3D 
Driftscope plot (m/z vs. Drift time vs. Intensity) for 20SNNFGAILSS29 showing the 
monomer and oligomers up to and including 22-mer. (The number adjacent to each 
peak represents the number of peptide subunits per oligomer e.g. 3 = trimer). b) The 
characterisation of oligomers contributing to the same m/z peaks is illustrated by 
the separation of the singly charged trimer, the doubly charged hexamer and the 
triply charged nonamer which generate isobaric ions at m/z 3,026-3,030. (i) the IMS-
MS drift time chromatogram of m/z 3026.6 shows three peaks with drift times of 
10.61, 13.42 and 19.62 ms; m/z spectra of the three peaks extracted from the 
driftscope chromatogram are shown in (ii) 19.62 ms, (iii) 13.42 ms, and (iv) 10.61 ms. 
The peaks are identified by their isotopic distributions; the peak with the shortest 
drift time corresponds to the triply charged nonamer (93+), as these ions have the 
highest number of charges and hence the highest mobility. 
 
The Driftscope plots (Figure 3-7) of the three fibril-competent peptides 
20SNNFGAILSS29, 20SNNFGAIL27 and 22NFGAIL27 and the non-amyloid control 
petide, 24GAIL27, show the oligomers observed 2 mins after dilution into 20 mM 
ammonium acetate buffer, pH 6.8,  concurrent with fibril formation for the amyloid 
competent sequences. For 20SNNFGAILSS29, 20SNNFGAIL27 and 22NFGAIL27, 
oligomers in excess of the 20-mer were observed. For all oligomers observed using 
ESI-IMS-MS, their CCS values were estimated from their drift times by use of the 
calibration approach described in Chapter 1 Section 1.4 . The IMS device was 
calibrated, as discussed in Chapter 1 Section 1.4, using denatured proteins 
(cytochrome c, lysozyme, myoglobin and ubiquitin) and a range of peptide ions 
(generated by trypsin proteolysis of cytochrome c and alcohol dehydrogenase) 
whose CCS values have been determined previously using conventional drift tube 
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IMS-MS (20, 188). The determined CCS values are shown in Table 3.1 for the 
peptides 20SNNFGAILSS29, 20SNNFGAIL27, and 22NFGAIL27. The drift times observed 
for different oligomeric species formed from the three peptides throughout fibril 
assembly were within 1 % of those measured after t = 2 min, suggesting that the 
oligomers do not undergo any significant structural rearrangement that results in 
a significant change to their CCS during the assembly process. The absolute errors 
on the CCS estimations are ~5-8% (16, 20), however the replicated experimental 
values typically vary by <1%.  
 
Figure 3-7. ESI-IMS-MS 3D Driftscope plots (m/z vs. Drift time vs. Intensity) for a) 
20SNNFGAILSS29, b) 20SNNFGAIL27, c), 22NFGAIL27 and d) 24GAIL27 showing the 
oligomers observed 2 mins after dilution of each peptide (100 μM) into 20 mM 
ammonium acetate (pH 6.8, 25 °C, 600 rpm). The number adjacent to each peak 
represents the oligomer order. 
 
In some cases, more than one peak was detected for a single charge state of a 
specific oligomer, indicating that this oligomer populates multiple conformers, 
each of which can be distinguished by IMS separation and hence they have a 
distinct CCS. The estimated CCSs of each species detected are shown in Table 3.1 
and are plotted vs. oligomer order in Figure 3-8. 
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Table 3.1. Collision cross-sectional areas of a) 20SNNFGAILSS29, b) 20SNNFGAIL27, and 
c) 22NFGAIL27 peptide oligomers (25 °C, 20 mM ammonium acetate, pH 6.8) detected 
by ESI-IMS-MS.  
a) 
b) 
c) 
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Figure 3-8. Collision cross-section (CCS) vs. oligomer order detected for the peptides 
a) 20SNNFGAILSS29, b) 20SNNFGAIL27, c) 22NFGAIL27, and d) 24GAIL27. For the non-
amyloidogenic peptide (d) 24GAIL27, only the monomer and dimer are observed. The 
yellow line in each case represents the isotropic fit (based on the CCS of the monomer 
scaled by n2/3, where n=number of  peptide subunits per oligomer(46)).  
 
 
Figure 3-8 also shows an estimation of the CCS increase with molecular weight 
expected for the peptides calculated based on isotropic growth, in which the CCS 
scales from the monomer value by a factor of n2/3 (where n is the number of 
peptide subunits per oligomer (46)). For all three of the fibril-competent peptides, 
the oligomers observed are of smaller CCS than that expected for a globular growth 
pattern. This result suggests that monomer units are densely packed within 
oligomeric species, and most likely highly ordered. The observed compactness 
could be a result of conformational transitions at distinct points in the aggregation 
pathway or the coming together of hydrophobic oligomers resulting a dense 
arrangement of pre-fibrillar units within a fibril. The pattern by which CCS 
increases with increasing oligomer order is interesting: the oligomers appear to 
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extend steadily up to a certain point before taking a step-up in size, rather than 
gradually increasing in CCS as oligomerisation proceeds. For example, in the case 
of 20SNNFGAIL27, there is a gradual increase in CCS between monomer and 
pentamer; the pentamer populates two conformers, the more extended of which is 
the first in a new series of oligomers (pentamer to octamer), before another step 
up in CCS is observed. Similar step-wise self-assembly patterns were observed for 
the other fibril-forming peptides, 20SNNFGAILSS29 and 22NFGAIL27 (Figure 3-8a-c). 
The three amyloidogenic hIAPP fragments studied here exhibit transitions similar 
to those observed for the insulin, sup 35 and IAPP derived peptides (VEALYL, 
NNQQNY and SSTNVG), studied by the Bowers group (46). One explanation for the 
progressive behaviour observed could be the gradual transition from unstructured 
oligomers to β-sheets with increasing oligomer size due to increasing β‐sheet 
content. Importantly, no oligomers higher than the dimer were detected for the 
non-aggregating peptide, 24GAIL27, supporting the notion that the gas-phase 
oligomers observed are involved in amyloid formation.  
The detection of a wide range of oligomers, each one differing from the next by a 
single monomer subunit, is consistent the growth mechanisms reported for other 
amyloid systems, for example β2-microglobulin (β2-m) (93) and Aβ40 (100) under 
certain pH and buffer conditions. In the case of β2-m, at pH 3.6 and with increased 
ionic strength (17 μM protein at 37 °C in 150 mM ammonium formate), high-order 
oligomers up to at least 14-mer are observed during worm-like fibril formation 
(94). In the case of Aβ40, when studied by positive mode ESI-TWIMS–MS at high 
peptide concentrations and near-neutral pH (200 μM peptide in 10 mM 
ammonium acetate, pH 7.4), oligomeric species from monomer to 13-mer 
inclusive, together with higher order species have been observed (100). These 
observations are in contrast with results obtained for both β2-m and Aβ40 under 
different conditions. Under long straight fibril-forming conditions (17 μM protein 
at 37 °C  in 100 mM ammonium formate, pH 2.5), oligomers only as large as the 
tetramer have been detected for β2-m (93, 94). For Aβ40 and Aβ42, assembly 
routes comprised of dimer and tetramer and no higher order species, and a dimer, 
tetramer, hexamer and dodecamer, respectively, have also been described (98). 
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The latter experiments were performed using negative mode ESI with a 
conventional drift tube (30-40 μM peptide in 25 mM ammonium acetate, pH 7.4). 
In the case of larger peptides and proteins, the critical nucleus required before the 
final re-organisation into amyloid fibrils and the mechanism of assembly into 
higher order structures remain elusive. Here, using short peptide fragments 
derived from full length amyloid sequences, we are able to observe higher order 
oligomeric structures thus enabling modelling of potential assembly mechanisms, 
providing insights into the amyloid assembly cascade.        
  
 Molecular modelling of potential oligomer structures  3.2.4
 
The work presented in this section was performed by Hlengisizwe Ndlovu (School 
of Physics & Astronomy, University of Leeds). 
As discussed in Chapter 1 Section 1.14, Bowers and co-workers reported recently 
the use of ESI-IMS-MS to determine oligomer cross-sections for a range of short-
chain peptides (46, 106). A conventional drift tube IMS-MS (rather than TWIMS-
MS) based study of amyloidogenic peptide sequences VEALYL, NNQQNY and 
SSTNVG derived from the amyloid proteins insulin, yeast sup 35 and hIAPP 
respectively, reported transitions from unstructured conformers to structured β-
sheet oligomers (46). It was suggested that for fibril-competent peptide sequences, 
oligomers grow isotropically (i.e. equal growth in every dimension) up to a certain 
oligomer order (depending on the peptide sequence). After this point, larger 
structures emerge which are not consistent with isotropic self-assembly leading to 
a hypothesis that conformational transitions form isotropic to β-sheet-containing 
structures occur at different oligomer orders for different peptide systems 
(Chapter 1 Section 1.14, Figure 1-15). 
In order to probe the growth mechanism observed for the hIAPP peptide 
fragments studied here using ESI-IMS-MS, molecular modelling was performed. 
The NAB molecular building tool was employed to construct β-sheet model 
oligomers of 20SNNFGAILSS29 from a fibril structure of this peptide obtained from 
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solid state NMR (ssNMR) measurements (204). This ssNMR study hypothesised 
that the fibril spine consists of two β-sheet layers arranged face-to-face, with 
parallel hydrogen-bonded peptide β- strands within each sheet (204). On the 
contrary, other ssNMR studies have shown that the fibril structure is anti-parallel, 
while others report both parallel and anti-parallel structures (88), demonstrating 
the polymorphic nature of this region of hIAPP (204). 
Singly, doubly, triply and quadruply stacked β-sheet model structures were 
generated for each oligomer order of 20SNNFGAILSS29 between monomer and 30-
mer.  CCS values of the model structures were determined using a projection 
approximation (20). Figure 3-9 shows the CCS values of β-sheet models for the 
20SNNFGAILSS29 oligomers of different mass. Comparison of the modelled 
structures with experimentally determined CCS values of 20SNNFGAILSS29 
indicates that the CCS data points obtained experimentally do not wholly fit with 
any one of the β-sheet models. Instead, the overall model of best fit involves a 
combination of the constructed β-sheet models. The obtained CCS values are 
consistent with a single β-sheet model between monomer and pentamer, a double 
β-sheet model between pentamer and decamer, a triple β-sheet model between 
decamer and 15-mer, and a quadruple β-sheet between 15-mer and 20-mer, as 
illustrated in Figure 3-9. The modelled β-sheet structures are all more compact 
than the isotropic growth model, and the ESI-IMS-MS data indicate that all 
oligomers above the pentamer are significantly more compact than the single β-
sheet model. Together, these observations suggest that the peptides are arranging 
into a densely packed structure from which fibril elongation proceeds.                 
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Figure 3-9. Molecular models for hIAPP peptide oligomers a) Theoretical β-sheet 
models showing CCSs vs. oligomer order for the 20SNNFGAILSS29 peptide. The 
structures are based upon ssNMR data of the 20SNNFGAILSS29 peptide (204). β-sheet 
models were built using the NAB molecular building tool. Transformations and 
duplications of the structure were performed to produce single, double, triple and 
quadruple stranded β-sheet fibrils. b) The assembly of 20SNNFGAILSS29 oligomers 
observed during fibril growth (blue diamonds) using ESI-IMS-MS is compared with 
the isotropic growth prediction (gold dotted line), and a predicted stacked fibril 
assembly (cf. Bowers et al. model where the distance between each oligomer is dimer-
monomer CCS (46)) (purple dashed line). The theoretical β-sheet models are shown 
(red triangles) as follows: single sheet pentamer, double sheet decamer, triple sheet 
15-mer and quadruple sheet 20-mer. 
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Time course ESI-IMS-MS experiments were performed in order to gain 
measurements of oligomer CCS values for 20SNNFGAILSS29, 20SNNFGAIL27 and 
22NFGAIL27 over the course of fibril assembly. All of the CCSs determined for the 
three peptides measured over the 20 h time course of assembly were within 1 % of 
those measured at t = 2 min, suggesting that there is no gross structural 
rearrangement within the oligomers as fibrillation proceeds. This is in contrast 
with other published ESI-IMS-MS studies that demonstrate conformational 
rearrangement within amyloid oligomers over the course of assembly. For 
example, during the lag phase of amyloid assembly by β2-microglobulin, trimeric 
and tetrameric oligomers become more compact and less amenable to subunit 
exchange (93).  
 
3.3 Discussion 
 
The data presented in this chapter show the applicability of TWIMS-MS to the 
study of both peptide structure and amyloid self-assembly. Measurement of CCS 
values for peptide oligomers is facilitated by the availability of conventional drift 
tube IMS data on denatured proteins and tryptic peptides of commercially 
available proteins. The applicability of TWIMS-MS to non-covalent systems makes 
it ideally suited to the interrogation of the oligomers occupied during amyloid fibril 
assembly, in terms of their relative abundances, sizes and conformations. 
Comparison with coarse-grain molecular models enables experimentally derived 
CCS values to be compared with known structures and assigned to potential 
growth models. TWIMS enables the observation of multiple lowly populated 
oligomeric states present within heterogeneous mixtures in a single spectrum thus 
providing multiple CCS data points for comparison with modelled structures.  
In the case of the three amyloidogenic hIAPP fragments studied here, observed CCS 
values are consistent with single β-sheet models for low order oligomers whilst 
higher order oligomers are consistent with stacking of multiple sheets. Insights 
into the detailed mechanism of aggregation are enabled by observation and 
interrogation of higher order oligomeric states, particularly in 20SNNFGAILSS29, 
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where oligomers up to and including n= 22 are observed. TWIMS-MS-derived CCS 
values indicate that initial assembly proceeds in one dimension via the formation 
of a single β‐sheet, while two dimensional self‐assembly occurs in higher-order 
oligomers at specific oligomer orders, observed as a separate oligomeric species 
that increase in size in a step-wise manner.  
This study highlights the power of TWIMS-MS for studying the mechanism of self-
assembly for amyloid systems, since all components of a complex mixture can be 
observed and their CCS measured in a single experiment. It also highlights the 
benefits of studying peptides as model systems for the study of protein self-
assembly, given that high order species can be observed in the gas phase and 
growth mechanisms deduced as a result. The work in this chapter shows that when 
ESI-TWIMS-MS is performed in conjunction with coarse-grained modelling, a 
comprehensive picture of the aggregation process in self-assembling peptide 
systems can be gained. Application of these methods to full-length amyloidogenic 
peptides and proteins under physiological conditions may enable a greater 
understanding of the elusive mechanisms that underlie amyloid assembly. This 
remains a challenge, given the difficulty of maintaining non-covalent, hydrophobic 
interactions in the absence of solvent. Studies of intact hIAPP, Aβ40 and variants of 
these sequences are described in the following chapters. 
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4 Ion mobility spectrometry - mass spectrometry 
defines the oligomeric intermediates in amylin 
amyloid formation and the mode of action of inhibitors 
 
4.1 Introduction  
 
The work described in this Chapter has been published in reference (102). 
In order to gain an understanding of the aggregation process of amyloid-prone 
peptides and proteins, the nature of oligomeric intermediates populated on- (or 
off-) pathway to fibrils must be interrogated. In Chapter 3, the high order 
oligomers of short peptide fragments from the amyloid core of hIAPP were 
investigated. Here, by exploiting the separative and investigative powers of MS 
coupled with IMS and CID-MS/MS, higher order oligomeric states populated by 
full-length, 37-residue hIAPP and rIAPP petides are described and their CCS, 
growth mechanism and relative gas-phase stabilities are elucidated. rIAPP is used 
throughout this chapter as a non-amyloidogenic control peptide, given that it is 
unable to fibrillate under any previously characterised conditions and rodents do 
not develop T2DM (114). 
Previous IMS-MS-based studies have proposed structural models for the IAPP 
monomer (48) and dimer (47), as well as the oligomers formed during self-
assembly of peptides derived from an amyloidogenic core sequence (20−29) of 
hIAPP (101) (Chapter 3). Using IMS-MS and replica-exchange molecular dynamics 
(REMD) simulations, Dupuis et al. proposed that full-length monomeric hIAPP 
occupies at least two conformations; both a helix−coil conformation and an 
extended β-hairpin conformation that has a significantly (18%) larger CCS (48). 
The extended hairpin structure was not significantly populated by the non-
amyloidogenic rIAPP peptide, leading to the conclusion that this conformer is an 
amyloid precursor. In a second study, Dupuis et al. investigated and compared the 
dimeric structures populated by hIAPP and rIAPP, using IMS-MS. These data 
revealed that the hIAPP dimers observed are significantly more extended than 
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those observed for rIAPP, indicative of a higher percentage of β-sheet content 
formed by the assembly of extended β-hairpin-containing monomers (47). These 
two studies led to a proposal that a conformational transition to β-sheet-rich 
conformers is an early step in hIAPP self-assembly, by contrast with other reports 
which have suggested a transition to amyloid via helix-rich oligomers (205, 206). 
None of these studies, however, reported the detection or identification of higher 
order species. Here, hIAPP and rIAPP oligomers, monomer through hexamer, 
inclusively, for both peptides are described. Their relative gas phase stabilities are 
also investigated and the factors that determine their marked difference in 
amyloid propensity are discussed. 
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4.2 Results 
 
 hIAPP  forms an array of oligomers early in amyloid 4.2.1
assembly 
 
Prior to analysis using ESI-IMS-MS, lyophilised, synthetic hIAPP and rIAPP 
peptides (Figure 4-1a) were each dissolved in 100% DMSO, to remove any pre-
formed aggregates (207), for 24 h at 37 ˚C. The sample was then diluted 100-fold 
into 20 mM ammonium acetate, pH 6.8. The distribution of oligomeric species was 
analysed immediately (time = 2 mins), and at various time points after dilution, 
using ESI-IMS-MS.  
As described in Chapter 1 Section 1.14, ESI-IMS-MS is ideally suited to the 
characterisation of heterogeneous, lowly-populated, transient amyloid precursors. 
Previous studies (205, 208, 209) have proposed the existence of oligomeric states 
for hIAPP (and rIAPP) peptides. However, to date, no study has separated and/or 
characterised these species in detail. The data obtained using ESI-IMS-MS (Figure 
4-1b), showed that oligomers up to, and including, hexamers are formed within 2 
min of dilution of hIAPP into buffer. Here, co-populated oligomeric ions with the 
same m/z have been separated and identified individually (e.g. dimer3+ and 
tetramer6+) (Figure 4-1b).   
Consistent with previous studies from Bowers and co-workers (47, 48), multiple 
charge states, predominantly doubly and triply charged, and different conformers, 
both compact and expanded for each charge state, are observed for the hIAPP 
monomer. The doubly charged monomer ions, for example, occupy two distinct 
peaks in the IMS-MS spectrum (Figure 4-1b) with drift times of 7.6 and 10.6 ms. 
By use of the calibration approach described in Chapter 1 Section 1.4, the CCS of 
each distinct conformation can be individually assigned (Table 4.1). Indeed, the 
two conformers of the doubly charged monomer ions have CCS values that differ 
by ~15% (consistent with previous results by Bowers et al. of ~18 % (48)). 
Although less well-resolved, the monomer 3+ ions also exhibit two distinct 
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conformations, with drift times of 6.0 and 8.0 ms, ~14%  different in CCS (~680 
and 790 Å2, respectively). Oligomers of hIAPP also populate a range of charge 
states and conformations (Figure 4-1), for each of which the CCS was determined 
(Table 4.1).   
 
 
Figure 4-1. hIAPP forms an array of oligomeric species during fibril formation. a) 
Comparison of hIAPP and rIAPP sequences. Both peptides have a disulfide bridge 
between Cys-2 and Cys-7 and have an amidated C-terminus. Residues that differ from 
those of the human peptide are colored pink in the rat sequence. b) ESI-IMS-MS 
driftscope plot of the hIAPP oligomers present 2 min after diluting the monomer to a 
final peptide concentration of 50 µM in 20 mM ammonium acetate, pH 6.8, 1% (v/v) 
DMSO. ESI-IMS-MS Driftscope plots show IMS drift time versus m/z versus intensity (z 
= square root scale) and the corresponding mass spectrum is shown on the left hand 
side. Numbers adjacent to peaks denote oligomer order, with the positive charge 
state of each oligomer ions in superscript. The ESI mass spectrum shows the +2 and 
+3 charge state ions of hIAPP monomer (labelled 1) and minor amounts of dimer and 
trimer (labelled 2 and 3, respectively). 
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Table 4.1. Experimental CCS values of hIAPP and rIAPP oligomers. CCS of hIAPP and 
rIAPP oligomers measured using ESI-IMS-MS (50 µM peptide), observed after 2 min 
incubation (37 ˚C, 600 rpm, 20 mM ammonium acetate buffer, pH 6.8). Experimental 
error is estimated to be  ± 5-8 % for all cross sections measured by use of an IMS-MS 
calibration (16). (i) and (ii) denote different conformers of the same ion. 
 
Ionic strength plays a pivotal role in determining aggregation propensities of 
numerous amyloid systems (210-214). Similarly, previous studies have shown that 
increased ionic strength increases the rate of aggregation of hIAPP (210). 
Consistent with these previous data, under the conditions employed, an enhanced 
rate of amyloid fibril formation is observed for hIAPP as the ionic strength is 
increased from 20 to 500 mM (Figure 4-2a), as determined by ThT fluorescence.  
To investigate whether the formation and subsequent disappearance of oligomers 
of hIAPP is concomitant with the peptide assembling into amyloid fibrils, 
oligomerisation was studied at varying ionic strengths of the buffer, with all other 
conditions unchanged. The ionic-strength dependency of oligomer formation 
observed using ESI-IMS-MS was then compared with the rate of fibril formation, 
measured using ThT fluorescence. As the ionic strength of the buffer was 
increased, a more rapid decrease in oligomer signal intensity over time was also 
detected using ESI-IMS-MS (Figure 4-2c), concomitant with the abolishment of a 
lag phase of fibril assembly. This result is consistent with the oligomers observed 
being involved in assembly into amyloid. The gross morphology of the final fibrils 
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(i.e. long, straight, typical amyloid fibrils) was unchanged under all buffer 
conditions employed (a representative TEM image is shown (Figure 4-2b).  
As discussed in Chapter 1 Section 1.4 CCS values for all hIAPP oligomers 
observed were estimated from the ESI-IMS-MS arrival time distributions. In order 
to probe the structural properties of these species, their experimentally 
determined CCS values were compared with CCS values estimated for theoretical 
models including a fit assuming isotropic growth (46), a globular fit based on the 
average density of a protein under similar conditions (0.44 Da/Å3) (62, 215) and a 
‘fibril’ model that assumes growth in a single dimension (46). Comparison of the 
determined CCS values with gross structural models (Chapter 1 Section 1.14) 
suggests that hIAPP oligomers ≥4-mer in size adopt relatively extended 
conformations i.e. when hIAPP oligomers grow beyond a tetramer, the measured 
CCS values cannot be explained by isotropic or spherical growth (Figure 4-2d). 
Further, the size, order and CCS of the oligomers observed are independent of ionic 
strength (Figure 4-2d), despite being formed and consumed at different rates. 
These data suggest that hIAPP oligomers form relatively elongated structures, 
particularly at higher orders (≥4-mer).  A degree of order is likely, however, given 
that given that the number of charges carried by each oligomer is never 
significantly more than its number of monomer subunits. Occupying highly 
unstructured conformations would result in oligomers to carrying a larger number 
of charges (216).  
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Figure 4-2. Dependence of hIAPP oligomer and fibril formation on ionic strength. a) 
ThT fluorescence intensity of hIAPP (50 µM peptide, 37 ˚C, 600 rpm) in 20 mM 
(squares/purple line), 100 mM (triangles/orange line) or 500 mM (circles/green 
line) ammonium acetate buffer, pH 6.8. A typical data set is shown, the experiment 
was performed over 5 replicates.  b) The inset shows a representative negative stain 
TEM image of hIAPP fibrils after 5 days in 100 mM buffer  (37 ˚C, 600 rpm) (scale bar 
= 100 nm). c) ESI-IMS-MS driftscope plots of hIAPP oligomers present at t= 2 min (left 
hand side) and t = 5 hours (right hand side) at different ionic strengths (20 mM, 100 
mM and 500 mM).  d) CCSs of hIAPP oligomers measured using ESI-IMS-MS plotted 
versus oligomer order showing that oligomers have the same CCS regardless of ionic 
strength: 20 mM (squares), 100 mM (triangles) and 500 mM (circles). The orange 
dashed line represents a globular fit based on the average density of a protein (0.44 
Da/Å3) (215); the grey dashed line represents a linear growth model (46) and the 
green dashed line represents an isotropic growth model (46). 
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 Non-amyloidogenic rIAPP  forms a similar array of 4.2.2
oligomers to hIAPP 
 
As discussed in Chapter 1 Section 1.11,  rIAPP does not form ordered amyloid 
fibrils under any previously characterised conditions (109). Despite its lack of 
amyloidogenicity, using ESI-IMS-MS, a similar array of oligomers for rIAPP was 
observed compared with that detected for hIAPP (Figure 4-3a, Table 4.1). Indeed, 
oligomers corresponding to monomer through hexamer, inclusively, were 
observed for the rIAPP peptide within 2 mins of dilution into buffer. Consistent 
with the data for hIAPP, multiple conformers are observed for the rIAPP monomer 
and oligomers, albeit at different relative intensities compared with those 
observed for hIAPP. Importantly, hIAPP monomer and oligomers consistently 
occupy a greater relative proportion of more expanded conformers than rIAPP 
(Figure 4-4).  
Although rIAPP has been reported previously not to form amyloid fibrils (109), 
turbidity measurements (Figure 4-3b) and TEM images (Figure 4-3c) 
demontrates that under the conditions employed here (20 mM ammoumium 
acetate, pH 6.8, 1% DMSO (v/v)) rIAPP forms small globular aggregates that scatter 
light. Despite some aggregation, the inability of rIAPP to form amyloid under the 
conditions employed was confirmed by the lack of fibrils observed using TEM 
(Figure 4-3c) and the lack of ThT fluorescence increase over a 20 h incubation 
period (Figure 4-3d).  
The rIAPP oligomers observed are similar in CCS, as well as size and mass, to those 
of hIAPP (Table 4.1, Figure 4-4 & Figure 4-5). The vastly different amyloid 
competencies of the two sequences, therefore, is not solely dependent on having 
oligomers of different numbers of subunits and/or CCS.  
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Figure 4-3. Oligomers formed from rIAPP resemble those of hIAPP. a) ESI-IMS-MS 
driftscope plot of rIAPP oligomers present at 2 min after dilution into 20 mM 
ammonium acetate buffer, pH 6.8 to a final peptide concentration of 50 µM. The 
number adjacent to each peak denotes oligomer order with charge state of the 
oligomer in superscript. b) Aggregation of rIAPP (diamonds) and hIAPP (circles) 
monitored using turbidity at 635 nm. In both cases, 50 µM peptide was incubated in 
20 mM ammonium acetate buffer, pH 6.8 (37 ˚C, 600 rpm). A typical data set is 
shown, the experiment was performed over 5 replicates. c) Negative stain TEM image 
of rIAPP aggregates after 5 days of incubation (37 ˚C, 600 rpm); scale bar = 100 nm. 
d) ThT fluorescence intensity of rIAPP (50µM peptide, 37 ˚C, pH 6.8, 600 rpm). The 
data are normalized to the signal intensity of a hIAPP fibril formation end point at 
the same peptide concentration. 
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Figure 4-4. Comparisons of hIAPP and rIAPP oligomers detected by ESI-IMS-MS. a) 
CCS of hIAPP oligomers (red) and rIAPP oligomers (blue) measured using ESI-IMS-
MS plotted versus oligomer order. Experimental error is ± 5% for all cross sections. b) 
Arrival time distribution (ATD) of the hIAPP (red) and rIAPP (blue) 3+ dimer (i) and 
3+ monomer (ii). The arrow highlights the second conformation of each ion. 
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Figure 4-5.  rIAPP oligomer cross sections. CCS of rIAPP oligomers measured using 
ESI-IMS-MS versus oligomer order for all charge states. The orange dashed line 
represents a spherical growth model based on the average density of a protein (0.44 
Da/Å3) (62, 215); the purple dashed line represents a linear growth model (46) and 
the green dashed line represents an isotropic growth model (46). 
 
 CID reveals differences in gas-phase stability between hIAPP 4.2.3
and rIAPP oligomers and monomers 
 
As discussed in Chapter 1 Section 1.6, the use of hybrid instruments such as the 
Synapt HDMS employed here allows peptide samples to be characterised using 
MS/MS by CID. During CID-MS/MS experiments, precursor ions of a specific m/z 
are selected in the first mass analyser before being accelerated, collided with the 
buffer gas molecules and unfolded or fragmented. The energies at which the ions 
unfold or fragment reveals their relative gas phase stabilities (217). 
To compare the stabilities of the hIAPP and rIAPP monomers, the dependence of 
the ATD profiles versus increasing the Trap energy was examined (Figure 4-6). 
Using CID-MS/MS, the triply charged hIAPP and rIAPP monomers (m/z 1301 and 
1307, respectively) were selected using the quadrupole analyser and subjected to 
increasing Trap voltages in order to unfold the ions. After collisions in the Trap 
cell, differentially-folded ions enter the ion mobility cell and unfolding can be 
observed in the ion’s ATD profiles. More unfolded monomeric conformers will be 
observed at longer drift times with respect to the more compact species. In 
addition, the overall profile should become wider and hence the conformational 
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ensemble more heterogeneous upon unfolding. The results of these experiments 
showed that hIAPP monomer 3+ ions unfold at lower Trap collision energies than 
those required for the rIAPP monomer, with hIAPP more readily converting to 
expanded conformers at lower trap voltages (Figure 4-6). At low Trap energies of 
10 V, the ATD profiles of hIAPP and rIAPP monomers are narrow and exist 
apparently as one dominant conformation with a drift time of 6 ms and a lowly 
populated, more expanded conformer observed as a tail at ~10.5 ms. The latter 
species is more pronounced in hIAPP compared with rIAPP (Figure 4-6). At high 
Trap energies of ≥75 V, the entire ATD profile of the hIAPP 3+ monomer is shifter 
to longer drift times and a much larger proportion of more unfolded conformers 
are observed. In contrast, the rIAPP 3+ monomer ATD profile remains narrow and 
are indistinguishable from the ATD at 10 V when subject to high Trap energies, 
suggesting that it is more stable hence more resistant to gas-phase unfolding 
(Figure 4-6). 
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Figure 4-6. ATDs of 3+ monomers of hIAPP (a) and rIAPP (b) at trap collision cell 
voltages 10 V - 100 V. A 1 Da m/z window was used in selection of ions prior to CIU. 
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Next, the gas-phase stabilities of oligomers of hIAPP and rIAPP were probed to 
investigate whether their stability to gas-phase dissociation can be related to the 
differences in the ability of these sequences to form amyloid. These oligomers are 
not amenable to solution-phase stability assays, as they are so lowly populated. 
Accordingly, CID-MS/MS was utilised to provide a side-by-side comparison of the 
gas-phase stabilities of hIAPP and rIAPP peptides in their oligomeric states. In this 
experiment, ions of specific m/z were selected by the quadrupole analyser, 
followed by IMS separation of the different oligomers contributing to this m/z, and 
then sequential fragmentation of the oligomer ions in the transfer collision cell 
immediately prior to the time-of-flight analyser. In this instance, because ion 
mobility is performed before fragmentation, unfolding and/or fragmentation are 
not observed in ATD profiles, but instead dissociation is measured from the 
relative contributions of oligomer and monomeric ions to the spectra after time-of-
flight analysis. In keeping with the observations for the monomeric peptides, the 
data revealed that hIAPP dimers have significantly lower gas-phase stabilities 
when compared with rIAPP dimers. hIAPP dimers were found to dissociate into 
monomer at an energy (40 V) which is lower than that required for the equivalent 
rIAPP dimers, which only began to dissociate at 70 V (Figure 4-7a). It is worth 
noting that total relative ion intensity in the CID plots is greater than one, given 
that the ESI-MS spectra acquired were relative to the base peak in the spectrum, 
giving the base peak an ion intensity of 100% thus a total ion intensity that is 
>100%.  
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Figure 4-7. Differences between rIAPP and hIAPP dimer and monomer stabilities in 
the gas-phase measured using CID. a) Collision Induced Dissociation (CID) MS/MS of 
rIAPP (blue) and hIAPP (red) dimers (50 µM peptide, 20 mM ammonium acetate 
buffer, pH 6.8).  Relative intensity of the 3+ dimer ions (squares) of each peptide is 
plotted versus increasing ion-accelerating voltage into the transfer T-wave collision 
cell. Monomer ion intensity (diamonds) increases as dimers (squares) dissociate. Bar 
chart (inset) showing the appearance of hIAPP (red) and rIAPP (blue) monomer from 
dissociation of dimer ions with increasing CID voltage. b) Arrival time distributions 
(ATDs) of  3+ hIAPP monomer ions 2 min after dissolving into 50 mM (green), 100 
mM (orange), or 500 mM (purple) ammonium acetate, pH 6.8. Bar chart (inset) 
showing relative intensity of monomer ions with increasing ion-accelerating voltage 
at different ionic strengths; 50 mM (green), 100 mM (orange), and 500 mM (purple), 
(25 µM peptide, 50/100/500 mM ammonium acetate buffer, pH 6.8). 
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Figure 4-8. Differences between rIAPP and hIAPP tetramer stabilities in the gas-
phase measured using CID. a) MS/MS collision induced dissociation (CID) of rIAPP 
(blue) and hIAPP (red) tetramer ions. Relative intensity of the 6+ tetramer ion 
(squares) of each peptide is plotted versus increasing ion-accelerating voltage into 
the transfer T-wave device (CID). Monomer ion intensity (diamonds) and trimer ion 
intensity (circles) increase as tetramer ions (squares) become dissociated. b) Bar 
charts showing appearance of hIAPP (red) and rIAPP (blue) monomer from 
dissociation of tetramer ions with increasing CID voltage. 
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The significant difference in the gas-phase stability of the dimer ions of hIAPP and 
rIAPP could be related to the capability of hIAPP to access amyloidogenic 
conformations more easily than its rIAPP counterpart. This could help towards 
explaining why two similar sequences that form the same size and order of 
oligomeric states have significantly different amyloid propensities. Consistent with 
this view, hIAPP monomer ions become increasingly unfolded (Figure 4-7b) and 
dimer ions become less stable in the gas-phase as the ionic strength of the buffer 
used is increased (Figure 4-7b), suggesting that high ionic strength 
destabilizes/unfolds oligomers and increases the rate of amyloid fibril formation. 
It is also possible that high ionic strength aids the formation of structurally distinct 
oligomers that have altered gas-phase stability, rather than merely altering the 
packing of monomer units within structurally similar species. This finding gives 
further evidence to the hypothesis that peptide gas-phase stability is correlated 
with the amyloid competence of IAPP. Higher order oligomeric species, including 
tetramer ions with six charges, also showed subtle differences in stability for the 
two sequences, the hIAPP tetramer6+ ions beginning to dissociate at 30 V whereas 
rat tetramer6+ ions remained fully associated until 40 V (Figure 4-8).  Both the 
hIAPP monomer and its oligomers are, therefore, less stable than their 
counterparts for the rat sequence, and hIAPP becomes increasingly unstable at 
high ionic strengths. The results suggest, therefore, that hIAPP monomers and 
oligomers can accesses amyloid conformations more readily than rIAPP, and even 
more readily when the ionic strength of the buffer is increased. 
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 Probing the mechanism of inhibition of hIAPP fibril 4.2.4
formation with small molecules 
 
Having identified the pre-fibrillar, oligomeric states populated by hIAPP, the next 
aim was to attempt to inhibit the formation of these higher order species and 
hence to prevent fibrillation. The mechanism of action of two known small 
molecule inhibitors of hIAPP fibril formation (EGCG and silibinin), therefore, was 
investigated using ESI-MS and ESI-IMS-MS. These compounds have been shown to 
prevent hIAPP fibril formation (141, 218), but the point of assembly at which they 
act and their mechanisms of action remained elusive. In these experiments, hIAPP 
(50 μM) was incubated at 37 °C in 20 mM ammonium acetate buffer, pH 6.8, in the 
presence of EGCG (141, 218) or silibinin (219) at molar ratios of small 
molecule:hIAPP of 0.1:1, 1:1 or 10:1. The monomer and oligomer populations were 
characterised immediately and at various time points after incubation, using ESI-
IMS-MS. To complement the gas-phase analyses, fibril formation was monitored by 
ThT fluorescence and peptide aggregates were characterised using negative stain 
EM. The primary objectives here were to determine how the presence (or binding) 
of each small molecule affects the distribution of monomeric conformers and 
populations of oligomers and, whether such changes can be correlated with the 
inhibition of hIAPP amyloid formation, and hence to elucidate the precise mode of 
action of each small molecule inhibitor.  
 
4.2.4.1 The action of EGCG on fibril formation of hIAPP probed by 
ESI-IMS-MS 
 
EGCG, discussed in detail in Chapter 1 Section 1.12, is a polyphenol flavanol 
extracted from green tea that has shown promise as a generic anti-amyloid agent. 
EGCG has been found to redirect aggregating proteins (including hIAPP (158), α-
synuclein and Aβ42 (141)) onto alternative pathways (141), or to maintain them in 
a monomeric state (220). It has also been shown to promote re-modelling of 
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mature amyloid fibrils (218), with recent work of Kelly et al. demonstrating that 
hydrophobic binding to the amyloid fibril by EGCG promotes such re-modelling 
(221). To identify the effects of EGCG on hIAPP aggregation, the binding 
capabilities of the hIAPP monomer for EGCG was investigated. The results revealed 
that EGCG binds to monomeric hIAPP (~10% monomer remains bound in gas 
phase when present at a 10-fold molar excess over peptide) (Figure 4-9a) and 
alters the equilibrium of monomer charge states present. The monomer 3+ ion 
becomes more highly populated in the presence of EGCG (compare Figure 4-1b 
and Figure 4-9a), with a change in ratio of 3+:2+ monomer in the spectra changing  
from ~1:2 to ~1:1.25. The observed ligand binding results in inhibition of the 
peptide’s assembly into higher order oligomers and amyloid fibrils no longer form 
(Figure 4-9b-d).  Binding of EGCG is observed to both of the charge states 
populated by the hIAPP monomer (2+ and 3+) (Figure 4-9a), and, indeed, to each 
monomeric conformer (both the expanded and the compact form of each charge 
state), (Figure 4-10). One or two copies of EGCG bind to one doubly-charged 
monomer and up three EGCG molecules bind to the triply-charged monomer, when 
EGCG is present at a 10-fold molar excess over hIAPP (Figure 4-9a). The low level 
of binding observed, despite complete inhibition of fibrillation (Figure 4-9b), is 
suggestive of a hydrophobic binding mechanism. It is possible that a greater 
proportion of the hIAPP monomers and bound by hIAPP in solution but that the 
ligands dissociate upon entry into the gas-phase given that hydrophobic 
interactions are not wholly maintained within the mass spectrometer.  A 
hydrophobic binding mechanism, consistent with that proposed by Kelly et al.,  
may help towards explaining the ability of EGCG to inhibit a wide range of natively 
unfolded polypeptides and IAPP mutants (156). 
ESI-IMS-MS data (Figure 4-9c and Figure 4-11) reveal that incubation with 
increasing molar ratios of EGCG:hIAPP prevents assembly into higher order 
oligomers, in a dose-dependent manner. At 0.1:1 and 1:1 molar ratios of 
EGCG:hIAPP, monomer through tetramer hIAPP oligomers are observed (Figure 
4-9c), but no pentamer or hexamer (monomer through hexamer are observed in 
the Driftscope plot of hIAPP incubated in isolation (Figure 4-1b)). At a 10:1 molar 
ratio of EGCG:hIAPP, no species greater than monomer are observed (Figure 
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4-9c). Under the latter conditions, there is no increase in ThT fluorescence and 
TEM images (Figure 4-9d panel iii) do not show any aggregated material, 
indicating complete inhibition of both aggregate and amyloid formation. Together, 
these results demonstrate that EGCG binds to, and traps, low order species, 
preventing the formation of higher order oligomers. This small molecule also 
differentially stabilises distinct monomeric charge states of hIAPP. The result of 
these combined observations is that amyloid fibrils cannot form.  An alternative 
explanation is that EGCG diverts low order oligomers of hIAPP onto other 
aggregation pathways that result in the formation of non-amyloid aggregates. In 
the latter scenario, oligomers populated must be of low abundance, low ionisation 
propensity, or too heterogeneous to be detected by ESI-IMS-MS. 
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4.2.4.2 Remodeling of mature IAPP fibrils by EGCG 
 
In addition to its ability to interfere with amyloid assembly (141), EGCG has been 
shown previously to interact with pre-formed amyloid,  remodelling a range of 
fibrils, including those formed from hIAPP (141, 158), into amorphous aggregate. 
Having determined the effect of EGCG on the pre-fibrillar aggregation landscape of 
hIAPP, the effect of this small molecule on the reverse reaction, fibril 
depolymerisation, was investigated. TEM was used to monitor fibril loss over time 
and ESI-IMS-MS was used to investigate how fibril re-modelling by EGCG alters the 
populations of pre-fibrillar oligomers. Fibril samples were first formed by 
incubation of hIAPP (50 µM) in the absence of small molecule at pH 6.8 for 5 days. 
A 10-fold molar excess of EGCG was then added to fibrillar samples were further 
incubated in 20 mM ammonium acetate buffer, pH 6.8 (37 °C, 600 rpm) for 5 days. 
The loss of fibrils and change in lower order species were monitored, by TEM and 
ESI-IMS-MS, respectively, at various time points after addition of the EGCG. Under 
the conditions employed, clumping of hIAPP fibrils followed by re-modelling into 
amorphous aggregates over a 24 h period was observed (Figure 4-9d iv-vi.). This 
remodelling is concomitant with a subtle increase in intensity of the signal arising 
from monomer ions, measured using ESI-IMS-MS, compared with the same sample 
prior to addition of EGCG (Figure 4-11a iv and b iv). The lack of higher order 
oligomers, however, suggests that fibril re-modelling by EGCG is not the reverse of 
amyloid formation and does not result in the re-formation of pre-fibrillar 
oligomeric species.  
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Figure 4-9. Inhibition of hIAPP fibril formation by EGCG. a) Positive ion ESI mass 
spectrum showing binding of EGCG (added at 500 µM to 50 µM peptide) to both the 
+2 (orange) and +3 (purple) charge state ions of hIAPP monomer. Stoichiometry of 
binding is shown by colour: 1:1 inhibitor molecule bound to an IAPP monomer is 
highlighted in green, 2:1 in pink and 3:1 in blue. EGCG is shown as an inset. b) ThT 
fluorescence intensity of hIAPP (black) (50 µM peptide, 20 mM ammonium acetate 
buffer, pH 6.8, 37 oC, 600 rpm) with increasing EGCG:hIAPP molar ratios: 0.1:1 (pink) 
and 1:1 (orange) and 10:1 (blue). c) ESI-IMS-MS driftscope plots of hIAPP oligomers 
formed in the presence of (i) 0.1:1, (ii) 1:1 and (iii) 10:1 molar ratios of EGCG:peptide 
monomer at t= 5 hours. The number of EGCG molecules bound to each species is 
shown as a colored dot. d) Negative stain TEM images of hIAPP incubated with (i) 
0.1:1, (ii) 1:1 and (iii) 10:1 molar ratios of EGCG for 5 days (37 oC, 600 rpm). (iv) 
hIAPP fibrils alone, and aggregates formed when a 10-fold molar excess of 
EGCG:hIAPP is added to preformed hIAPP fibrils after 5 h (v)  and 24 h (vi), scale bar 
is 100 nm. 
 
 
 
Figure 4-10. EGCG binds to all conformers of IAPP. Arrival time distributions (ATDs) 
show that the 3+ monomer ions of hIAPP occupy two conformers (tD = ~6 & 8 ms) (a 
i) and the 2+ monomer ion also occupies two conformers (tD = ~7.6 & 10.6 ms) (b i).  
EGCG binds to the both the expanded conformer (green/red) and to the compact 
conformer (orange/blue) of both the 3+ and 2+ monomer ions (a and b ii-iii). 
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Figure 4-11. IMS Time courses of inhibition of hIAPP oligomer formation by EGCG. 
Driftscope plots of hIAPP oligomers formed in the presence of 0.1:1, 1:1 or 10:1 molar 
ratios of EGCG at t= 2 min/’0 h’ (a)  and t= 5 hours (b). The right hand driftscopes 
shows hIAPP alone after 24 h incubation (a iv) and after subsequent addition of a 5-
fold molar excess of EGCG (b iv) (ammonium acetate buffer pH 6.8, 37oC, 600 rpm). 
Circles represent number of bound EGCG molecules. 
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4.2.4.3 The action of silibinin on fibril formation of hIAPP probed 
by ESI-IMS-MS 
 
Silibinin, a flavonol extracted from seeds of the herb milk thistle, has been 
proposed as a potential therapeutic for amyloidosis associated with T2DM (219). 
Here, the precise nature of the interaction of this small molecule with hIAPP was 
also probed using ESI-IMS-MS. The resulting data (Figure 4-12a) revealed that 
silibinin binds only to the 3+ charge state ions of monomeric hIAPP (~20% 
remaining bound in the gas phase), with no detectable binding to the 2+ charge 
state ions of the monomer. This preferential binding to one monomeric charge 
state could be indicative of the selectivity of the small molecule, or alternatively 
could be explained by the low abundance of the 2+ charge state in its presence.  
Similar to the observation in the presence of EGCG, but more pronounced, the 
presence of a 10:1 molar ratio of silibinin alters the equilibrium of the two 
different charge states of monomeric hIAPP, favoring the population of the triply-
charged monomer ions. The ratio of 3+:2+ monomer in the spectra is altered from 
~1:2 to ~3:1 between the absence and presence of a ten-fold molar excess of 
silibinin, respectively (compare Figure 4-1 and Figure 4-12a). ESI-IMS-MS data 
indicate that silibinin prevents hIAPP oligomer formation even when present at 
sub-stoichiometric ratios of silibinin:hIAPP (Figure 4-12b and Figure 4-13). More 
specifically, detailed analysis of the ESI-IMS-MS data reveals that the binding of 
silibinin is only observed to the more expanded conformer of the 3+ monomer ions 
(Figure 4-12c) 5-5but does not significantly impact the ratio of monomeric 
conformations present. This expanded conformer (CCS=~790 Å2) is adopted by the 
hIAPP monomer but not by the rIAPP monomer (Figure 4-4b ii.). Indeed, there is 
no detectable binding of silbinin to the rIAPP monomer, which lacks this 
conformation, when analysed under identical conditions (Figure 4-14). 
Interestingly, Bowers et al. have previously proposed that this expanded 
monomeric conformer is an on-pathway, amyloid-competent conformation which 
precedes the generation of extended dimers and beta-sheet rich oligomers (47, 
48). Specific binding to this expanded hIAPP monomer conformation is thus  
consistent with the ability of silibinin to inhibit amyloid assembly. ThT data 
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(Figure 4-12d) demostrate that aggregation of hIAPP decreases significantly as 
the concentration of silibinin is increased, although in a 10-fold molar excess of 
silibinin a weak positive ThT signal is still observed (Figure 4-12d), likely due to 
the presence of small aggregates not visible by ESI-IMS-MS. TEM images indicated 
that incubation of monomeric hIAPP with silibinin for 5 days leads to few 
aggregates, with none visible by TEM when a 10-fold molar excess of 
silibinin:hIAPP is added (Figure 4-12e i-iii).  
 
4.2.4.4 Re-modelling of mature IAPP fibrils by silibinin 
 
Although silibinin has been shown previously to inhibit the forward reaction of 
amyloid assembly by hIAPP (219), unlike studies on EGCG, the interaction of 
silibinin with pre-formed amyloid fibrils had not been reported. Pre-formed hIAPP 
fibrils were incubated, therefore, with a 10-fold molar excess of silibinin and the 
effect of addition of the small molecule on the disassembly reaction was monitored 
using TEM and ESI-IMS-MS. The results showed that addition of silbinin results in 
the de-polymerisation of pre-formed fibrils over a 24 h time period during which 
time fibrils decrease in length (Figure 4-12e iv-vi). Concomitant with fibril 
depolymerisation observed by TEM, ESI-IMS-MS revealed a increase in abundance 
of low-order oligomeric species (Figure 4-13b). The re-population of hIAPP 
oligomers suggests that de-polymerisation may occur via oligomer release. 
Alternatively, monomer release may result in the rapid re-formation of oligomers 
in solution, i.e. the forward reaction is re-established. CCS measurements reveal 
that the hIAPP oligomers re-formed upon fibril de-polymerisation are comparable 
in size and shape to those formed during amyloid formation. 
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Figure 4-12. Inhibition of hIAPP fibril formation by silibinin. a) Positive ion ESI mass 
spectrum  showing binding of silibinin molecules (added at 500 µM to 50 µM peptide) 
0.1:1  1:1  10:1 
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to the 3+ monomer ions (purple) and absence of binding to the 2+ monomer ions 
(orange) at a molar ratio of silibinin:hIAPP of 10:1. The structure of silibinin is inset. 
b) ESI-IMS-MS driftscope plots showing the lack of hIAPP oligomers in the presence of 
0.1:1, 1:1 and 10:1 molar ratios of silibinin:hIAPP at t= 5 hours. c) Arrival time 
distribution of 3+ monomer ions shows two conformers are present (tD = 6 & 8 ms).  
Silibinin binds to the expanded conformer of the 3+ monomer ions (pink) but does not 
bind detectably to the compact conformer (blue). d) ThT fluorescence intensity of 
hIAPP (black) (50 µM peptide, 20 mM ammonium acetate buffer, pH 6.8,  37 oC, 600 
rpm) with increasing silibinin:hIAPP molar ratios: 0.1:1 (pink), 1:1 (orange) and 10:1 
(blue). e) Negative stain TEM images of hIAPP incubated with (i) 0.1:1, (ii) 1:1 and 
(iii) 10:1 molar ratios of silibinin:hIAPP for 5 days (37 oC, 600 rpm). Lower panels 
show hIAPP fibrils alone (iv) and aggregates formed when a 10-fold molar excess of 
silibinin:hIAPP is added to preformed hIAPP fibrils after 5 h (v) and 24 h (vi), scale 
bar is 100 nm. 
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Figure 4-13. IMS Time courses of inhibition of hIAPP oligomer formation by silibinin. 
Driftscope plots of hIAPP oligomers formed in the presence of 0.1:1, 1:1 or 10:1 molar 
ratios of silibinin at t= 2 min (a) and t= 5 hours (b). The right hand driftscope plots 
show hIAPP alone after 24 h incubation (a panel iv) and after subsequent addition of 
a 5-fold molar excess of silbinin (b panel iv) (ammonium acetate buffer pH 6.8, 37oC, 
600 rpm). Circles represent number of bound silibinin molecules. 
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Figure 4-14. Positive ion ESI mass spectrum showing the absence of binding of 
silibinin to rIAPP monomers (added at 500 µM to 50 µM peptide) to the 3+ monomer 
ions (purple) and to the 2+ monomer ions (orange) at a molar ratio of silibinin:rIAPP 
of 10:1. Zoomed regions of the spectra at which bound peaks would appear are inset. 
 
 
 Formation of hetero-oligomers and hetero-fibrils of hIAPP 4.2.5
and rIAPP 
 
A range of peptide inhibitors has been developed against hIAPP (222-225). The 
lack of structural information available on the intermediate states occupied by the 
peptide has made it difficult, however, to rationalise why some are more effective 
than others. The rIAPP peptide has been used previously as the basis for design of 
an FDA approved therapy to treat T2DM (226), despite being only a moderately 
effective inhibitor of hIAPP amyloid formation when added at equimolar 
concentrations (114).  A recent two-dimensional infrared spectroscopy study by 
Zanni et al. revealed that the non-amyloidogenic rIAPP peptide can become 
amyloid-competent in the presence of hIAPP, converting from a natively 
disordered rIAPP monomer into an ordered β-sheet rich complex with hIAPP 
(227). To determine why the rIAPP peptide is an ineffective inhibitor of hIAPP 
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assembly and to identify how the hIAPP-rIAPP complex forms, ESI-IMS-MS was 
used to study the oligomeric structures present in a mixture (1:1 molar ratio) of 
the two peptides.  
By contrast with the decrease in oligomer populations of hIAPP observed in the 
presence of the two small molecule inhibitors studied in Section 4.2.4 (EGCG and 
silibinin), oligomers up to, and including, hexamer are observed upon incubation of 
the hIAPP and rIAPP at a 1:1 molar ratio (Figure 4-15a), comparable with results 
observed when each peptide is incubated in isolation. Consistent with previous 
reports suggesting that the rat peptide must be present in an ~10-fold molar 
excess to inhibit hIAPP amyloid formation (114, 227), the presence of equimolar 
rIAPP does not prevent fibrillation of hIAPP under the conditions of these 
experiments (Figure 4-15b). The fibrils formed from the mixed sample were of 
similar morphology (long, straight) to those formed by hIAPP in isolation, as 
judged by TEM (Figure 4-15c). Mixed oligomers were observed using ESI-IMS-MS 
with m/z values corresponding to all-hIAPP, all-rIAPP and oligomers containing a 
mixture of hIAPP and rIAPP monomer subunits. The triply-charged dimer ions 
(Figure 4-15a, inset), for example, have an m/z of 2608, corresponding to one 
hIAPP monomer  (3904 Da) and one rIAPP monomer (3921 Da), carrying three 
positive charges. Mixed trimers (2:1 and 1:2 hIAPP:rIAPP monomer units) and 
higher order oligomers were observed also, as well as homo-oligomers of both 
peptides. The ability to form mixed oligomers helps explain why rIAPP is 
inefficient at inhibiting hIAPP amyloid formation. After co-incubation of the two 
peptide sequences for 5 days, fibrils formed were ultra-centrifuged and 
depolymerised by incubation in 100% HFIP for 24 h with agitation (Chapter 2 
Section 2.4.4). Samples were then air-dried and re-suspended in denaturing 
solvent (50:40:10 acetonitrile/water/acetic acid (v/v/v)). Crucially, the resulting 
mass spectra (Figure 4-15d i) revealed that  both hIAPP and rIAPP monomer 
subunits are incorporated into the fibrillar state, with approximately twice as 
many hIAPP monomer units being incorporated into the fibrils compared with 
rIAPP monomers under the conditions employed. Both monomers were also found 
in the supernatant of the original mixed sample, with rIAPP monomers being in 
excess in this fraction (Figure 4-15d ii).  
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Figure 4-15. Lack of hIAPP inhibition by rIAPP. a) ESI-IMS-MS driftscope plot of 
oligomers present at t= 2 min in a mixed sample of hIAPP and rIAPP at a 1:1 molar 
ratio (50 µM final peptide concentration, 20 mM ammonium acetate buffer, pH 6.8, 
25 oC). Extracted driftscope peak shows masses corresponding to a mixed dimer of 
one hIAPP monomer and one rIAPP monomer (inset). b) ThT fluorescence intensity of 
hIAPP: rIAPP 1:1 (50 µM final peptide concentration, 20 mM ammonium acetate 
buffer, pH 6.8, 37 oC, 600 rpm). Data for three replicates are shown. c) Negative stain 
TEM image of 1:1 hIAPP: rIAPP fibrils after 5 days. Scale bar = 100 nm. d) ESI mass 
spectra of depolymerized fibrils showing the presence of both hIAPP and rIAPP 
monomer constituents in the (i) pellet and (ii) supernatant following 
ultracentrifugation. 
CID-MS/MS was next utilised in order to probe the stability of the hetero-
oligomers formed from the 1:1 hIAPP:rIAPP mixture by subjecting the hetero-
dimer and hetero-tetramer ions to increasing transfer collision cell voltages to 
promote gas-phase dissociation. Interestingly, the hetero-oligomers exhibited 
intermediate gas-phase stabilities with respect to homo-oligomers of hIAPP and 
rIAPP of the same mass, being less stable than rIAPP oligomers, but more stable 
than hIAPP oligomers (Figure 4-16.). The data indicate that mixing of the two 
sequences does not greatly perturb the amyloid competence of the human 
sequence but does enhance the amyloid competence of the rat sequence. The 
intermediate stabilities of the mixed assemblies, however, suggest a compromise 
in the properties of the two sequences with respect to homo-assemblies. 
Taken together, therefore, the ESI-IMS-MS and CID-MS/MS data suggest that 
differences in gas-phase stability of monomer and low order oligomers between 
hIAPP and rIAPP sequences could be related to their differences in amyloid 
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propensity. Indeed, de-stabilisation of the monomeric or oligomeric states, either 
due to changes in amino acid sequence or conditions, correlates with increased 
amyloid propensity, as seen in the comparison of the hIAPP and rIAPP stabilities 
and the salt-dependence experiments, respectively. 
 In addition, small molecule binding to amyloidogenic hIAPP sequence prevents its 
assembly into fibrils by preventing oligomer assembly via binding to monomers. 
As a result, the aggregation pathway is diverted to alternative routes that result in 
the formation of low order species and/or amorphous aggregates.  
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Figure 4-16. Differences between the gas-phase stabilities of hIAPP, rIAPP and 
hIAPP/rIAPP mixed oligomers, measured using CID. a) Collision induced dissociation 
of mixed (a) dimers and (b) tetramers. a) The relative intensity of the 3+ mixed dimer 
ions (squares) plotted against increasing ion-accelerating voltage into the transfer T-
wave device. hIAPP (red) and rIAPP (blue) are also plotted for comparison. b) The 
relative intensity of the mixed 6+ tetramer ions (squares) plotted against transfer 
voltage. Monomer (circle) and trimer (diamonds) ions appear with increasing CID 
voltage and trimer ion intensity subsequently decreases again as they are dissociated 
to monomer. In both cases mixed oligomers show intermediate stability with respect 
to oligomers formed from hIAPP alone and rIAPP alone. 
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4.3 Discussion 
 
The study of pre-fibrillar amyloid oligomers is a significant challenge, yet is vitally 
important for the unravelling of the complex mechanisms underlying protein 
aggregation in disease. In order to determine the specific culprits of toxicity and to 
design therapeutics to prevent their formation, all species on the energy misfolding 
and aggregation landscapes, both on- and off-pathway, must be identified and 
characterised. Here, using ESI-IMS-MS, oligomers of hIAPP and rIAPP have been 
characterised in detail for the first time, and their structures and relative gas-
phase stabilities compared.  
Previous IMS-MS data from Bowers and co-workers suggested that hIAPP 
monomer and dimer undergo a conformational transition to an extended structure 
early in amyloid assembly (47, 48). Here, populations of monomer through 
hexamer have been detected, using ESI-IMS-MS, for both peptides. The hIAPP and 
rIAPP oligomers may assemble via monomer addition, since every species from 
monomer to hexamer is observed. No further monomer association into higher 
order oligomers is observed for hIAPP.  Fibril formation may, therefore, occur 
either without a population of larger oligomeric intermediates, or with higher 
order states being occupied that are too lowly populated, too transient or too 
heterogeneous to be detected by ESI-IMS-MS. 
CCS calculations of hIAPP oligomers indicate that elongated species, rather than 
globulamers, are popluated, akin to the oligomers observed during β2m assembly 
into amyloid (93). Interestingly, oligomers of rIAPP are similar in size and CCS to 
those of hIAPP, as judged by ESI-IMS-MS, but are significantly more stable in the 
gas-phase as judged by CID experiments. Although solution-phase stability cannot 
be directly inferred from gas-phase stability (5, 228) the difference in stability 
observed may help towards explaining the difference in amyloid competence of the 
two peptides.  Assuming that a conformational change is necessary for fibril 
formation, the greater stability of the rIAPP peptide may impede the structural re-
organisation required for amyloid assembly whereas the less stable hIAPP peptide 
may transition readily.  
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It was also revealed that hIAPP and rIAPP can form hetero-oligomeric species en 
route to hetero-fibrils in vitro, thus rationalising why rIAPP is an inefficient 
inhibitor of hIAPP amyloid formation. In theory, rIAPP would be expected to be a 
good inhibitor of hIAPP since it combines a recognition motif with a β-sheet 
breaker unit (114). This study highlights, therefore, the pitfalls associated with 
designing peptide inhibitors based on amino acid sequence. 
Having characterised the hIAPP oligomers, the binding and mode of action of two 
potent small molecule inhibitors of hIAPP (EGCG and silibinin) have been 
determined using ESI-IMS-MS. Data are presented which show show that both of 
the two small molecule inhibitors block oligomer and fibril assembly when added 
to hIAPP monomer, prior to initiation of assembly.  
Interestingly, the two small molecules show different binding characteristics and 
have different effects on the equilibrium of species present, yet both inhibit 
oligomerisation and fibrillation to a similar extent. EGCG was found to bind to both 
observed charge states of the hIAPP monomer, inhibiting early oligomer formation 
in a dose-dependent manner and preventing fibril formation. By contrast, silibinin 
was found to bind only to the most expanded conformer of the monomer 3+ ion 
within the dynamic ensemble of intrinsically disordered monomeric 
conformations, blocking oligomerisation and fibrillation. The inhibitory effect of 
silibinin, despite such specific binding, supports the notion of the role of the 
extended state of the monomer 3+ species in the fibril assembly mechanism of 
hIAPP. The hIAPP conformer bound by silibinin is absent in rIAPP and hence this 
conformer may be an important amyloid precursor. Inhibition via monomer 
binding may inhibit assembly directly or, alternatively, binding may create a 
structure that associates with other monomers to generate non-amyloidogenic 
aggregates. EGCG and silibinin were found to be effective as amyloid inhibitors at 
sub-stoichiometric concentrations, suggesting that the small molecules may bind 
to oligomers, as well as the monomer. Due to the low intensity of oligomers in the 
presence of small molecules and the known disruption of hydrophobic interactions 
in the gas-phase, however, binding of small molecules to oligomeric species could 
not be observed by ESI-IMS.  
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Both EGCG and silibinin alter the equilibrium of the monomeric charge states of 
hIAPP present, with the presence of each small molecule favouring the population 
of the triply-charged monomer ions.  Binding to these extended species that may 
be direct amyloid precursors (47, 48) then prevents monomer self-assembly into 
amyloid.  ESI-IMS-MS studies on β2m have previously demonstrated that altering 
the equilibrium between different monomeric conformers can have profound 
effects on the assembly pathways (44), diverting protein assembly from the 
amyloid pathway (resulting in highly-ordered β-sheet rich fibrillar assemblies) to 
non-amyloid pathways (resulting in the formation of spherical/amorphous 
aggregates). For hIAPP, these alternative aggregation pathways are presumably 
kinetically or thermodynamically unfavourable in the absence of the inhibitory 
small molecules, but made feasible upon ligand binding to more highly charged 
(3+), unfolded hIAPP monomers. In addition to inhibiting the forward reaction of 
amyloid assembly, both EGCG and silibinin are capable of disaggregating pre-
formed hIAPP amyloid fibrils. Disassembly occurs in distinguishable manners for 
each small molecule, with EGCG remodelling fibrils into amorphous aggregates 
without reformation of low order oligomers, and silibinin depolymerising fibrils 
and re-establishing the pre-fibrillar array of monomer plus early oligomeric 
species. 
Early oligomeric states are widely believed to be key to protein self-assembly and 
subsequent toxicity in amyloid disease; therefore elucidation of their structure and 
dynamics of pre-amyloid oligomers is of vital importance. Here, using ESI-IMS-MS 
the conformational properties of hIAPP monomer and oligomeric structures have 
been interrogated, revealing that specific, lowly-populated hIAPP monomeric 
conformers are capable of binding small molecule ligands. Having identified 
monomer through hexameric forms of hIAPP, the effect of ligand binding on each 
individual species populated within heterogeneous amyloid mixtures prior to fibril 
formation was assessed. The experimental results obtained provide support for a 
route to hIAPP amyloid fibrils via monomer addition to form oligomers which have 
relatively elongated structures. Stability may be related to the amyloidogenicity of 
IAPP, given that hIAPP is less stable relative to the non-amyloidogenic rIAPP 
peptide. hIAPP, therefore, may more readily unfold and occupy more extended 
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monomer and oligomeric conformations that have increased amyloid propensity. 
Binding to, and stabilising amyloid-prone monomer conformations, thereby 
preventing their polymerisation, could be key to the mechanism of inhibition of 
amyloid by EGCG and silibinin. 
 
4.4 Conclusions 
 
The data presented herein, and previously by Bowers and co-workers (47, 48), 
support a hypothesis that hIAPP self-assembly into amyloid begins initially with 
the formation of extended structures. Binding of small molecule inhibitors to these 
amyloid-prone extended structures results in alteration of the distribution of 
conformers present and results in the inhibition of oligomerisation and fibril 
formation by hIAPP. The results obtained demonstrate that stability plays a role in 
the sequence-dependence of IAPP amyloid competence, given that oligomers of the 
non-amyloidogenic rat peptide are similar in size and shape to those of the human 
peptide, but the former oligomers are significantly more stable in the gas-phase. In 
addition, results are presented which demonstrate that the mixing of hIAPP and 
rIAPP sequences leads to co-polymerisation into hetero-oligomers and hetero-
fibrils, hence rationalising the lack of inhibition of hIAPP fibril formation by rIAPP.  
Having characterised in detail the monomeric and oligomeric species occupied by 
hIAPP and having demonstrated the suitability of ESI-IMS-MS for studying small 
molecule-hIAPP interactions, the project progressed toward the screening of novel 
inhibitors of amyloid assembly. 
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5 Screening and classifying small molecule inhibitors of 
amyloid formation using ion mobility spectrometry-
mass spectrometry 
5.1 Introduction 
 
The work described in this Chapter has been published in references (182, 229). 
Due to the complex mechanisms involved in amyloid diseases and the elusive 
nature of toxic species, commonly available therapies focus only on ameliorating 
the symptoms (127). There are, however, a number of promising therapeutic 
avenues currently being investigated, including the use of small molecule 
inhibitors to block and/or re-direct aberrant aggregation pathways. The ability to 
screen for small molecules that are able to interfere with protein aggregation, and 
assess their mode of action, is therefore instrumental in the quest for novel 
therapies against protein misfolding disorders. For folded proteins, structure-
based design can be utilised in order to create small molecules able to stabilise the 
native state and thus prevent the conformational changes that precede protein 
aggregation (230-232). For aggregation-prone proteins that are intrinsically 
disordered, discovery of novel small molecule inhibitors of aggregation is limited 
to screening assays that rely on relatively low resolution techniques, such as dye 
binding assays. The majority of biophysical techniques available lack the 
sensitivity and resolution to allow detection and individual characterisation of 
oligomeric states occupied during aggregation and, therefore, do not allow 
determination of the unique pre-fibrillar protein subspecies with which the small 
molecule inhibitor interacts (233). Another caveat is that dye binding assays are 
often compromised by competitive binding of the small molecule to the dye-
binding site on the protein and by inner filter effects which can interfere with the 
fluorescence of the dye (234, 235). 
ESI-IMS-MS circumvents the disadvantages of other in vitro screening techniques 
and enables the rapid identification of small molecule inhibitors, the 
characterisation of their mode of action, and the identification of the individual 
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subspecies with which the inhibitor interacts (44, 102, 181). In this chapter, the 
capability of ESI-IMS-MS to screen for, and analyse, the mode of interaction of a 
range of small molecules is demonstrated using hIAPP and Aβ40 as examples of 
aggregating systems. Screening using ESI-IMS-MS has a number of advantages over 
conventional biophysical screening methods: it is rapid (taking <1 
minute/sample), consumes low amounts of sample (~1000 molecules 
screened/mg protein), does not require sample labeling or immobilisation, and 
provides stoichiometric and conformer-specific information. In addition, colloidal 
inhibitors that self-aggregate and physically sequester proteins non-specifically 
(236), that may erroneously be classified as “hits” in other assays, are immediately 
identified. 
While several small molecules have been shown to inhibit the fibrillation of hIAPP 
and/or Aβ40 in vitro (102, 141, 144, 152, 157, 162, 237), including EGCG and 
silibinin detailed in Chapter 4, their mechanisms of action remain largely 
undetermined. Using the selection of small molecules described below (Section 
5.1.1), we demonstrate the ability of ESI-IMS-MS to differentiate and classify 
compounds that do not bind (‘negatives’), those that bind specifically (‘positives’), 
and those that interact non-specifically or colloidally, with hIAPP and Aβ40 
(Figure 5-1). Furthermore, we use the method developed to screen a further thirty 
compounds to demonstrate that it can be implemented in a high throughput mode 
and, in doing so, reveal new specific inhibitors of hIAPP and Aβ40 aggregation.  
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Figure 5-1. Schematic diagram of the basis of the ESI-MS screen and a selection of 
the small molecules utilised for screen validation. (a-d) Schematic of expected ESI 
mass spectra resulting from different interactions between peptide/protein monomer 
(denoted m) and potential inhibitors (denoted L). Oligomers are denoted o; charge 
states are in superscript. (a) A specific ligand (termed ‘positive’) will result in a 
binomial distribution of bound peaks (pink)(238); (b) the presence of a colloidal 
inhibitor will lead to spectra containing overlapping peaks resulting from the 
heterogeneous self-association of the small molecule (orange peaks); (c) a non-
specific ligand will bind and result in a Poisson distribution of bound peaks 
(green)(238); (d) the addition of a non-interacting small molecule (termed 
‘negative’) will result in spectra similar to those of peptide alone; (e) list of ten small 
molecules analysed initially for inhibition of hIAPP aggregation during ESI-MS screen 
validation. Colours correspond to binding-mode classification by mass spectra (a-d); 
specific = pink, colloidal = yellow, non-specific = green, negative = grey. Figure taken 
from Young et al. (182). 
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 Selection of small molecules used for screen validation 5.1.1
 
‘Positives’: Fast green FCF (FG) (1), a triarylmethane food dye, has been shown 
previously to inhibit amyloid formation by hIAPP (239) and is used here as an 
example of inhibition by specific binding. Previous studies, described in Chapter 4, 
have shown that EGCG (102, 156, 158, 240, 241) (2) and silibinin (102, 219) (3) 
also act as specific inhibitors of hIAPP amyloid formation and are included here for 
comparison. EGCG is the most well characterised ‘positive’ aggregation inhibitor of 
a variety of proteins (e.g. α-synuclein (162), hIAPP (102, 156, 158, 240, 241) and 
Aβ40/42 (141, 156, 162, 181)) both in vitro and in vivo (139, 141, 156, 157, 162, 
164, 242). In contrast, to our knowledge, silibinin has been reported to inhibit only 
hIAPP self-assembly (102, 219). 
‘Colloidal’: Congo red (CR) (4), a dye commonly used to detect the presence of 
amyloid fibrils (243), was reported initially to bind to numerous protein 
aggregates (132, 243, 244), prevent aggregation in vitro (133, 245) and reduce 
neurotoxicity in vivo (246, 247). It has since been reported, however, to function 
via a colloidal mechanism (236). This mode of inhibition is likely due to the ability 
of CR to self-assemble into micelle-like species, driven by stacking of its aromatic 
rings (248). 
‘Non-specific’: Tramiprosate (6) has been used as a negative control for hIAPP 
inhibition in vitro (237, 239). 1H-benzimidazole-2-sulfonic acid (1H-B-SA) (5), 
previously not assessed against hIAPP, was included in the analysis as it possesses 
a sulfonic acid moiety and is aromatic in nature, features known to be important 
for the interaction of small molecules with amyloid proteins and peptides (153). 
‘Negatives’: Benzimidazole (9), hemin (10) and the non-steroidal anti-
inflammatory drugs (NSAID) aspirin (7) and ibuprofen (8) contain charged and/or 
aromatic functional groups which are prevalent in known amyloid inhibitors, but 
have not been assessed previously for their interaction with hIAPP. Aspirin has 
been reported to inhibit fibrillogenesis of Aβ40 and Aβ42 (151, 249), and 
ibuprofen to reduce cognitive deficits in vivo and also to reduce Aβ aggregation in 
vitro (250, 251). Benzimidazole was used in the screen described here to 
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determine whether the interaction observed between hIAPP and 1H-B-SA could 
result from the presence of a negatively charged sulfonated group interacting with 
the positively charged hIAPP in the gas-phase. Hemin has been reported previously 
to inhibit fibrillogenesis of Aβ (144), however, it has not been assessed for its 
interactions with hIAPP. The mass of molecules 1-10 are listed in Table 5.1. 
No. Compound Average 
MW (Da) 
1 Fast Green FCF 
ethyl-[4-[[4 -[ethyl-[(3-sulfophenyl) methyl] 
amino] phenyl]-(4-hydroxy-2-sulfophenyl) 
methylidene]-1-cyclohexa-2,5-dienylidene]-
[(3-sulfophenyl) methyl] azanium 
765.9 
2 Silibinin 
(2R,3R)-3,5,7-trihydroxy-2-[(2R,3R)-3-(4-
hydroxy-3-methoxyphenyl)-2-
(hydroxymethyl)-2,3-dihydro-
benzo[b][1,4]dioxin-6-yl]chroman-4-one 
482.4 
3 EGCG 
[(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxy-
phenyl) chroman-3-yl] 3,4,5-
trihydroxybenzoate 
458.4 
4 Congo red 
4-amino-3-[4-[4-(1-amino-4-sulfonato-
naphthalen-2-
yl)diazenylphenyl]phenyl]diazenyl-
naphthalene-1-sulfonate 
652.7 
5 1H-benzimidazole-2-sulfonic acid 198.2 
6 Tramiprosate 
3-Aminopropane-1-sulfonic acid 
139.2 
7 Aspirin 
2-acetoxybenzoic acid 
180.2 
8 Benzimidazole 
1H-benzimidazole 
118.1 
9 Ibuprofen 
(RS)-2-(4-(2-methylpropyl)phenyl)propanoic 
acid 
206.3 
10 Hemin 
chloro[3,7,12,17-tetramethyl-8,13-
divinylporphyrin-2,18-
dipropanoato(2−)]iron(III) 
651.9 
Table 5.1. Molecular masses of small molecules initially screened, confirmed as MH+ 
ions using ESI-IMS. 
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5.2 Results 
 
 hIAPP forms oligomeric assemblies and fibrils in absence of 5.2.1
inhibitor  
 
As described in detail in Chapter 4 Section 4.2.1, hIAPP (Figure 5-2a), occupies 
monomeric through to hexameric states, inclusively, under aggregating conditions. 
These oligomers, which are readily observed using ESI-MS and ESI-IMS-MS 
(Figure 5-2b&c), appear and subsequently disappear as aggregation proceeds, 
resulting in the formation of long straight amyloid fibrils (Figure 5-2 inset). 
 
 
Figure 5-2. hIAPP forms an array of oligomeric species en route to long-straight 
amyloid fibrils. (a) Primary sequence of hIAPP. The peptide has a disulfide bridge 
between Cys-2 and Cys-7 and an amidated C-terminus; (b) ESI-MS mass spectrum of 
hIAPP. Numbers above peaks denote oligomer order, with the positive charge state of 
ions in superscript; (c) ESI-IMS-MS Driftscope plot of the hIAPP monomer (1) through 
hexamer (6), present 2 min after diluting the monomer to a final peptide 
concentration of 32 µM in 200 mM ammonium acetate, pH 6.8. ESI-IMS-MS 
Driftscope plots show IMS drift time versus mass/charge (m/z) versus intensity (z = 
square root scale). Inset: negative stain TEM image of hIAPP fibrils after 5 days in 
200 mM ammonium acetate pH 6.8 buffer (25 °C, quiescent) (scale bar = 100 nm). 
Figure taken from Young et al. (182). 
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 ESI-IMS-MS-based screening approach 5.2.2
 
10 compounds (Section 5.1.1 and Table 5.1) were evaluated initially in order to 
determine their mode of action and/or inhibition of hIAPP self-assembly (Figure 
5-1), based on their known effect on hIAPP aggregation. These compounds, or 
their analogues, have been proposed previously to inhibit, or not inhibit, amyloid 
formation, as described in Section 5.1.1. In each case, molar ratios of small 
molecule: hIAPP of 1:1 and 10:1 were used, with a hIAPP concentration of 32 µM in 
every case. Upon incubation of the peptide with each of the small molecules in 96-
well plates, samples were infused into the mass spectrometer via an automated 
sampler and the monomer and oligomer populations occupied were characterised 
immediately. Small molecule binding modes were then observed and classified 
(Section 2.2) (Figure 5-3). Depending on the system, this technique can be 
implemented successfully to determine and rank ligand binding affinities (252-
254). However, because hydrophobic interactions are not wholly maintained in the 
ESI-IMS-MS process, underestimation of binding affinity and/or false negative 
results are possible (228). For this reason, fibril formation was also monitored 
using ThT fluorescence and the morphologies of the resulting aggregates were 
assessed using negative stain TEM. The objectives of these analyses were to (i) 
observe interactions between amyloid peptide monomeric/oligomeric states and 
each small molecule; (ii) determine how these interactions affect the distribution 
of monomeric and oligomeric conformers populated; and (iii) elucidate whether 
any changes observed can be correlated with the inhibition (or lack of inhibition) 
of hIAPP amyloid assembly.  
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Figure 5-3. Schematic of the ESI-IMS-MS experimental procedure. The protein of 
interest (pink) is mixed individually with small molecules from a compound library in 
96-well plate format via a Triversa NanoMate automated nano-ESI interface, the 
samples are infused into the mass spectrometer, wherein separation occurs based on 
the mass to charge ratio (m/z) and collisional cross-sectional area (CCS). The small 
molecules are classified according to their protein-binding modes. Figure taken from 
Young et al. (229). 
 
 Mode of action of a positive inhibitor of hIAPP fibril 5.2.3
assembly 
 
One of the 10 compounds selected for preliminary analyses (Section 5.1.1 and 
Table 5.1) was Fast Green FCF (1) (FG), a known inhibitor of hIAPP fibril 
formation (239).  
Consistent with previous reports (239), ThT fluorescence and TEM (Figure 
5-4a,b) confirmed that FG inhibits fibril formation from hIAPP in vitro. The 
mechanism by which it inhibits assembly, however, has thus far remained elusive. 
Here, using ESI-IMS-MS, FG was found to bind to both the 2+ and 3+ monomer 
charge states of hIAPP (Figure 5-4c ii-iii).  
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Figure 5-4. Inhibition of hIAPP amyloid assembly by Fast Green FCF (FG). (a) ThT 
fluorescence intensity over time of hIAPP alone (black circles) (32 µM peptide, 200 
mM ammonium acetate buffer, pH 6.8, 25 °C, quiescent) and with increasing 
FG:hIAPP molar ratios: 1:1 (orange) and 10:1 (green), showing dose dependant 
decrease in formation of ThT-postive hIAPP species upon addition of FG. (b) Negative 
stain TEM images of hIAPP incubated with (i) 1:1 or (ii) 10:1 molar ratios of 
FG:hIAPP for 5 days (25 °C, quiescent) (scale bar = 100 nm), showing lack of 
fibrillation and formation of small/amorphous aggregate of hIAPP in the presence of  
FG. (c) Positive ion ESI mass spectra showing FG alone (i), or added at 32 µM (ii), or 
320 µM (iii), to hIAPP (32 µM). FG binds to the 2+ and 3+ charge state ions of hIAPP 
monomer (bound peaks denoted with orange or green circles; number of circles 
represents number of ligands bound), and to the 4+ charge state of the hIAPP dimer 
(bound peak denoted with white circle). This binding mode is classified as ‘positive’. 
Figure taken from Young et al. (182). 
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The work described in Chapter 4 (102), and that of others (48), has shown that 
each hIAPP monomeric charge state (2+ and 3+) populates at least two conformers 
(extended and compact, with the more expanded structure proposed to be 
amyloid-prone). Analysis of the ESI-IMS-MS data reveals that FG alters the 
distribution of charge states and the monomeric conformers present, increasing 
the relative abundance of the 3+ monomer ion (Figure 5-4c). In addition, the 
proportion of compact conformers is increased compared with those observed for 
hIAPP alone, especially obvious for the monomer 2+ ion (Figure 5-5). This ion 
appears to be significantly compacted in the presence of FG, with dominant 
conformer changing in drift time from 7.05 to 6.28 ms and a new, even more 
compacted species emerging with a drift time of 5.25 ms (Figure 5-5). 
 
Figure 5-5. Comparisons of hIAPP monomer drift times in the absence (black) or 
presence (green) of excess FG. (a) Arrival time distribution (ATD) of the hIAPP 3+ 
monomer ions displays one distinct conformer (drift time = ~5.8 ms) and a small 
component of a more extended conformation (drift time = ~7.0 ms) in the absence 
and presence of FG; (b) Arrival time distribution (ATD) of the hIAPP 2+ monomer 
ions displays two distinct conformers in the absence of FG (drift times = ~7.1 and ~9.6 
ms). In the presence of FG, the hIAPP 2+ monomer displays three distinct conformers 
(drift times = ~5.3, ~6.3 and ~9.6 ms); (c) ESI-IMS-MS Driftscope plots of monomeric 
conformers observed for hIAPP alone; and (d) when FG is present at a 10-fold molar 
excess over hIAPP. Monomer peaks are enclosed by white boxes. Circles represent 
number of FG molecules bound to each species. Figure taken from Young et al. (182). 
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The interaction of FG likely involves the sulfonated groups forming favorable 
electrostatic interactions with positively charged hIAPP at pH 6.8 (hIAPP pI ≃ 8.9). 
Consistent with this, the extent of binding is dependent on the buffer ionic strength 
(Figure 5-6a), with a lesser extent of binding being maintained as the ionic 
strength of the buffer is increased from 10 mM to 100 mM.  
 
Figure 5-6. Ionic strength dependence of ligand binding. Positive ion ESI mass 
spectra showing (a) FG; (b) EGCG; and (c) 1H-B-SA added at a 1:1 molar ratio to 
hIAPP (32 µM) in 10 mM (a. i, b. i, c. i) or 100 mM (a. ii, b. ii, c. ii) ammonium acetate 
buffer, pH 6.8. Ligand bound peptide peaks are highlighted in green (FG), pink 
(EGCG) and blue (1H-B-SA). Figure taken from Young et al. (182). 
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Factors other than electrostatic complementarity must contribute to the specific 
binding of FG, however, as not all sulfonated small molecules are inhibitors of 
hIAPP amyloid assembly (Section 5.1.1, Figure 5-1e and Figure 5-10). For the 
two other known positive inhibitors described in Chapter 4, EGCG (102, 157) (2) 
and silibinin (102, 219) (3), low levels of binding are observed, despite complete 
inhibition of fibrillation, indicative of hydrophobic interactions playing a role in the 
binding interface. Unlike the hIAPP-FG interaction, this mode of binding is 
relatively insensitive to buffer ionic strength (Figure 5-6b), with comparable 
amounts of ligand binding being observed as the ionic strength of the buffer is 
increased from 10 mM to 100 mM.    
 
 Colloidal inhibition characterized using ESI-IMS-MS 5.2.4
 
The influence of the presence of Congo red (CR) (4), a known colloidal inhibitor, on 
the self-assembly of hIAPP was analysed next (243). At a 1:1 molar ratio of hIAPP: 
CR, a small increase in the rate of fibril formation was observed (Figure 5-7a,b), 
with no significant change in the monomer or oligomeric states observed in the 
hIAPP mass spectrum (Figure 5-7a-c). However, at a 10:1 molar ratio of CR: 
hIAPP, no fibrillation was observed (Figure 5-7a,b). These data are consistent with 
previous reports that CR promotes fibril formation in some systems at low 
concentrations (255) but inhibits protein self-assembly when present at high 
concentrations (100-200 µM)(236).  
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Figure 5-7. Colloidal inhibition and non-specific binding observed using ESI-IMS. ThT 
fluorescence intensity of hIAPP (black) (32 µM peptide, 200 mM ammonium acetate 
buffer, pH 6.8, 25 °C, quiescent) with Congo red (CR):hIAPP molar ratios: 1:1 
(orange) and 10:1 (red) and with 1H-benzimidazole-2-sulfonic acid (1H-B-SA):hIAPP 
molar ratio: 10:1 (blue). Significant inhibition of the formation of ThT-positive 
species is observed only in the presence of excess  (10x)CR. (b) Negative stain TEM 
images of hIAPP incubated with 1:1 (i) or 10:1 (ii) molar ratios of CR or a 10:1 molar 
ratio of 1H-B-SA (iii) for 5 days (25 °C, quiescent) (scale bar = 100 nm). Fibrils are 
observed in the presence of equimolar CR and excess (10x) 1H-B-SA but not in the 
presence of excess (10x)CR. (c) Positive ion ESI mass spectra showing CR added at 32 
µM (i) or 320 µM (ii) or 1H-B-SA added at 320 µM (iii), to hIAPP (32 µM). CR is not 
observed to bind to hIAPP when added at 32 µM (i) or 320 µM (ii), however CR self-
aggregates at 320 µM (ii) (denoted nx+, where n is the number of CR molecules and x 
is the charge state of the aggregate (red peaks). This binding mode is classified as 
colloidal. Multiple copies of 1H-B-SA bind to the 2+ and 3+ charge state ions of hIAPP 
monomer (bound peaks denoted with blue circles, number of circles represents 
number of ligands bound), and to the hIAPP dimer (bound peaks denoted with white 
circles). This binding mode is classified as non-specific. Figure taken from Young et al. 
(182). 
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Using ESI-IMS-MS, it is possible to observe the self-association of CR at high 
concentrations (320 µM), with aggregates ranging in size from ~5-11 copies 
(Figure 5-8). No direct binding of CR monomer to monomeric hIAPP was observed 
(Figure 5-7c), consistent with colloidal inhibition resulting from supramolecular 
assemblies of CR inhibiting self-association of amyloid proteins at high ligand 
concentrations. 
 
 
Figure 5-8. ESI-MS spectrum of 320 µM Congo red (200 mM ammonium acetate, pH 
6.8), showing self-aggregation (5- to 11-mers). Figure taken from Young et al. (182). 
 
 Non-specific binding and lack of inhibition characterised 5.2.5
using ESI-IMS-MS 
 
Although not reported previously as an inhibitor of hIAPP amyloid formation, 1H-
B-SA (5) possesses both aromatic and anionic moieties known to be important for 
the interaction of small molecules with amyloid proteins and peptides (153). The 
mass spectrum of a 10:1 molar ratio of 1H-B-SA and hIAPP clearly demonstrates a 
non-specific binding profile which results in a series of ions with multiple ligands 
bound, following a Poisson-like distribution (238, 252) (Figure 5-7c iii.). As an 
interaction of this type (electrostatic/hydrophilic) is often determined by charge 
and size complementarity, it is less sensitive to structure but can be well 
maintained during the ESI process (252). Further, these types of interactions can 
be more stable in the gas-phase than hydrophobic interactions (254), such as 
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thoseproposed between hIAPP and EGCG (2)(102) thus resulting in more 
extensive ligand-binding being observed for non-specific interactions with respect 
to specific interactions. Consistent with this, the ion intensity of the 1H-B-SA: 
hIAPP complex is decreased at increased ionic strength (Figure 5-6c), with less 
intense bound peaks being observed when the ionic strength of the buffer was 
increased from 10 mM to 100 mM. Non-specific interactions can be distinguished 
from specific interactions (that show a binomial distribution (238)) by comparison 
of the binding profiles (Figure 5-1a and c). To confirm annotation as a non-specific 
binding ligand, a second analysis performed at lower ligand: peptide ratio may be 
required to avoid ambiguity that may arise by specific binding of molecules 
forming multiply bound complexes at high ligand: peptide ratios. ThT fluorescence 
and TEM data confirm that the non-specific binding of 1H-B-SA to hIAPP does not 
inhibit fibril formation by the peptide (Figure 5-7a,b). Similarly, the mass 
spectrum of a 10:1 molar ratio of tramiprosate (3-amino-1-propanesulfonic acid) 
(6) and hIAPP is also indicative of a non-inhibitory, non-specific interaction, which 
is confirmed by TEM (Figure 5-9).  
 
 
Figure 5-9. ESI-MS spectrum of hIAPP (32 µM) in the presence of tramiprosate(320 
µM). Protein-ligand bound peaks are coloured pink. Inset shows negative stain TEM 
image of fibrils formed by hIAPP when incubated with a 10:1 molar ratio of 
tramiprosate: hIAPP for 5 days (25 °C, quiescent) (scale bar = 500 nm). Figure taken 
from Young et al. (182). Contaminants in small molecule sample lead to peak 
broadening and adducts. 
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Although non-specific binding interactions between ligands and the amyloid 
protein are encountered in some instances due the nature of the screen, a lack of 
any interaction between ligand and peptide is the most likely scenario in the 
absence of an inhibitory effect. Indeed, for the compounds aspirin (7), ibuprofen 
(8), benzimidazole (9) and hemin (10) (Section 5.1.1 and Table 5.1), no evidence 
for binding to monomeric hIAPP, alteration in the monomer charge state 
distribution, or oligomer population, was observed using ESI-IMS-MS (Figure 
5-10).  In each case, incubation of hIAPP with an excess of a non-binding small 
molecule, fibrils were formed, as observed by TEM (Figure 5-10 a-d inset). Earlier 
studies using CD spectroscopy and Congo red binding assays incorrectly 
determined that aspirin is an inhibitor of hIAPP amyloid formation (256), 
demonstrating the efficacy of ESI-IMS-MS in circumventing false positive results. 
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Figure 5-10. Lack of inhibition of hIAPP amyloid assembly by (a) aspirin; (b) 
ibuprofen; (c) benzimidazole; and (d) hemin. Positive ion ESI mass spectra showing 
no observed binding when each small molecule is added at 320 µM to hIAPP peptide 
(32 µM). Insets: negative stain TEM images of hIAPP incubated with 10:1 molar 
ratios of small molecule: hIAPP for 5 days (25 °C, quiescent) (scale bar = 100 nm). 
Figure taken from Young et al. (182).The peak at m/z 2000 in the hIAPP + 10 x 
ibuprofen spectrum is an adduct that results from contaminants in the small 
molecule sample. 
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The relationship between the structure of a small molecule, including the 
functional groups that it possesses, with its ability to interact with a peptide or 
protein of interest is not straight-forward. Indeed, predicting the inhibitory 
potential of small molecules against amyloid formation from their structure alone 
is a significant challenge, demonstrated by the fact that analogues can show 
significant variability in aggregation inhibition. Rifamycin SV, for example, can 
block fibril formation by β2m, while other structurally similar rifamycins are 
ineffective (44). Similarly, derivatives of EGCG have marked differences in their 
inhibitory capacity (158), and no single feature of EGCG is crucial in determining 
inhibition (158). In order to investigate the diversity in hydrophobicity of the 
compounds tested and to determine whether there is any correlation with their 
ability to inhibit amyloid formation, the LogP value (the log of the 
aqueous/hydrophobic partition coefficient) of each small molecule was calculated 
using www.molinspiration.com software, which determines the hydrophobic 
parameters of the substituents (Figure 5-11). The LogP values of the positive 
inhibitors range from -4.4 (FG) to +2.2 (EGCG), demonstrating that polarity is not 
the only important factor required for binding to target. Both hydrophilic FG and 
hydrophobic EGCG inhibit hIAPP aggregation, confirming that the MS-based 
method for screening inhibitors is capable of observing both electrostatic and 
hydrophobic interactions between amyloidogenic peptides and aggregation 
inhibitors. 
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Figure 5-11. LogP values (the log of the aqueous/hydrophobic partition coefficient) 
were calculated for the ten small molecules. using www.molinspiration.com software, 
which determines the hydrophobic parameters of the substituents. Molecules with 
high +ve LogP values have high hydrophobicity and molecules with high -ve LogP 
values are highly polar. Colours denote inhibitor classification: positive (red), 
colloidal (yellow), non-specific (green) and negative (grey). Figure taken from Young 
et al. (182). 
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Further analyses using Collision Induced Dissociation (CID) MS/MS (Section 
2.2.4) showed that the specific inhibitors bind more tightly to hIAPP than their 
non-specific counterparts, as judged by the gas-phase stability of the peptide-
ligand complexes (Figure 5-12). The quadrupole analyser was used to select 
ligand-bound peptide ions and increasing collision energy was applied to the trap 
collision cell in 10 V increments from 10 to 100 V until the ligands were completely 
dissociated from the monomer ions. Quantification of precursor ion intensity 
relative to total ion intensity was calculated using area under peaks. 
Indeed, 1H-B-SA dissociates from hIAPP at lower collision energies (10 V) than 
that required to dissociate either the hydrophobically bound ‘positive’ EGCG or the 
electrostatically bound ‘positive’ FG, which begin to dissociate after 30 and 50 V, 
respectively. This MS/MS method of interrogation provides an additional means of 
selecting ligands for further analysis after the initial screening for binding has been 
performed.  
 
Figure 5-12. Differences between peptide-ligand complex stabilities in the gas-phase 
measured using Collision Induced Dissociation (CID). CID MS/MS of FG-hIAPP 
(green), EGCG-hIAPP (pink) and 1H-B-SA-hIAPP (blue) complexes (32 µM peptide, 
320 µM ligand, 200 mM ammonium acetate buffer, pH 6.8). Relative intensity of the 
2+ monomer ions bound to ligand is plotted versus increasing ion-accelerating 
voltage into the trap collision cell. Percentage of ligand associated is relative to base 
peak in spectrum, which in the case of FG and 1-H-B-SA is ligand bound peptide and 
in the case of EGCG is apo-hIAPP. Figure taken from Young et al. (182).  
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Arrival time distribution (ATD) plots from ESI-IMS-MS experiments also provide 
evidence for the type of interaction occurring. By extracting the whole-spectrum 
IMS-MS ATD data, observation of the average conformation of species present 
within a heterogenous mixture is enabled. The samples may consist of a mixture of 
protein-only species, ligand-only species and ligand-bound protein species. In the 
absence of small molecule, the hIAPP alone whole-spectrum ATD (Figure 5-13a) is 
comprised of intense peaks at short drift times (~3-10 ms) owing largely to the 
presence of the monomeric ions and less intense oligomeric contributions at 
longer drift times (~7-17 ms). With FG bound, there is a shift in the ATD plot 
towards more compact hIAPP monomeric protein species (compare Figure 5-13a 
and b). Additionally, there is a decrease in the oligomeric contributions at longer 
drift times in the presence of FG, likely due to inhibition of monomer assembly. 
When CR is bound, the overall ATD shifts to longer drift times (Figure 5-13c) due 
to the presence of CR aggregate and no compaction of the monomer is observed. In 
the presence of 1H-B-SA, a tail in the hIAPP monomer ATD profile is observed due 
to the presence of the non-specific binding (Figure 5-13d). There is an absence of 
species having longer drift times, possibly due to large amounts of non-specific 
binding masking signal from any lowly populated oligomeric states occupied in the 
presence of 1H-B-SA. The changes in whole-spectrum ATDs demonstrated can be 
explained more clearly when analysing Driftscope plots (Section 5.2.6) that allow 
unambiguous identification of every individual species present. 
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Figure 5-13. ATDs of hIAPP in the absence or presence of inhibitors. Comparisons of 
whole spectra arrival time distributions (ATDs) of hIAPP (a) in the absence (grey) or 
presence of a 10-fold molar excess of (b) FG (green), (c) CR (red) or (d) 1H-B-SA 
(blue). Figure taken from Young et al. (182). A clear overall compaction of hIAPP 
monomeric conformations is observed in the presence of FG (b)with respect to hIAPP 
alone (a). 
a. 
 
 
 
b. 
 
 
 
 
c. 
 
 
 
 
d. 
 SCREENING FOR INHIBITORY COMPOUNDS 
 
136 
 
 Oligomer formation in the presence of small molecule 5.2.6
inhibitors 
 
The ability of ESI-IMS-MS to monitor oligomerisation of amyloid proteins enables 
the screen not only  to observe binding of ligands to a protein monomer of interest, 
but further, to determine the impact this binding may or may not have on the 
higher order species populated in the aggregation landscape. Here, ESI-IMS-MS 
was utilised to determine the individual nature and abundance of the lowly-
populated hIAPP oligomers in the presence of each class of small molecule. In the 
absence of small molecule, hIAPP forms monomer through hexamer, inclusively, 
within 2 minutes of dilution into buffer (Figure 5-2c) (102). In the presence of a 
10-fold molar excess of a ‘negative’, non-interacting small molecule such as 
ibuprofen (8), the same array of oligomers is observed as for the peptide alone 
(Figure 5-2c and Figure 5-14a). When a ‘positive’ specific inhibitor (e.g. FG) (1) is 
present, binding of the small molecule to the peptide monomer is observed, with 
an absence of higher order hIAPP species detected (Figure 5-14b). This lack of 
oligomers is likely due to perturbation of self-assembly achieved by small molecule 
binding to the monomeric peptide. When a non-specific binder (e.g. 1H-B-SA (5)) is 
present, multiple copies of ligands (≤ seven molecules) can be seen binding to each 
monomeric charge state (Figure 5-14c), indicative of a non-specific interaction. 
Conversely, the spectrum of hIAPP in the presence of CR (4) (Figure 5-14d) shows 
a multitude of higher order species. However, the majority of these peaks have m/z 
values corresponding to multimers of CR, rather than hIAPP, resulting from self-
association of the small molecule alone. Peptide monomers are observed in the 
spectrum, but no peptide oligomers are visible, resulting either from their low 
intensities compared with CR aggregates, or their absence. The ESI-IMS-MS data 
presented reveal clear differences between the spectral ‘fingerprint’ of hIAPP 
undergoing no interaction, specific inhibitory interactions, non-specific 
interactions and colloidal interactions with small molecules. ‘Hits’ from screens of 
potential small molecule inhibitors can thus be distinguished visually from 
negative, colloidal or non-specifically bound molecules using ESI-IMS-MS and 
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selected for further characterisation or optimisation based on simple 
categorisation of the spectral features.  
 
 
Figure 5-14. ESI-IMS-MS demonstrates the mode of inhibition 
(specific/colloidal/non-specific) or lack of inhibition of hIAPP amyloid formation by 
small molecules. a–d, ESI–IMS–MS Driftscope plots of hIAPP and ibuprofen (a), FG 
(b), 1H-B-SA (Hb) (c) and CR (d) (all at 320 μM) to hIAPP (32 μM). Examples of a 
negative (a), a positive (b), a nonspecific (c) and a colloidal inhibitor (d) are 
illustrated. The numbers on the Driftscope plots indicate the oligomer order and the 
adjacent superscript numbers show the charge state of those ions. In b, the bound 
peaks are denoted with yellow (13+ bound) or green (12+ bound) circles (the number 
of circles represents the number of ligands bound); in c, the bound peaks are denoted 
with blue circles; in d, the colloidal aggregates are denoted nx+, where n is the 
number of CR molecules and x is the charge state of the aggregate. Background noise 
observed in Driftscope plots is a result of displaying the data on a log scale. Figure 
taken from Young et al. (182). 
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 Screening mixtures of small molecules using ESI-IMS-MS 5.2.7
 
To validate the high-throughput potential of this ESI-IMS-MS-based screen for 
small molecule interactions with aggregating proteins/peptides, several small 
molecules were mixed together and added to hIAPP in combination. In the mixed 
samples, the ability to categorise the compounds according to the simple ESI-IMS-
MS ‘spectral-fingerprint’ analysis was assessed. These analyses test the 
applicability of the screen to differentiate between molecules able to bind 
specifically to the target protein/peptide from their non-binding or non-specific 
binding counterparts, when added in combination to the target peptide. This 
approach has two advantages: firstly, it decreases the time taken to screen a 
library of compounds (5-10 molecules/min rather than 1 molecule/min); secondly, 
in competition, the best binders as observed in the gas-phase should out-compete 
negative, weak or colloidal inhibitors. This method is demonstrated using FG 
(positive) (1), CR (colloidal) (5), 1H-B-SA (non-specific) (5) and four small 
molecules that do not bind to hIAPP (negative) (7-10). When added to hIAPP (32 
µM) in combination (160 µM each small molecule), FG and CR behave as each one 
behaved when added individually, i.e. the ‘positive’ compound FG binds specifically 
to the target peptide and the colloidal compound CR self-associates without any 
specific protein interaction being observed (Figure 5-15a). Further, the presence 
of equimolar CR does not prevent FG from interacting with hIAPP, nor does the 
presence of equimolar FG prevent the self-association of CR. The ability of FG to 
bind hIAPP in the presence of mixtures of small molecules that do not bind (aspirin 
(7), ibuprofen (8), benzimidazole (9) and hemin (10)) was also tested. The results 
showed that of the five small molecules present, only FG binds to hIAPP (Figure 
5-15b).  
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Figure 5-15. Screening mixtures of positive, colloidal and negative compounds. 
Positive ion ESI mass spectra and corresponding ESI-IMS-MS Driftscope plots 
showing hIAPP peptide (32 µM) with mixtures of (a) FG (160 µM) and CR (160 µM); 
and (b) FG (160 µM), aspirin (160 µM), ibuprofen (160 µM), benzimidazole (160 µM) 
and hemin (160 µM). FG bound monomer peaks denoted with yellow (13+ bound) or 
green (12+ bound) circles and a white circle when dimer bound. Number of circles 
represents number of ligands bound. ESI-IMS-MS Driftscope plots are shown to the 
right of the corresponding spectra. Figure taken from Young et al. (182). 
 
Further, the presence of an excess of the non-specifically binding ligand, 1H-B-SA, 
did not perturb the ‘positive’ interaction between FG and hIAPP (Figure 5-16a). In 
the statistically unlikely event that two positive inhibitors are encountered in the 
same mixture, the molecule which binds most stably in the gas-phase should out-
compete the other. This is the case when FG (1) and EGCG (2) are each added in a 
5-fold molar excess to hIAPP (Figure 5-16b). FG and hIAPP have favourable 
electrostatic interactions (239), whereas EGCG is thought to bind principally via 
hydrophobic interactions (156). Given that electrostatic interactions are more 
likely to be maintained in the gas-phase over their hydrophobic counterparts, FG 
out-competes EGCG. The relative affinity of these two different ligands for hIAPP, 
therefore, cannot be deduced from these data. Thus, in order to control for the 
effects of the chemistry of binding determining the relative intensity of bound 
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peaks observed by ESI-MS (252, 253), the Kd of small molecules identified as a “hit” 
in a mixture of compounds should be confirmed using other biophysical methods 
in solution. Additionally, when a positive inhibitor is encountered, all compounds 
within the mixture could be re-examined against the target separately, to avoid any 
false-negative results. 
 
 
Figure 5-16. Screening mixtures of positive and non-specific compounds. Positive ion 
ESI mass spectra and IMS-MS Driftscope plots showing hIAPP peptide (32 µM) in 
solution with mixtures of compounds. (a) hIAPP with Fast Green FCF (FG) (160 µM) 
and 1H-benzimidazole-2-sulfonic acid (1H-B-SA) (160 µM), FG bound monomer 
peaks denoted with green circles and a white circle when dimer bound, 1H-B-SA 
bound monomer peaks denoted with blue circles; (b) hIAPP with Fast Green FCF (160 
µM) and EGCG (160 µM). FG bound monomer peaks denoted with green circles. EGCG 
bound peaks are denoted with purple circles. Number of circles represents number of 
ligands bound. Background noise observed in Driftscope plots is a result of displaying 
the data on a log scale. Figure taken from Young et al. (182). 
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 ESI-IMS-MS as a generic screen for amyloid inhibitors 5.2.8
 
Having demonstrated successfully the applicability of the ESI-IMS-MS-based 
screen to classify inhibitors of hIAPP aggregation, the same method was applied to 
Aβ40 assembly (257). These analyses were performed in order to assess the 
method developed as a generic tool for screening and classifying inhibitors of 
aggregating systems.  The 37-residue hIAPP (Figure 5-2a) and 40-residue Aβ40 
(Figure 5-18a) sequences share 25 % identity and 47 % similarity (Figure 5-17). 
The core sequences of each peptide, Aβ40 (residues 26–32) and hIAPP (residues 
21–27), believed to be involved in the self-assembly of each peptide (101, 199, 
258), are most similar.  
 
 
Figure 5-17. Sequence alignment of Aβ40 and hIAPP. Recombinant expression of 
Aβ40 results in an additional N-terminal methionine (187). The intramolecular 
disulfide bond in hIAPP is indicated by a blue line, and the amidated C-terminal is 
shown. Lines between hIAPP and Aβ40 sequences indicate exact amino acid matches, 
dashes indicate chemical similarity.  
 
Here, Aβ40 (expressed recombinantly, Section 2.1.5) (32 µM) was incubated alone 
or with tramiprosate (6), hemin (10) or EGCG (2) at 10:1 molar ratio of small 
molecule to Aβ40. Preliminary analysis of Aβ40 in isolation using ESI-MS revealed 
that the peptide gives rise to dominant 3+ and 4+ monomer charge state ions 
(Figure 5-18b) and oligomeric species (dimer ≥ pentamer) (Figure 5-18c) en 
route to long straight amyloid fibrils. 
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Tramiprosate (6) has been shown previously to inhibit Aβ40 and Aβ42 fibrillation 
in vivo, likely via competition with glycosaminoglycan (GAG) binding to the peptide 
(259, 260). The mass spectrum of a 10:1 molar ratio of tramiprosate:Aβ40 peptide 
(Figure 5-18d) indicates a non-specific interaction which may help towards 
explaining how tramiprosate interferes with glycosaminoglycan (GAG) binding to 
Aβ in vivo (259). ThT and TEM data reveal fibrillation in the absence and presence 
of tramiprosate (6) (Figure 5-18e and f ii), corroborating the findings that this 
interaction is non-specific and non-inhibitory. Hemin (10) (along with other 
porphyrins) has also been reported to interfere with Aβ fibrillation (144, 245). On 
the contrary, here, hemin has no observed effect on Aβ self-assembly, 
demonstrated by its inability to bind to Aβ40 as judged by ESI-MS (Figure 5-18d 
ii) and the resultant formation of Aβ40 fibrils in its presence, as judged by TEM 
(Figure 5-18f iii). Notably, no increase in ThT fluorescence is observed in the 
presence of hemin, presumably because the small molecule either interferes with 
ThT fluorescence or prevents ThT binding (Figure 5-18e), a common caveat of 
screening methods reliant on ThT data to infer inhibition. Conversely, EGCG (2), 
binds specifically to Aβ40 monomer, forming a 1:1 EGCG: Aβ40 complex (Figure 
5-18d iii), resulting in the formation of amorphous aggregates and the absence of 
long straight amyloid fibrils (Figure 5-18e and f iv). The results demonstrate, 
therefore, the applicability of ESI-MS as a generic screen for inhibitors of two 
different amyloid systems. Further description of Aβ40 peptide oligomers and 
small molecule screening using Aβ40 as a target are discussed in Section 5.2.10.2. 
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Figure 5-18. ESI-mass spectra of Aβ40 alone and with non-specific, negative and 
specific binding small molecules. (a) Primary sequence of recombinantly expressed 
Aβ40 (with an additional methionine at the N-terminus); (b) ESI mass spectrum of 
Aβ40. Numbers adjacent to peaks denote oligomer order, with the positive charge 
state of each oligomer ions in superscript; (c) ESI-IMS-MS Driftscope plot of the Aβ40 
alone (32 µM in 200 mM ammonium acetate, pH 6.8). ESI-IMS-MS Driftscope plots 
show IMS drift time versus m/z versus intensity (z = square root scale); (d) positive 
ion ESI mass spectra showing 320 µM tramiprosate (i), hemin (ii) or EGCG (iii) added 
to Aβ40 peptide (32 µM). Tramiprosate binds multiple copies to the 3+ and 4+ charge 
state ions of Aβ40 monomer (bound peaks denoted with pink circles, number of 
circles represents number of ligands bound). This binding mode is classified as non-
specific. Hemin (ii) does not bind and is classified as negative, and EGCG (iii) binds to 
both the 3+ and 4+ charge state ions of Aβ40 monomer (bound peaks are denoted 
with blue circles) and is classified as specific. (e) ThT fluorescence intensity of Aβ40 
alone (black circles) and with tramiprosate (pink circles), EGCG (blue circles) and 
hemin (orange circles) all present at small molecule:Aβ40 molar ratios of 10:1 (25 oC, 
quiescent). Significant inhibition of the formation of ThT-positive species is observed 
in the presence of excess EGCG and interference with ThT fluorescence is observed 
only in the presence of excess hemin. (f) Negative stain TEM images of Aβ40 alone (i) 
or incubated with 10:1 molar ratios of tramiprosate (ii), hemin (iii) or  EGCG (iv) for 
5 days (25 °C, quiescent); scale bar = 100 nm.  Fibrils are observed by Aβ40 alone and 
in the presence of excess tramiprosate and  hemin but not in the presence of excess 
EGCG. Figure taken from Young et al. (182). 
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 Focused screen for the identification of novel inhibitors of 5.2.9
amylin amyloid formation 
 
To validate further the MS-based assays and to begin screening for new inhibitors, 
I next performed the ESI-IMS-MS screen using a library of novel molecules (11-30) 
with structural similarity to the aggregation inhibitors previously reported (Table 
5.2). We reasoned that a focussed screen of this type would be a rigorous test for 
the ESI-IMS-MS assay and indicate the suitability of this approach for high 
throughput screening (HTS). 
The selection of compounds via virtual screening was performed by Charlotte H. 
Revill and Richard J. Foster (School of Chemistry, University of Leeds), as described 
in Chaper 2, Section 2.4.5. 
Focused screening is a method well-versed in improving the hit-rate of a HTS by 
seeding a screening library with compounds which have a higher probability to 
bind to and/or inhibit the target with respect to random screening (261). This 
screening method uses the structural information from known bioactive ligands to 
identify novel compounds with similar structure, and hence greater potential for 
biological activity against a target of interest. For initial proof of principle 
experiments, five inhibitors of hIAPP and/or Aβ40 amyloid formation from the 
literature (vanillin (262), resveratrol (263), curcumin (264), 
chloronaphthoquinine-tryptophan (265) and EGCG (102)) were selected as 
queries from which to seed a focussed library of compounds for screening using 
ESI-IMS-MS. In the seeding process, each of the inhibitors is assessed for structural 
similarity to an in-house, structurally diverse library of 50,000 lead-like small 
molecules using the programme Rapid Overlay of Chemical Structures 
(ROCS)(194).  After seeding, a subset of 20 compounds was then chosen for 
analysis using the comparator (ROCS Combiscore) with consideration to maximal 
structural diversity of the proposed screening set. This subset of 20 compounds 
(molecules 11-30) were then screened against hIAPP, along with a further 10 
compounds (molecules 31-40) which have been reported to inhibit aggregation by 
other amyloidogenic polypeptides (Table 5.2). LogP values of all 30 compounds 
are shown in Figure 5-19. 
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Table 5.2. Focused high throughput screen (HTS) results. Molecule number 26 
inhibits hIAPP aggregation by specific binding (red peaks); compounds 13, 25, 27 
exhibit non-specific binding (green peaks). TEMs are shown only for compounds in 
which binding is observed (scale bar in nm is indicated at the foot of each TEM 
image). Table taken from Young et al. (182). 
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Table 1.2 continued 
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Table 1.2 continued 
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Figure 5-19. LogP values of the 20 compounds identified from the focused screen and 
10 other small molecules : LogP values (the log of the aqueous/hydrophobic partition 
coefficient) were calculated for the 20 small molecules identified from the focused 
screen (compounds 11-30) using www.molinspiration.com software, which 
determines the hydrophobic parameters of the substituents, plus 10 other small 
molecules reported to inhibit amyloid formation by other polypeptide sequences 
(compounds 31-40). Molecules with high +ve LogP values have high hydrophobicity. 
Colours denote inhibitor classification: positive (pink), non-specific (green) and 
negative (grey). Figure taken from Young et al. (182). 
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Of these 30 compounds assayed in this screen, one was found to bind specifically 
and inhibit hIAPP aggregation (compound 26), three demonstrated non-specific 
binding to hIAPP (compounds 13, 25 and 27) but a lack of inhibition, and the 
remainder did not bind, nor did they inhibit (Table 5.2). The newly discovered 
‘positive’ inhibitor (compound 26) is a non-obvious structural mimetic of 
chloronaphthoquinine–tryptophan (Figure 5-20), selected only as a result of 
focussed screening and ROCS analysis. 
 
 
Figure 5-20. ROCS-derived overlay of molecule number 26 with 
chloronaphthoquinine–tryptophan (a) Chemical structure of chloronaphthoquinine–
tryptophan; (b) chemical structure of molecule number 26; (c) ROCS-derived overlay 
of chloronaphthoquinine–tryptophan (green sticks) and molecule number 26 (cyan 
sticks). Figure taken from Young et al., kindly provided by Charlotte H. Revill (School 
of Chemistry, University of Leeds) (182). 
 
In the presence of a 10-fold molar excess of compound 26, hIAPP monomer shows 
evidence of specific ligand binding (Figure 5-21a), lack of high order oligomer 
formation (Figure 5-21b) and amorphous aggregates are formed in the absence of 
fibrils (Figure 5-21 inset). These data highlight the applicability of a focused ESI-
IMS-MS screen to rapidly identify novel small molecules capable of inhibiting 
aggregating peptides in a specific manner. 
  
a. 
b. 
c
. 
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Figure 5-21. ESI-IMS-MS analysis of ‘hit’ compound number 26. Inhibition of hIAPP 
fibril formation by compound 26. (a) Positive ion ESI mass spectrum showing binding 
of compound 26 (6-([4-(2-fluorophenyl)-1-piperazinyl]carbonyl)-3-methyl-5H-
[1,3]thiazolo[3,2-a]pyrimidin-5-one) (added at 320 μM to 32 μM peptide) to both the 
+2 and +3 charge state ions of hIAPP monomer (bound peaks coloured red). The 
structure of compound 26 and negative stain TEM images of hIAPP incubated with 
10:1 molar ratios of molecule:hIAPP for 5 days (25 °C, quiescent) are inset; (b) ESI-
IMS-MS Driftscope plot shows hIAPP species detected in the presence a 10:1 molar 
ratio of compound 26:peptide monomer at t = 2 min. Bound monomer peaks are 
denoted with a white circle. Figure taken from Young et al. (182). 
 
Use of an automated sampling device enables the utility of ESI-MS to identify novel 
compounds from focused libraries in the form of a semi-HTS. For proof of 
principle, I performed analyses from a 96-well plate format, with data acquisitions 
of one minute per well. The results demonstrate that in doing so, spectra of high 
quality can be obtained in a reproducible manner (Figure 5-22). Using robotic 
automation, a minimum of 96 novel potential inhibitors could be screened per 
plate, consuming ~1 mg peptide thus ~1000 compounds can be screened in less 
than 24 hours. By assaying mixtures of five compounds in parallel, 480 molecules 
could be screened per plate, increasing the screening rate to ~5000 novel 
compounds per day. 
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Figure 5-22. Proof of principle 96-well plate automated semi-HTS Proof of principle 
96-well plate automated semi-HTS by ESI-MS. (a) 10 µL samples containing aqueous 
CsI (A/E 1-12) for calibration, hIAPP (B1-12), hIAPP:FG (C1-12) hIAPP:CR (D1-12), 
Aβ40 (F1-12), FG alone (G1-12),  and CR alone (H1-12) were prepared in 96-well 
plates. Peptide samples (32 μM) were dissolved in 200 mM ammonium acetate (pH 
6.8) in the absence or presence of 320 μM small molecule; (b) samples were infused 
into the mass spectrometer via a Triversa NanoMate automated nano-ESI interface; 
(c) spectra resulting from the first and twelfth well of each row of the 96-well plate 
(annotated A1, A12, respectively) demonstrate the reproducibility of the assay. 
Figure taken from Young et al. (182). 
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 Screen for the inhibitors of Aβ amyloid formation 5.2.10
 
To validate further the use of MS-based assays in conjunction with focussed 
screening for the discovery of novel inhibitors of multiple amyloid systems, I next 
performed the screen of compounds 11-30, previously assayed against hIAPP 
(Section 5.2.9), against Aβ40. This work has been published in reference (229). 
 
5.2.10.1 Aβ40 forms an array of oligomers early in amyloid 
assembly 
 
Prior to performing screening, I first investigated the higher order oligomeric 
states populated by Aβ40, under conditions compatible both with ESI-MS and fibril 
formation (as judged by TEM) (Figure 5-23a), and elucidated the CCSs of species 
formed. Aβ40 was dissolved initially in 100 % DMSO to remove any preformed 
aggregates and diluted 100-fold into 200 mM ammonium acetate buffer, pH 6.8 
before centrifugation (13,000 g, 4 °C, 10 min) to remove any larger order species 
that may persist. The distribution of soluble oligomeric species was then analysed 
immediately (within 2 min, post centrifugation), using ESI-IMS-MS. The data 
obtained (Figure 5-23) showed that high order oligomers are formed within 10 
min of dilution of Aβ40 into buffer, consistent with previous analyses (98, 100). 
Co-populated oligomers with the same m/z can be separated using IMS-MS, for 
example, the dimer4+ and trimer6+ ions (Figure 2b). Multiple charge states, 
predominantly triply and quadruply charged, and different conformers, both 
compact and expanded, are observed for the Aβ40 monomer (98, 100). Aβ40 
oligomer CCSs were estimated from the ESI-IMS-MS arrival time distributions and 
compared with CCSs estimated for theoretical oligomer growth models (described 
in Section 1.14) including a fit assuming isotropic growth (46), a fit assuming 
globular oligomers based on the average density of a protein under similar 
conditions (0.44 Da/Å3) (93), and a model that assumes growth in a single 
dimension (linear growth) (46). CCS determination suggests that Aβ40 oligomers > 
trimer in size adopt relatively extended conformations rather than spherical or 
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isotropic growth conformations (Figure 5-23a). More detailed analysis of 
oligomeric structures under different solution and MS conditions is required in 
order to agree or disagree with any previously published growth models for this 
sytem (98, 100). Ultimately, under the conditions used, long, straight fibrils typical 
of amyloid form (Figure 5-23 inset). 
 
Figure 5-23. Analysis of Aβ40 oligomer distribution and CCSs. a. ESI-MS mass 
spectrum of Aβ40. Numbers above peaks denote oligomer order, with the positive 
charge state of ions in superscript. Inset: negative stain TEM image of Aβ40 fibrils 
after 5 days in 200 mM ammonium acetate buffer, pH 6.8  (25 °C, quiescent) (scale 
bar = 500 nm). b. ESI-IMS-MS Driftscope plot of the Aβ40 oligomers present 12 min 
after diluting the monomer to a final peptide concentration of 32 μM in 200 mM 
ammonium acetate, pH 6.8, 25 °C. ESI-IMS-MS Driftscope plots show IMS drift time 
versus m/z versus intensity (z = square root scale); c. CCSs of Aβ40 oligomers 
measured using ESI-IMS-MS versus oligomer order; the CCS of the lowest charge state 
of each oligomer is shown (black triangles). The orange dashed line represents a fit 
based on globular oligomers and the average density of a protein (0.44 Da/Å3) (39), 
the purple dashed line represents a linear growth model (46) and the blue dashed 
line represents an isotropic growth model(46) (models described in detail in Section 
1.14). Figure taken from Young et al. (229). 
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5.2.10.2 Focused screen for the identification of novel 
inhibitors of Aβ amyloid formation 
 
Using the ESI-IMS-MS-based screening approach described above and in Sections 
5.2.2 and 5.2.9, the exact same 20 compounds (11-30), selected by ROCS analysis 
(Charlotte H. Revill and Richard J. Foster, School of Chemistry) based upon their 
structural similarity to bioactive ligands o-vanillin (262), resveratrol (263), 
curcumin (264), chloronaphthoquinine-tryptophan (Cl-NQTrp) (265) and (-)-
epigallocatechin gallate (EGCG) (102, 153) (Table 5.3), previously analysed for 
bidning to hIAPP (Table 5.2. Focused high throughput screen (HTS) results.), were 
added individually to monomeric Aβ40 and the binding mode of each was assessed 
by analysis of the resulting ESI-IMS-mass spectra. In parallel, the ability of the 
molecules to inhibit fibril formation was determined using negative stain TEM, 
after 5 days incubation at a 10:1 molar ratio of small molecule to Aβ40.  
The compounds were categorised according to the binding mode classification 
system described in Section 5.2.2. Of the 20 compounds screened, two were found 
to inhibit Aβ40 aggregation (compound 13 and compound 26, Table 5.3 and 
Figure 5-24a), one exhibited colloidal binding (compound 19) (Table 5.3 and 
Figure 5-24b) and two demonstrated non-specific binding, (compounds 25 and 
27) (Table 5.3 and Figure 5-24c). The remainder did not bind to Aβ40 (Table 
5.3).  
It is important to note that the ability to distinguish between specific and non-
specific binding is not always straight forward. At a ten-fold molar excess of small 
molecule, it is conceivable that a ‘positive’ small molecule will bind multiple copies 
to its target protein. Additionally, the nature of interaction i.e. hydrophobic or 
electrostatic will contribute to the number of observed ligands bound, with a 
higher proportion of electrostatic binding being maintained in the gas-phase. In a 
screen of this nature, it would be beneficial to take all binding compounds forward, 
both those that appear initially to be specific and those that appear to be non-
specific. All binders should be assayed at eqimolar concentrations with the target 
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peptide and EM images should be taken of the products of their incubation with 
the target. Only then should they be definitively classified according to this system. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.3. Focused high throughput screen (HTS) results. Mass spectra labels 
indicate number of ligands (L) bound to each charge state of Aβ40. Binding modes as 
determined from the mass spectra are denoted as positive, negative, non-specific or 
colloidal. Molecule numbers 13 and 26 exhibit positive (specific) binding to Aβ40 
(purple peaks); compounds 25 and 27 exhibit non-specific binding (pink peaks) and 
compound 19 exhibits colloidal binding (green peaks; each multimer of the small 
molecule is denoted nL, where n=oligomer number. The interaction of each small 
molecule with hIAPP is also shown (182).  Table taken from Young et al. (229). 
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Table 5.3 continued 
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Despite interacting with Aβ40, non-specific and colloidal binding of small 
molecules to target proteins is not useful therapeutically. The newly discovered 
inhibitors, compound 13 and compound 26 are structurally similar to, but 
chemically distinct (as determined by ROCS Combiscore), from the known 
inhibitors of Aβ40 aggregation, resveratrol (263) and  Cl-NQTrp (265), 
respectively (Figure 5-25). In the presence of a 10-fold molar excess of either 
compound, Aβ40 shows evidence of specific ligand binding and depletion of higher 
order oligomers such that only dimers and trimers are observed. Neither of the 
latter species is detected to bind the small molecule. TEM analysis confirms that 
fibril formation is inhibited and amorphous or short fibrillar aggregates 
accumulate (Figure 5-24a). The low levels of binding observed for the ‘positive’ 
inhibitors, despite complete inhibition of fibrillation, are consistent with the fact 
that hydrophobic interactions are not wholly maintained in the gas-phase. Similar 
low levels of binding have been observed for ‘positive’ inhibitors of hIAPP, 
including EGCG (102). Gas-phase analysis of hydrophobic interactions between 
protein and ligands could lead to underestimation of binding affinity and/or false 
negative results (254).  
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Figure 5-24. Positive, colloidal and non-specific binding molecules from focused HTS. 
a) Molecule numbers 13 (i) and 26 (ii) exhibit ‘positive’ (specific) binding to Aβ40 
monomer (purple peaks)  according to the ESI-IMS-MS classification system and 
negative stain TEM images of Aβ40 incubated with 10:1 molar ratios of molecule: 
Aβ40 for 5 days in 200 mM ammonium acetate buffer, pH 6.8 (25 °C, quiescent) show 
the absence of fibrils after incubation. b)  Compound 19 (i) exhibits colloidal binding 
to itself (peaks denoted + nL where n is the number of small molecules present in the 
aggregate) and to Aβ40 (green peaks). c) Compounds 25 (i) and 27 (ii) exhibit non-
specific binding to Aβ40 (pink peaks). Compounds 19, 25 and 27 fail to prevent 
fibrillation of Aβ40 (scale bar in nm is indicated at the foot of each TEM image). 
Circles in ESI-IMS-MS Driftscope images indicate the number of small molecules 
bound to each ion. Figure taken from Young et al. (229). 
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Remarkably, 18 of the 20 lead compounds screened exhibit similar interactions 
with human islet amyloid polypeptide (hIAPP) (182) and Aβ40 (Table 5.3). The 
two exceptions are compound 13 (specific binding to Aβ40, non-specific binding to 
hIAPP (182)) (Table 5.3) and compound 19 (colloidal binding in the presence of 
Aβ40, no binding in the presence of hIAPP (182)) (Table 5.3). Interestingly, 
compound 26 binds specifically to both hIAPP and Aβ40, and inhibits fibrillation of 
both peptides in vitro (182). Although hIAPP and Aβ40 share only 25 % sequence 
identity and 47 % sequence similarity (Figure 5-17), the core sequences of both, 
believed to key for self-assembly (4, 40), share 57 % identity and 86 % similarity 
(NNFGAIL in hIAPP, SNKGAII in Aβ40). The ability of compound 26 to interrupt the 
fibrillation process of both these peptides suggests that this small molecule may be 
either interacting directly with these comparable amyloidogenic sequences, or 
with an early oligomeric species with interaction interfaces common to both 
fibrillation pathways.     
Combined with previous success in the discovery of new inhibitors of hIAPP 
aggregation (Section 5.2.9) (182), I envision that ESI-IMS-MS will play a pivotal 
role in future compound discovery in the anti-amyloid therapeutic field as a whole. 
 
Figure 5-25. Structural comparison of Aβ40 inhibitors with their parent compounds 
in ROCS analysis. a. Compound 13 (blue) and the parent molecule resveratrol 
(green). b. Compound 26 (blue) and the parent molecule Cl-NQTrp (green). Figure 
taken from Young et al. (229). 
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5.3 Conclusions 
 
The data presented in this chapter demonstrate the utility of ESI-IMS-MS as a HTS 
for inhibitors of self-assembly from amyloid proteins. This approach allows rapid 
identification of protein-ligand interactions, using microliter sample volumes and 
milligrams of protein, and provides information-rich data concerning the identity 
of the interacting species (monomer or oligomer), the nature of binding (specific, 
non-specific or colloidal) and the effect of the ligand on protein aggregation 
(monomer binding, shift in monomer equilibrium, disassembly of oligomers). The 
use of IMS in conjunction with ESI-MS serves further to allow a reliable and easily 
interpretable visual screen based purely on the appearance of 3D Driftscope plots, 
without requiring complex data analysis. The results establish this method as a 
powerful tool with unique analytical capability for the discovery of small molecule 
leads in the anti-amyloid drug discovery field. Additionally, novel inhibitors of both 
hIAPP and Aβ40 aggregation have been identified based on analysis of a library of 
small molecules, illustrating the potential of this method as a HTS.
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6 Concluding remarks and future directions 
 
Inhibition of aberrant protein aggregation is a vital step towards alleviating some 
of the developed world’s most prevalent diseases, ranging from neurodegenerative 
disorders including AD to systemic diseases including T2DM. These amyloid 
diseases share the key pathological hallmark of large fibrillated structures known 
as amyloid plaques that form as a result of the accumulation of 
misfolded/aggregated peptides and proteins (89, 266). The current hypothesis in 
the amyloid field is that prefibrillar intermediates (rather than mature fibrils), 
either low molecular weight soluble oligomers or higher order prefibrillar 
aggregates, are the agents of toxicity (66, 72, 267, 268).  
The principle achievements of this thesis was the characterisation of the transient 
oligomeric species present during the lag-phase of amyloid fibril formation of 
hIAPP and the observation of the alterations in the aggregation landscape in the 
presence of small molecule inhibitors. The thesis focussed primarily on 
interrogating the amyloidogenic peptide hIAPP associated with T2DM, and the 
Aβ40 peptide associated with AD has been probed as a secondary system. The 
aims were accomplished by applying a range of synergistic mass spectrometry-
based approaches, including ESI-MS to observe protein-ligand binding, ESI-IMS-MS 
to interrogate co-populated oligomeric states occupied during amyloid assembly 
and ESI-IMS-MS-CID fragmentation to determine the stability of protein-protein 
and protein-ligand complexes. Combined, these techniques have yielded significant 
insights into the mechanisms of hIAPP fibril formation in vitro and have lead to 
new methods for identifying novel inhibitors of amyloid assembly using ESI-IMS-
MS. The work presented demonstrates that ESI-IMS-MS can facilitate the 
identification and analysis of protein-ligand interactions required for amyloid 
inhibition thereby offering new avenues for the development of novel therapeutic 
strategies to circumvent fibrillation and/or cytotoxicity in amyloid disease. 
Firstly, this thesis showed the capability of ESI-IMS-MS to probe the mechanism of 
amyloid assembly from both short fragment peptides derived from amyloid 
sequences (Chapter 3) and full length amyloidogenic peptides (Chapter 4). The 
data in Chapter 3, demonstrate that when ESI-IMS-MS is performed in conjunction 
 CONCLUSIONS AND FUTURE DIRECTIONS 
 
163 
 
with coarse-grained modelling, a comprehensive picture of the aggregation 
process in self-assembling peptide systems can be gained. In Chapter 4, oligomers 
from an otherwise intractable amyloid system, IAPP, are identified and 
characterised in detail for the first time. From the ESI-MS and ESI-IMS-MS data 
presented, it remained unclear as to whether the subtle differences observed in the 
structure and relative abundances of hIAPP and rIAPP oligomers could account for 
their stark differences in amyloidogenicity. MS/MS experiments were performed 
and revealed significant differences in the gas-phase stabilities of the two peptides 
both in the monomeric and oligomeric states, which may explain the striking 
differences in their aggregation landscapes.  In Chapter 4, the use of mass 
spectrometry-based techniques to study amyloid inhibition is also demonstrated, 
which inspired the development of the screening method detailed in Chapter 5. 
Having characterised amyloid oligomers formed from several peptides, the next 
aim was to prevent the formation of these, and any other potentially toxic species. 
One approach to prevent aggregation of amyloid proteins is the use of small 
molecules that bind specifically to the protein of interest, and inhibit the initial 
stages of misfolding and/or aggregation (269-271). IAPP and Aβ40, along with 
many aggregation-prone peptides and proteins, are intrinsically disordered, and, 
therefore their structural intricacies remain elusive and screening against the 
monomer poses a significant challenge (272). As discussed in Chapter 1 and 
Chapter 5, a number of techniques are inappropriate to use in isolation when 
screening for small molecule inhibitors of aggregation. By relying too heavily on 
dye binding studies, for example, several groups have mistakenly identified 
‘inhibitors’ of aggregation, whereby in fact, the ‘hits’ were only interfering with the 
dye binding to the fibril (273, 274). The ESI-IMS-MS method described (Chapter 
5), demonstrates that a number of these claimed inhibitors do not, in fact, have any 
effect on amyloid assembly. Significantly, the ESI-IMS-MS-based method is able to 
differentiate between specific inhibitors of protein aggregation and non-
specifically or colloidally interacting molecules (Chapter 5). ESI-IMS-MS enables 
observation of multimeric species resulting from self-assembly of compounds as 
well as protein-only oligomers and protein-ligand complexes, all within one 
spectrum. This is an important requirement of an inhibitor screen, as any molecule 
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that erroneously and/or non-specifically interacts with the protein of interest is 
not an appropriate therapeutic. Other studies have identified inhibitors of protein 
aggregation, albeit using >20-fold molar excess of small molecule inhibitor: protein 
(273-275). The use of such high concentrations of potentially inhibitory 
compounds can lead to physical perturbation of protein aggregation in a colloidal 
manner. Colloidal inhibitors are identified rapidly and disregarded in the ESI-IMS-
MS-based screen, due to the direct observation of their self-assembly.  This 
approach, therefore, has the potential to identify lead compounds which 
specifically bind to monomeric amyloid precursor proteins and eliminate 
unsuitable molecules in the early stages of screening, thus increasing the 
throughput of small molecule drug discovery.   
The amyloid cascade underlies more than fifty human disorders (64). Both social 
and economic burdens associated with amyloid disease are increasing 
exponentially with our ageing population and increasingly sedentary lifestyles. As 
such, the ability to screen large numbers of potential aggregation inhibitors against 
a diverse range of protein targets is paramount. The ESI-IMS-MS method described 
is rapid, effective, uses only µL sample volumes and has been shown to be 
applicable to multiple amyloid systems. Furthermore, the data in Chapter 5 
demonstrate that the assay is amenable to automation in the form of an HTS, which 
results in increased throughput (~5000 compounds/ day) and reduced protein 
requirements (~ 1 mg/  5000 compounds). Further automation of the assay is 
crucial to exploiting its full potential, particular in terms of data interpretation, 
which may be amenable to pattern recognition analysis. As such, this is to be 
investigated within the laboratory, over the coming months.  
To date, only one successful small molecule therapeutic, Tafamadis, that 
specifically targets a protein aggregation disorder has been developed (276-278). 
With increasing resources now being directed towards the detection of compounds 
as new therapeutics with the potential to interfere with amyloid cascade, cures for 
some of the world’s most debilitating diseases world may become available in the 
future. The challenges of developing such therapies, however, are not limited 
merely to the identification of molecules that inhibit protein aggregation. Once 
identified, these compounds must be developed into stable drug formulations that 
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maintain the potency of the original lead compound. A further challenge in the case 
of neurodegenerative diseases, such as AD, is that any drug candidate will have the 
formidable task of needing to cross the blood-brain-barrier. Moreover, many anti-
amyloid therapies have failed in clinical trials, largely because the drugs are 
administered too late in the patient’s disease progression (279). If early detection 
was implemented, prior to the manifestation of symptoms, the preventative 
therapies could be administered prior to the onset of irreparable damage. Given 
the multifaceted nature of amyloid diseases, it is unlikely that a single therapeutic 
avenue will provide the ‘silver bullet’. However, rapid identification of aggregation 
inhibitors is a first, and vital step towards therapeutic intervention into such 
devastating disorders. The ESI-IMS-MS-based method described here may prove a 
valuable tool towards achieving these goals, by allowing direct identification of 
small molecule inhibitors of amyloid assembly. 
166 
 
References 
1. DOLE, M. Molecular beams of Macroions. J. Chem. Phys., 1968, 49(3), pp.2240-
2249. 
2. FENN, J.B., M. MANN, C.K. MENG, S.F. WONG and C.M. WHITEHOUSE. 
Electrospray ionization for mass spectrometry of large biomolecules. Science, 
1989, 246(4926), pp.64-71. 
3. HILLENKAMP, F. and M. KARAS. Mass spectrometry of peptides and proteins by 
matrix-assisted ultraviolet laser desorption/ionization. Methods Enzymol., 
1990, 193, pp.280-95. 
4. MEHMOOD, S., T.M. ALLISON and C.V. ROBINSON. Mass spectrometry of 
protein complexes: from origins to applications. Ann. Rev. Phys. Chem., 2015, 
66, pp.453-74. 
5. MARCOUX, J. and C.V. ROBINSON. Twenty years of gas phase structural biology. 
Structure, 2013, 21(9), pp.1541-50. 
6. WOODS, L.A., S.E. RADFORD and A.E. ASHCROFT. Advances in ion mobility 
spectrometry-mass spectrometry reveal key insights into amyloid assembly. 
BBA - Gen. Sub., 2013, 1834(6), pp.1257-68. 
7. PRINGLE, S.D., K. GILES, J.L. WILDGOOSE, J.P. WILLIAMS, S.E. SLADE, K. 
THALASSINOS, R.H. BATEMAN, M.T. BOWERS and J.H. SCRIVENS. An 
investigation of the mobility separation of some peptide and protein ions using 
a new hybrid quadrupole/travelling wave IMS/oa-ToF instrument. Int. J. Mass 
Spectrom., 2007, 261(1), pp.1-12. 
8. GRIFFITHS, W.J., A.P. JONSSON, S. LIU, D.K. RAI and Y. WANG. Electrospray and 
tandem mass spectrometry in biochemistry. Biochem. J., 2001, 355(Pt 3), 
pp.545-61. 
9. KARAS, M., M. GLUCKMANN and J. SCHAFER. Ionization in matrix-assisted laser 
desorption/ionization: singly charged molecular ions are the lucky survivors. J. 
Mass Spectrom., 2000, 35(1), pp.1-12. 
10. IRIBARNE, J.V. and B.A. THOMSON. On the evaporation of small ions from 
charged droplets. J. Chem. Phys., 1976, 64(6), pp.2287–2294. 
11. BENESCH, J.L., B.T. RUOTOLO, D.A. SIMMONS and C.V. ROBINSON. Protein 
complexes in the gas phase: technology for structural genomics and 
proteomics. Chem. Rev., 2007, 107(8), pp.3544-67. 
12. YUE, X., S. VAHIDI and L. KONERMANN. Insights into the mechanism of protein 
electrospray ionization from salt adduction measurements. J. Am. Soc. Mass 
Spectrom., 2014, 25(8), pp.1322-31. 
13. WILM M, M.M. Analytical properties of the nanoelectrospray ion source. Anal. 
Chem., 1996, 68(1), pp.1-8. 
14. FENN, J.B. Electrospray wings for molecular elephants (Nobel lecture). Angew. 
Chem. Int. Ed., 2003, 42(33), pp.3871-94. 
15. GUO, J.P., T. ARAI, J. MIKLOSSY and P.L. MCGEER. Abeta and tau form soluble 
complexes that may promote self aggregation of both into the insoluble forms 
observed in Alzheimer's disease. Proc. Natl. Acad. Sci., 2006, 103(6), pp.1953-8. 
16. RUOTOLO, B.T., J.L. BENESCH, A.M. SANDERCOCK, S.J. HYUNG and C.V. 
ROBINSON. Ion mobility-mass spectrometry analysis of large protein 
complexes. Nat. Protoc., 2008, 3(7), pp.1139-52. 
 REFERENCES 
 
167 
 
17. UETRECHT, C., R.J. ROSE, E. VAN DUIJN, K. LORENZEN and A.J. HECK. Ion 
mobility mass spectrometry of proteins and protein assemblies. Chem. Soc. 
Rev., 2010, 39(5), pp.1633-55. 
18. VERBECK, G.F., B.T. RUOTOLO, H.A. SAWYER, K.J. GILLIG and D.H. RUSSELL. A 
fundamental introduction to ion mobility mass spectrometry applied to the 
analysis of biomolecules. J Biomol. Tech., 2002, 13(2), pp.56-61. 
19. KANU, A.B., P. DWIVEDI, M. TAM, L. MATZ and H.H. HILL, JR. Ion mobility-mass 
spectrometry. J. Mass Spectrom., 2008, 43(1), pp.1-22. 
20. SMITH, D.P., T.W. KNAPMAN, I. CAMPUZANO, R.W. MALHAM, J.T. BERRYMAN, 
S.E. RADFORD and A.E. ASHCROFT. Deciphering drift time measurements from 
travelling wave ion mobility spectrometry-mass spectrometry studies. Eur. J. 
Mass Spectrom., 2009, 15(2), pp.113-30. 
21. SHVARTSBURG, A.A. and R.D. SMITH. Fundamentals of Traveling Wave Ion 
Mobility Spectrometry. Anal. Chem., 2008, 80(24), pp.9689-9699. 
22. GILES, K., S.D. PRINGLE, K.R. WORTHINGTON, D. LITTLE, J.L. WILDGOOSE and 
R.H. BATEMAN. Applications of a travelling wave-based radio-frequency-only 
stacked ring ion guide. Rapid Commun. Mass Spectrom., 2004, 18(20), pp.2401-
14. 
23. VALENTINE, S.J., A.E. COUNTERMAN, C.S. HOAGLUND, J.P. REILLY and D.E. 
CLEMMER. Gas-phase separations of protease digests. J. Am. Soc. Mass 
Spectrom., 1998, 9(11), pp.1213-6. 
24. CLEMMER, D.E.H., R. R.; JARROLD, M. F. Naked Protein Conformations: 
Cytochrome c in the Gas Phase. J. Am. Chem. Soc., 1995, 117, pp.10141-10142. 
25. MESLEH, M.F., J.M. HUNTER, A.A. SHVARTSBURG, G.C. SCHATZ and M.F. 
JARROLD. Structural information from ion mobility measurements: Effects of 
the long-range potential (vol 100, pg 16082, 1996). J Phys. Chem. A, 1997, 
101(5), pp.968-968. 
26. SHVARTSBURG, A.A. and M.F. JARROLD. An exact hard-spheres scattering 
model for the mobilities of polyatomic ions. Chem. Phys. Lett., 1996, 261(1-2), 
pp.86-91. 
27. BLEIHOLDER, C., T. WYTTENBACH and M.T. BOWERS. A novel projection 
approximation algorithm for the fast and accurate computation of molecular 
collision cross sections (I). Method. Int. J Mass Spectrom., 2011, 308(1), pp.1-
10. 
28. STEPHENS, W. Pulsed Mass Spectrometer with Time Dispersion. Bull. Am. Phys. 
Soc., 1946, 21(2), p.22. 
29. WILEY, W.C. and I.H. MCLAREN. Time-Of-Flight Mass Spectrometer with 
Improved Resolution. Rev. of Sci. Instrum., 1955, 26(12), p.1150. 
30. BROWN, R.S. and J.J. LENNON. Mass resolution improvement by incorporation 
of pulsed ion extraction in a matrix-assisted laser desorption/ionization linear 
time-of-flight mass spectrometer. Anal. Chem., 1995, 67(13), pp.1998-2003. 
31. MAMYRIN, B.A., V.I. KARATAEV, D.V. SHMIKK and V.A. ZAGULIN. Mass-
Reflectron a New Nonmagnetic Time-of-Flight High-Resolution Mass-
Spectrometer. Zh Eksp Teor Fiz+, 1973, 64(1), pp.82-89. 
32. DEHOFFMANN, E. Tandem mass spectrometry: A primer. J. Mass Spectrom., 
1996, 31(2), pp.129-137. 
 REFERENCES 
 
168 
 
33. SHUKLA, A.K. and J.H. FUTRELL. Tandem mass spectrometry: dissociation of 
ions by collisional activation. J. Mass Spectrom., 2000, 35(9), pp.1069-1090. 
34. ROSTOM, A.A. and C.V. ROBINSON. Disassembly of intact multiprotein 
complexes in the gas phase. Curr. Opin. Struct. Biol., 1999, 9(1), pp.135-41. 
35. NIU, S. and B.T. RUOTOLO. Collisional unfolding of multiprotein complexes 
reveals cooperative stabilization upon ligand binding. Protein Sci., 2015, 24(8), 
pp.1272-81. 
36. WYSOCKI, V.H., K.A. RESING, Q.F. ZHANG and G.L. CHENG. Mass spectrometry 
of peptides and proteins. Methods, 2005, 35(3), pp.211-222. 
37. CHOWDHURY, S.K., V. KATTA and B.T. CHAIT. Electrospray ionization mass 
spectrometric peptide mapping: a rapid, sensitive technique for protein 
structure analysis. Biochem. Biophys. Res. Commun., 1990, 167(2), pp.686-92. 
38. KALTASHOV, I.A. and A. MOHIMEN. Estimates of protein surface areas in 
solution by electrospray ionization mass spectrometry. Anal. Chem., 2005, 
77(16), pp.5370-9. 
39. LORENZEN, K., A.S. OLIA, C. UETRECHT, G. CINGOLANI and A.J. HECK. 
Determination of stoichiometry and conformational changes in the first step of 
the P22 tail assembly. J. Mol. Biol., 2008, 379(2), pp.385-96. 
40. UETRECHT, C., C. VERSLUIS, N.R. WATTS, W.H. ROOS, G.J.L. WUITE, P.T. 
WINGFIELD, A.C. STEVEN and A.J.R. HECK. High-resolution mass spectrometry 
of viral assemblies: Molecular composition and stability of dimorphic hepatitis 
B virus capsids. Proc. Natl. Acad. Sci., 2008, 105(27), pp.9216-9220. 
41. BERESZCZAK, J.Z., M. HAVLIK, V.U. WEISS, M. MARCHETTI-DESCHMANN, E. VAN 
DUIJN, N.R. WATTS, P.T. WINGFIELD, G. ALLMAIER, A.C. STEVEN and A.J.R. 
HECK. Sizing up large protein complexes by electrospray ionisation-based 
electrophoretic mobility and native mass spectrometry: morphology selective 
binding of Fabs to hepatitis B virus capsids. Anal. Bioanal. Chem., 2014, 406(5), 
pp.1437-1446. 
42. KNAPMAN, T.W., V.L. MORTON, N.J. STONEHOUSE, P.G. STOCKLEY and A.E. 
ASHCROFT. Determining the topology of virus assembly intermediates using ion 
mobility spectrometry-mass spectrometry. Rapid Commun. Mass Spectrom., 
2010, 24(20), pp.3033-3042. 
43. HECK, A.J.R. Ion mobility mass spectrometry applied to virus structure and 
assembly. Abstr. Pap. Am. Chem. Soc., 2010, 240. 
44. WOODS, L.A., G.W. PLATT, A.L. HELLEWELL, E.W. HEWITT, S.W. HOMANS, A.E. 
ASHCROFT and S.E. RADFORD. Ligand binding to distinct states diverts 
aggregation of an amyloid-forming protein. Nat. Chem. Biol., 2011, 7(10), 
pp.730-9. 
45. GESSEL, M.M., S. BERNSTEIN, M. KEMPER, D.B. TEPLOW and M.T. BOWERS. 
Familial Alzheimer’s disease mutations differentially alter amyloid β-protein 
oligomerization. ACS Chem. Neurosci., 2012, 3(11), pp.909-918. 
46. BLEIHOLDER, C., N.F. DUPUIS, T. WYTTENBACH and M.T. BOWERS. Ion mobility-
mass spectrometry reveals a conformational conversion from random assembly 
to β-sheet in amyloid fibril formation. Nat. Chem., 2011, 3(2), pp.172-7. 
47. DUPUIS, N.F., C. WU, J.E. SHEA and M.T. BOWERS. The amyloid formation 
mechanism in human IAPP: dimers have β-strand monomer-monomer 
interfaces. J. Am. Chem. Soc., 2011, 133(19), pp.7240-3. 
 REFERENCES 
 
169 
 
48. DUPUIS, N.F., C. WU, J.E. SHEA and M.T. BOWERS. Human islet amyloid 
polypeptide monomers form ordered beta-hairpins: a possible direct 
amyloidogenic precursor. J. Am. Chem. Soc., 2009, 131(51), pp.18283-92. 
49. BERNSTEIN, S.L., D. LIU, T. WYTTENBACH, M.T. BOWERS, J.C. LEE, H.B. GRAY 
and J.R. WINKLER. Alpha-synuclein: stable compact and extended monomeric 
structures and pH dependence of dimer formation. J. Am. Soc. Mass Spectrom., 
2004, 15(10), pp.1435-43. 
50. SINZ, A. The advancement of chemical cross-linking and mass spectrometry for 
structural proteomics: from single proteins to protein interaction networks. 
Expert Rev. Proteomics, 2014, 11(6), pp.733-43. 
51. SINZ, A. Chemical cross-linking and mass spectrometry to map three-
dimensional protein structures and protein-protein interactions. Mass 
Spectrom. Rev., 2006, 25(4), pp.663-82. 
52. RAND, K.D., M. ZEHL and T.J. JORGENSEN. Measuring the hydrogen/deuterium 
exchange of proteins at high spatial resolution by mass spectrometry: 
overcoming gas-phase hydrogen/deuterium scrambling. Acc. Chem. Res., 2014, 
47(10), pp.3018-27. 
53. RAND, K.D., S.D. PRINGLE, J.P. MURPHY, 3RD, K.E. FADGEN, J. BROWN and J.R. 
ENGEN. Gas-phase hydrogen/deuterium exchange in a traveling wave ion guide 
for the examination of protein conformations. Anal. Chem., 2009, 81(24), 
pp.10019-28. 
54. DILL, K.A. and H.S. CHAN. From Levinthal to pathways to funnels. Nat. Struc. 
Biol., 1997, 4(1), pp.10-9. 
55. DOBSON, C.M. Protein-misfolding diseases: Getting out of shape. Nature, 2002, 
418(6899), pp.729-730. 
56. CHITI, F. and C.M. DOBSON. Protein misfolding, functional amyloid, and human 
disease. Ann. Rev. Biochem., 2006, 75, pp.333-66. 
57. HARTL, F.U. and M. HAYER-HARTL. Converging concepts of protein folding in 
vitro and in vivo. Nat. Struc. Mol. Biol., 2009, 16(6), pp.574-581. 
58. BROCKWELL, D.J. and S.E. RADFORD. Intermediates: Ubiquitous species on 
folding energy landscapes? Curr. Opin. Struct. Biol., 2007, 17(1), pp.30-37. 
59. DOBSON, C.M. Protein folding and misfolding. Nature, 2003, 426(6968), 
pp.884-90. 
60. STEFANI, M. and C.M. DOBSON. Protein aggregation and aggregate toxicity: 
new insights into protein folding, misfolding diseases and biological evolution. J 
Mol.Med., 2003, 81(11), pp.678-99. 
61. VENDRUSCOLO, M., J. ZURDO, C.E. MACPHEE and C.M. DOBSON. Protein 
folding and misfolding: a paradigm of self-assembly and regulation in complex 
biological systems. Philos. Transact. A Math. Phys. Eng. Sci., 2003, 361(1807), 
pp.1205-22. 
62. SIPE, J.D., M.D. BENSON, J.N. BUXBAUM, S.-I. IKEDA, G. MERLINI, M.J.M. 
SARAIVA and P. WESTERMARK. Nomenclature 2014: Amyloid fibril proteins and 
clinical classification of the amyloidosis. Amyloid, 2014, 21(4), pp.221-224. 
63. ROSS, C., POIRIER, M.,. Protein aggregation and neurodegenerative disease. 
Nat. Med., 2004, 10, pp.S10-S17. 
64. SIPE, J.D., M.D. BENSON, J.N. BUXBAUM, S.-I. IKEDA, G. MERLINI, M.J.M. 
SARAIVA and P. WESTERMARK. Amyloid fibril protein nomenclature: 2012 
 REFERENCES 
 
170 
 
recommendations from the Nomenclature Committee of the International 
Society of Amyloidosis. Amyloid, 2012, 19(4), pp.167-170. 
65. VENDRUSCOLO, M., T.P. KNOWLES and C.M. DOBSON. Protein solubility and 
protein homeostasis: a generic view of protein misfolding disorders. Cold Spring 
Harb. Perspect. Biol., 2011, 3(12). 
66. KAYED, R., E. HEAD, J.L. THOMPSON, T.M. MCINTIRE, S.C. MILTON, C.W. 
COTMAN and C.G. GLABE. Common structure of soluble amyloid oligomers 
implies common mechanism of pathogenesis. Science, 2003, 300(5618), 
pp.486-489. 
67. NORRBY, E. Prions and protein folding diseases. J. Internal Med., 2011, 270(1), 
pp.1-14. 
68. NOMURA, Y. Molecular approaches to the treatment, prophylaxis, and 
diagnosis of Alzheimer's disease. J Pharmacol.Sci., 2012, 118(3), pp.317-318. 
69. JAIN, S., N. WOOD and D. HEALY. Molecular genetic pathways in Parkinson's 
disease: a review. Clin. Sci., 2005, 109, pp.355-364. 
70. KIERNAN, M.C., S. VUCIC, B.C. CHEAH, M.R. TURNER, A. EISEN, O. HARDIMAN, 
J.R. BURRELL and M.C. ZOING. Amyotrophic lateral sclerosis. Lancet, 377(9769), 
pp.942-955. 
71. ROSS, C.A. and S.J. TABRIZI. Huntington's disease: from molecular pathogenesis 
to clinical treatment. Lancet Neurol., 2011, 10(1), pp.83-98. 
72. WESTERMARK, P., A. ANDERSSON and G.T. WESTERMARK. Islet amyloid 
polypeptide, islet amyloid, and diabetes mellitus. Physiol. Rev., 2011, 91(3), 
pp.795-826. 
73. SHIKAMA, Y., J.-I. KITAZAWA, N. YAGIHASHI, O. UEHARA, Y. MURATA, N. 
YAJIMA, R. WADA and S. YAGIHASHI. Localized amyloidosis at the site of 
repeated insulin injection in a diabetic patient. Intern. Med., 2010, 49(5), 
pp.397-401. 
74. TEOH, C., M.W. GRIFFIN and G. HOWLETT. Apolipoproteins and amyloid fibril 
formation in atherosclerosis. Protein Cell, 2011, 2(2), pp.116-127. 
75. MERLINI, G., R.L. COMENZO, D.C. SELDIN, A. WECHALEKAR and M.A. GERTZ. 
Immunoglobulin light chain amyloidosis. Exp. Rev. Hematol., 2014, 7(1), pp.143-
156. 
76. PETTERSSON, T., Y. KONTTINEN and C. MAURY. Treatment strategies for 
amyloid A amyloidosis. Exp. Opin. Pharmacother., 2008, 9(12), pp.2117-2128. 
77. SMITH, D., A. ASHCROFT and S. RADFORD. Hemodialysis-related amyloidosis. In: 
M. RAMIREZ-ALVARADO, J. KELLY and C. DOBSON, eds. Protein misfolding 
diseases: current and emerging principles and therapies.  Hoboken, New Jersey: 
John Wiley & Sons, Inc., 2010. 
78. GRANEL, B., S. VALLEIX, J. SERRATRICE, P. CHÉRIN, A. TEXEIRA, P. DISDIER, P. 
WEILLER and G. GRATEAU. Lysozyme amyloidosis: report of 4 cases and a 
review of the literature. Medicine, 2006, 85(1), pp.66-73. 
79. HYUNG, S.J., C.V. ROBINSON and B.T. RUOTOLO. Gas-phase unfolding and 
disassembly reveals stability differences in ligand-bound multiprotein 
complexes. Chem. Biol., 2009, 16(4), pp.382-90. 
80. ADAMCIK, J. and R. MEZZENGA. Study of amyloid fibrils via atomic force 
microscopy. Curr. Opin. Colloid. In., 2012, 17(6), pp.369-376. 
 REFERENCES 
 
171 
 
81. SERPELL, L.C. Alzheimer's amyloid fibrils: structure and assembly. Bba-Mol Basis 
Dis, 2000, 1502(1), pp.16-30. 
82. BENDITT, E.P., N. ERIKSEN and C. BERGLUND. Congo red dichroism with 
dispersed amyloid fibrils, an extrinsic cotton effect. Proc. Natl. Acad. Sci., 1970, 
66(4), pp.1044-51. 
83. BAN, T., D. HAMADA, K. HASEGAWA, H. NAIKI and Y. GOTO. Direct observation 
of amyloid fibril growth monitored by thioflavin T fluorescence. J. Biol. Chem., 
2003, 278(19), pp.16462-5. 
84. HOBBS, J.R. and A.D. MORGAN. Fluorescence Microscopy with Thioflavine-T in 
Diagnosis of Amyloid. J Pathol. Bacteriol., 1963, 86(2), pp.437-&. 
85. LADEWIG, P. Double-Refringence of the Amyloid-Congo-Red-Complex in 
Histological Sections. Nature, 1945, 156(3951), pp.81-82. 
86. BIANCALANA, M. and S. KOIDE. Molecular mechanism of Thioflavin-T binding to 
amyloid fibrils. BBA - Gen. Sub., 2010, 1804(7), pp.1405-12. 
87. FERRONE, F. Analysis of protein aggregation kinetics. Method Enzymol., 1999, 
309, pp.256-274. 
88. MADINE, J., E. JACK, P.G. STOCKLEY, S.E. RADFORD, L.C. SERPELL and D.A. 
MIDDLETON. Structural insights into the polymorphism of amyloid-like fibrils 
formed by region 20-29 of amylin revealed by solid-state NMR and X-ray fiber 
diffraction. J Am. Chem. Soc., 2008, 130(45), pp.14990-5001. 
89. WESTERMARK, P. Amyloid in the islets of Langerhans: thoughts and some 
historical aspects. Ups. J. Med. Sci., 2011, 116(2), pp.81-9. 
90. KARAMANOS, T.K., A.P. KALVERDA, G.S. THOMPSON and S.E. RADFORD. 
Visualization of transient protein-protein interactions that promote or inhibit 
amyloid assembly. Mol. Cell, 2014, 55(2), pp.214-26. 
91. KUMAR, A., L.C. PASLAY, D. LYONS, S.E. MORGAN, J.J. CORREIA and V. 
RANGACHARI. Specific Soluble Oligomers of Amyloid-β Peptide Undergo 
Replication and Form Non-fibrillar Aggregates in Interfacial Environments. J. 
Biol. Chem., 2012, 287(25), pp.21253-64. 
92. LAMBERT, M.P., A.K. BARLOW, B.A. CHROMY, C. EDWARDS, R. FREED, M. 
LIOSATOS, T.E. MORGAN, I. ROZOVSKY, B. TROMMER, K.L. VIOLA, P. WALS, C. 
ZHANG, C.E. FINCH, G.A. KRAFFT and W.L. KLEIN. Diffusible, nonfibrillar ligands 
derived from Aβ1–42 are potent central nervous system neurotoxins. Proc. Natl. 
Acad. Sci., 1998, 95(11), pp.6448-6453. 
93. SMITH, D.P., S.E. RADFORD and A.E. ASHCROFT. Elongated oligomers in beta2-
microglobulin amyloid assembly revealed by ion mobility spectrometry-mass 
spectrometry. Proc. Natl. Acad. Sci., 2010, 107(15), pp.6794-8. 
94. SMITH, A.M., T.R. JAHN, A.E. ASHCROFT and S.E. RADFORD. Direct observation 
of oligomeric species formed in the early stages of amyloid fibril formation 
using electrospray ionisation mass spectrometry. J. Mol. Biol., 2006, 364(1), 
pp.9-19. 
95. FRIMPONG, A.K., R.R. ABZALIMOV, V.N. UVERSKY and I.A. KALTASHOV. 
Characterization of intrinsically disordered proteins with electrospray ionization 
mass spectrometry: conformational heterogeneity of alpha-synuclein. Proteins, 
2010, 78(3), pp.714-22. 
 REFERENCES 
 
172 
 
96. LIU, Y., J.A. CARVER, A.N. CALABRESE and T.L. PUKALA. Gallic acid interacts with 
alpha-synuclein to prevent the structural collapse necessary for its aggregation. 
Biochim. Biophys. Acta, 2014, 1844(9), pp.1481-5. 
97. WILLIAMS, D.M. and T.L. PUKALA. Novel insights into protein misfolding 
diseases revealed by ion mobility-mass spectrometry. Mass Spectrom. Rev., 
2013, 32(3), pp.169-87. 
98. BERNSTEIN, S.L., N.F. DUPUIS, N.D. LAZO, T. WYTTENBACH, M.M. CONDRON, G. 
BITAN, D.B. TEPLOW, J.E. SHEA, B.T. RUOTOLO, C.V. ROBINSON and M.T. 
BOWERS. Amyloid-β protein oligomerization and the importance of tetramers 
and dodecamers in the aetiology of Alzheimer's disease. Nat. Chem., 2009, 1(4), 
pp.326-31. 
99. ZHENG, X., M.M. GESSEL, M.L. WISNIEWSKI, K. VISWANATHAN, D.L. WRIGHT, 
B.A. BAHR and M.T. BOWERS. Z-Phe-Ala-diazomethylketone (PADK) disrupts 
and remodels early oligomer states of the Alzheimer disease Aβ42 protein. J. 
Biol. Chem., 2012, 287(9), pp.6084-6088. 
100. KLONIECKI, M., A. JABLONOWSKA, J. POZNANSKI, J. LANGRIDGE, C. HUGHES, I. 
CAMPUZANO, K. GILES and M. DADLEZ. Ion mobility separation coupled with 
MS detects two structural states of Alzheimer's disease Abeta1-40 peptide 
oligomers. J Mol. Biol., 2011, 407(1), pp.110-24. 
101. YOUNG, L., H. NDLOVU, T. KNAPMAN, S. HARRIS, S. RADFORD and A. 
ASHCROFT. Monitoring oligomer formation from self-aggregating amylin 
peptides using ESI-IMS-MS. Int. J. Ion Mobil. Spectrom., 2013, 16(1), pp.29-39. 
102. YOUNG, L.M., P. CAO, D.P. RALEIGH, A.E. ASHCROFT and S.E. RADFORD. Ion 
mobility spectrometry-mass spectrometry defines the oligomeric intermediates 
in amylin amyloid formation and the mode of action of inhibitors. J. Am. Chem. 
Soc., 2014, 136(2), pp.660-70. 
103. MCCAMMON, M.G., D.J. SCOTT, C.A. KEETCH, L.H. GREENE, H.E. PURKEY, H.M. 
PETRASSI, J.W. KELLY and C.V. ROBINSON. Screening transthyretin amyloid fibril 
inhibitors: characterization of novel multiprotein, multiligand complexes by 
mass spectrometry. Structure, 2002, 10(6), pp.851-63. 
104. SUSA, A.C., C. WU, S.L. BERNSTEIN, N.F. DUPUIS, H. WANG, D.P. RALEIGH, J.-E. 
SHEA and M.T. BOWERS. Defining the molecular basis of amyloid inhibitors: 
human islet amyloid polypeptide–insulin interactions. J. Am. Chem. Soc., 2014, 
136(37), pp.12912-12919. 
105. NETTLETON, E.J., P. TITO, M. SUNDE, M. BOUCHARD, C.M. DOBSON and C.V. 
ROBINSON. Characterization of the oligomeric states of insulin in self-assembly 
and amyloid fibril formation by mass spectrometry. Biophys. J., 2000, 79(2), 
pp.1053-65. 
106. GRABENAUER, M., C. WU, P. SOTO, J.E. SHEA and M.T. BOWERS. Oligomers of 
the prion protein fragment 106-126 are likely assembled from beta-hairpins in 
solution, and methionine oxidation inhibits assembly without altering the 
peptide's monomeric conformation. J. Am. Chem. Soc., 2010, 132(2), pp.532-9. 
107. ABEDINI, A. and A.M. SCHMIDT. Mechanisms of islet amyloidosis toxicity in type 
2 diabetes. FEBS Lett., 2013, 587(8), pp.1119-1127. 
108. WESTERMARK, P., C. WERNSTEDT, E. WILANDER, D.W. HAYDEN, T.D. O'BRIEN 
and K.H. JOHNSON. Amyloid fibrils in human insulinoma and islets of 
Langerhans of the diabetic cat are derived from a neuropeptide-like protein 
 REFERENCES 
 
173 
 
also present in normal islet cells. Proc. Natl. Acad. Sci., 1987, 84(11), pp.3881-
3885. 
109. WESTERMARK, P., A. ANDERSSON and G.T. WESTERMARK. Islet amyloid 
polypeptide, islet amyloid, and diabetes mellitus. Physiol. Rev., 2011, 91(3), 
pp.795-826. 
110. YAN, L.M., M. TATAREK-NOSSOL, A. VELKOVA, A. KAZANTZIS and A. 
KAPURNIOTU. Design of a mimic of nonamyloidogenic and bioactive human 
islet amyloid polypeptide (IAPP) as nanomolar affinity inhibitor of IAPP 
cytotoxic fibrillogenesis. Proc Natl Acad Sci U S A, 2006, 103(7), pp.2046-51. 
111. MAREK, P., A.M. WOYS, K. SUTTON, M.T. ZANNI and D.P. RALEIGH. Efficient 
microwave-assisted synthesis of human islet amyloid polypeptide designed to 
facilitate the specific incorporation of labeled amino acids. Org Lett, 2010, 
12(21), pp.4848-51. 
112. SARAOGI, I., J.A. HEBDA, J. BECERRIL, L.A. ESTROFF, A.D. MIRANKER and A.D. 
HAMILTON. Synthetic alpha-helix mimetics as agonists and antagonists of islet 
amyloid polypeptide aggregation. Angew Chem Int Ed Engl, 2010, 49(4), 
pp.736-9. 
113. WESTERMARK, P., U. ENGSTROM, K.H. JOHNSON, G.T. WESTERMARK and C. 
BETSHOLTZ. Islet amyloid polypeptide: pinpointing amino acid residues linked 
to amyloid fibril formation. Proc Natl Acad Sci U S A, 1990, 87(13), pp.5036-40. 
114. CAO, P., F. MENG, A. ABEDINI and D.P. RALEIGH. The ability of rodent islet 
amyloid polypeptide to inhibit amyloid formation by human islet amyloid 
polypeptide has important implications for the mechanism of amyloid 
formation and the design of inhibitors. Biochem., 2010, 49(5), pp.872-81. 
115. TENIDIS, K., M. WALDNER, J. BERNHAGEN, W. FISCHLE, M. BERGMANN, M. 
WEBER, M.L. MERKLE, W. VOELTER, H. BRUNNER and A. KAPURNIOTU. 
Identification of a penta- and hexapeptide of islet amyloid polypeptide (IAPP) 
with amyloidogenic and cytotoxic properties. J Mol Biol, 2000, 295(4), pp.1055-
71. 
116. MENG, F., D.P. RALEIGH and A. ABEDINI. Combination of kinetically selected 
inhibitors in trans leads to highly effective inhibition of amyloid formation. J. 
Am. Chem. Soc., 2010, 132(41), pp.14340-2. 
117. YAN, L.M., M. TATAREK-NOSSOL, A. VELKOVA, A. KAZANTZIS and A. 
KAPURNIOTU. Design of a mimic of nonamyloidogenic and bioactive human 
islet amyloid polypeptide (IAPP) as nanomolar affinity inhibitor of IAPP 
cytotoxic fibrillogenesis. Proc.  Nat. Acad. Sci., 2006, 103(7), pp.2046-51. 
118. MORIARTY, D.F. and D.P. RALEIGH. Effects of sequential proline substitutions 
on amyloid formation by human amylin20-29. Biochem., 1999, 38(6), pp.1811-
8. 
119. CAO, P., A. ABEDINI, H. WANG, L.H. TU, X. ZHANG, A.M. SCHMIDT and D.P. 
RALEIGH. Islet amyloid polypeptide toxicity and membrane interactions. Proc. 
Natl. Acad. Sci., 2013, 110(48), pp.19279-84. 
120. SAKAGASHIRA, S., H.J. HIDDINGA, K. TATEISHI, T. SANKE, T. HANABUSA, K. 
NANJO and N.L. EBERHARDT. S20G mutant amylin exhibits increased in vitro 
amyloidogenicity and increased intracellular cytotoxicity compared to wild-type 
amylin. Am. J. Pathol., 2000, 157(6), pp.2101-9. 
 REFERENCES 
 
174 
 
121. TU, L.H., A.L. SERRANO, M.T. ZANNI and D.P. RALEIGH. Mutational analysis of 
preamyloid intermediates: the role of his-tyr interactions in islet amyloid 
formation. Biophys. J., 2014, 106(7), pp.1520-7. 
122. LEE, V.M.Y. Amyloid binding ligands as Alzheimer’s disease therapies. 
Neurobiology of Aging, 2002, 23(6), pp.1039-1042. 
123. MINATI, L., T. EDGINTON, M. GRAZIA BRUZZONE and G. GIACCONE. Reviews: 
Current concepts in Alzheimer's disease: A multidisciplinary review. Am. J. 
Alzheimers Dis. Other Demen., 2009, 24(2), pp.95-121. 
124. LANDAU, M., M.R. SAWAYA, K.F. FAULL, A. LAGANOWSKY, L. JIANG, S.A. 
SIEVERS, J. LIU, J.R. BARRIO and D. EISENBERG. Towards a pharmacophore for 
amyloid. PLoS Biol., 2011, 9(6), p.e1001080. 
125. MAK, J.C.W. Potential role of green tea catechins in various disease therapies: 
Progress and promise. Clin. Exp.Pharmacol. Physiol., 2012, 39(3), pp.265-273. 
126. BULAWA, C.E., S. CONNELLY, M. DEVIT, L. WANG, C. WEIGEL, J.A. FLEMING, J. 
PACKMAN, E.T. POWERS, R.L. WISEMAN, T.R. FOSS, I.A. WILSON, J.W. KELLY 
and R. LABAUDINIÈRE. Tafamidis, a potent and selective transthyretin kinetic 
stabilizer that inhibits the amyloid cascade. Proc. Natl. Acad. Sci., 2012. 
127. HAMLEY, I.W. The amyloid beta peptide: a chemist’s perspective. Role in 
Alzheimer’s and fibrillization. Chem. Rev., 2012, 112(10), pp.5147-5192. 
128. PORAT, Y., A. ABRAMOWITZ and E. GAZIT. Inhibition of amyloid fibril formation 
by polyphenols: structural similarity and aromatic interactions as a common 
inhibition mechanism. Chem. Biol. Drug Des., 2006, 67(1), pp.27-37. 
129. LORENZO, A. and B.A. YANKNER. Beta-amyloid neurotoxicity requires fibril 
formation and is inhibited by Congo red. Proc. Natl. Acad. Sci., 1994, 91(25), 
pp.12243-12247. 
130. POLI, G., W. PONTI, G. CARCASSOLA, F. CECILIANI, L. COLOMBO, P. DALL’ARA, 
M. GERVASONI, M.L. GIANNINO, P.A. MARTINO, C. POLLER, S. VILLA and M. 
SALMONA. In vitro evaluation of the anti-prionic activity of newly synthesized 
Congo red derivatives. Arzneim.-Forsch., 2003, 53(12), pp.875-888. 
131. MISHRA, R., B. BULIC, D. SELLIN, S. JHA, H. WALDMANN and R. WINTER. Small-
molecule inhibitors of islet amyloid polypeptide fibril formation. Angew. Chem. 
Int. Ed., 2008, 47(25), pp.4679-4682. 
132. WU, C., J. SCOTT and J.-E. SHEA. Binding of Congo red to amyloid protofibrils of 
the Alzheimer Aβ9–40 peptide probed by molecular dynamics simulations. 
Biophys. J., 2012, 103(3), pp.550-557. 
133. TURNELL, W.G. and J.T. FINCH. Binding of the dye Congo red to the amyloid 
protein pig insulin reveals a novel homology amongst amyloid-forming peptide 
sequences. J. Mol. Biol., 1992, 227(4), pp.1205-1223. 
134. KIM, Y.-S., T.W. RANDOLPH, M.C. MANNING, F.J. STEVENS and J.F. CARPENTER. 
Congo red populates partially unfolded states of an amyloidogenic protein to 
enhance aggregation and amyloid fibril formation. J. Biol. Chem., 2003, 278(12), 
pp.10842-10850. 
135. PALHANO, F.L., J. LEE, N.P. GRIMSTER and J.W. KELLY. Toward the molecular 
mechanism(s) by which EGCG treatment remodels mature amyloid fibrils. J. 
Am. Chem. Soc., 2013, 135(20), pp.7503-7510. 
136. MENG, F., A. ABEDINI, A. PLESNER, C.B. VERCHERE and D.P. RALEIGH. The 
flavanol (-)-epigallocatechin 3-gallate inhibits amyloid formation by islet 
 REFERENCES 
 
175 
 
amyloid polypeptide, disaggregates amyloid fibrils, and protects cultured cells 
against IAPP-induced toxicity. Biochem., 2010, 49(37), pp.8127-8133. 
137. CAO, P. and D.P. RALEIGH. Analysis of the inhibition and remodeling of islet 
amyloid polypeptide amyloid fibers by flavanols. Biochem., 2012, 51(13), 
pp.2670-2683. 
138. YOUNG, L.M., P. CAO, D.P. RALEIGH, A.E. ASHCROFT and S.E. RADFORD. Ion 
mobility spectrometry–mass spectrometry defines the oligomeric 
intermediates in amylin amyloid formation and the mode of action of 
inhibitors. J. Am. Chem. Soc., 2013, 136(2), pp.660-670. 
139. FERREIRA, N., M.J. SARAIVA and M.R. ALMEIDA. Natural polyphenols inhibit 
different steps of the process of transthyretin (TTR) amyloid fibril formation. 
FEBS Lett., 2011, 585(15), pp.2424-2430. 
140. HUDSON, S.A., H. ECROYD, F.C. DEHLE, I.F. MUSGRAVE and J.A. CARVER. (−)-
Epigallocatechin-3-gallate (EGCG) maintains κ-casein in its pre-fibrillar state 
without redirecting its aggregation pathway. J. Mol. Biol., 2009, 392(3), pp.689-
700. 
141. EHRNHOEFER, D.E., J. BIESCHKE, A. BOEDDRICH, M. HERBST, L. MASINO, R. 
LURZ, S. ENGEMANN, A. PASTORE and E.E. WANKER. EGCG redirects 
amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat. 
Struc. Mol. Biol., 2008, 15(6), pp.558-66. 
142. AISEN, P.S. The development of anti-amyloid therapy for alzheimer's disease: 
From secretase modulators to polymerisation inhibitors. CNS Drugs, 2005, 
19(12), pp.989-996. 
143. TANIGUCHI, S., N. SUZUKI, M. MASUDA, S.-I. HISANAGA, T. IWATSUBO, M. 
GOEDERT and M. HASEGAWA. Inhibition of heparin-induced Tau filament 
formation by phenothiazines, polyphenols, and porphyrins. J. Biol. Chem., 2005, 
280(9), pp.7614-7623. 
144. HOWLETT, D., P. CUTLER, S. HEALES and P. CAMILLERI. Hemin and related 
porphyrins inhibit β-amyloid aggregation. FEBS Lett., 1997, 417(2), pp.249-251. 
145. ONO, K., K. HASEGAWA, H. NAIKI and M. YAMADA. Curcumin has potent anti-
amyloidogenic effects for Alzheimer's β-amyloid fibrils in vitro. J Neurosci. Res., 
2004, 75(6), pp.742-750. 
146. JIANG, T., X.-L. ZHI, Y.-H. ZHANG, L.-F. PAN and P. ZHOU. Inhibitory effect of 
curcumin on the Al(III)-induced Aβ42 aggregation and neurotoxicity in vitro. 
Biochim. Biophys. Acta, 2012, 1822(8), pp.1207-1215. 
147. DAVAL, M., S. BEDROOD, T. GURLO, C.-J. HUANG, S. COSTES, P.C. BUTLER and R. 
LANGEN. The effect of curcumin on human islet amyloid polypeptide misfolding 
and toxicity. Amyloid, 2010, 17(3-4), pp.118-128. 
148. SPARKS, S., G. LIU, K.J. ROBBINS and N.D. LAZO. Curcumin modulates the self-
assembly of the islet amyloid polypeptide by disassembling α-helix. Biochem. 
Biophys. Res. Commun., 2012, 422(4), pp.551-555. 
149. PANDEY, N., J. STRIDER, W. NOLAN, S. YAN and J. GALVIN. Curcumin inhibits 
aggregation of α-synuclein. Acta Neuropathol., 2008, 115(4), pp.479-489. 
150. BORANA, M.S., P. MISHRA, R.R.S. PISSURLENKAR, R.V. HOSUR and B. AHMAD. 
Curcumin and kaempferol prevent lysozyme fibril formation by modulating 
aggregation kinetic parameters. BBA - Proteins Proteomics, 2014, 1844(3), 
pp.670-680. 
 REFERENCES 
 
176 
 
151. HARRIS, J.R. In vitro fibrillogenesis of the amyloid β1–42 peptide: cholesterol 
potentiation and aspirin inhibition. Micron, 2002, 33(7–8), pp.609-626. 
152. PORAT, Y., Y. MAZOR, S. EFRAT and E. GAZIT. Inhibition of islet amyloid 
polypeptide fibril formation: a potential role for heteroaromatic interactions. 
Biochem., 2004, 43(45), pp.14454-62. 
153. PORAT, Y., A. ABRAMOWITZ and E. GAZIT. Inhibition of amyloid fibril formation 
by polyphenols: structural similarity and aromatic interactions as a common 
inhibition mechanism. Chem. Biol. Drug. Des., 2006, 67(1), pp.27-37. 
154. MASUDA, M., M. HASEGAWA, T. NONAKA, T. OIKAWA, M. YONETANI, Y. 
YAMAGUCHI, K. KATO, S.-I. HISANAGA and M. GOEDERT. Inhibition of α-
synuclein fibril assembly by small molecules. FEBS Lett., 2009, 583(4), pp.787-
791. 
155. CHENG, B., H. GONG, H. XIAO, R.B. PETERSEN, L. ZHENG and K. HUANG. 
Inhibiting toxic aggregation of amyloidogenic proteins: A therapeutic strategy 
for protein misfolding diseases. Biochem. Biophys. Res. Commun., 2013, 
1830(10), pp.4860-4871. 
156. PALHANO, F.L., J. LEE, N.P. GRIMSTER and J.W. KELLY. Toward the molecular 
mechanism(s) by which EGCG treatment remodels mature amyloid fibrils. J. 
Am. Chem. Soc., 2013, 135(20), pp.7503-10. 
157. MENG, F., A. ABEDINI, A. PLESNER, C.B. VERCHERE and D.P. RALEIGH. The 
flavanol (-)-epigallocatechin 3-gallate inhibits amyloid formation by islet 
amyloid polypeptide, disaggregates amyloid fibrils, and protects cultured cells 
against IAPP-induced toxicity. Biochem., 2010, 49(37), pp.8127-33. 
158. CAO, P. and D.P. RALEIGH. Analysis of the inhibition and remodeling of islet 
amyloid polypeptide amyloid fibers by flavanols. Biochem., 2012, 51(13), 
pp.2670-83. 
159. AHMAD, E., A. AHMAD, S. SINGH, M. ARSHAD, A.H. KHAN and R.H. KHAN. A 
mechanistic approach for islet amyloid polypeptide aggregation to develop 
anti-amyloidogenic agents for type-2 diabetes. Biochimie, 2011, 93(5), pp.793-
805. 
160. JIANG, L., C. LIU, D. LEIBLY, M. LANDAU, M. ZHAO, M.P. HUGHES, D.S. 
EISENBERG and J. KURIYAN. Structure-based discovery of fiber-binding 
compounds that reduce the cytotoxicity of amyloid beta. eLife, 2013, 2, 
p.e00857. 
161. ARMSTRONG, A.H., J. CHEN, A.F. MCKOY and M.H. HECHT. Mutations that 
replace aromatic side chains promote aggregation of the Alzheimer's Aβ 
peptide. Biochem., 2011, 50(19), pp.4058-4067. 
162. BIESCHKE, J., J. RUSS, R.P. FRIEDRICH, D.E. EHRNHOEFER, H. WOBST, K. 
NEUGEBAUER and E.E. WANKER. EGCG remodels mature α-synuclein and 
amyloid-β fibrils and reduces cellular toxicity. Proc. Natl. Acad. Sci., 2010, 
107(17), pp.7710-7715. 
163. FERREIRA, N., M.J. SARAIVA and M.R. ALMEIDA. Epigallocatechin-3-gallate as a 
potential therapeutic drug for TTR-related amyloidosis: “in vivo” evidence from 
FAP mice models. PLoS ONE, 2012, 7(1), p.e29933. 
164. CHOI, Y.-T., C.-H. JUNG, S.-R. LEE, J.-H. BAE, W.-K. BAEK, M.-H. SUH, J. PARK, C.-
W. PARK and S.-I. SUH. The green tea polyphenol (−)-epigallocatechin gallate 
 REFERENCES 
 
177 
 
attenuates β-amyloid-induced neurotoxicity in cultured hippocampal neurons. 
Life Sci., 2001, 70(5), pp.603-614. 
165. CEGELSKI, L., J.S. PINKNER, N.D. HAMMER, C.K. CUSUMANO, C.S. HUNG, E. 
CHORELL, V. Ã…BERG, J.N. WALKER, P.C. SEED, F. ALMQVIST, M.R. CHAPMAN 
and S.J. HULTGREN. Small-molecule inhibitors target Escherichia coli amyloid 
biogenesis and biofilm formation. Nat. Chem. Biol., 2009, 5(12), pp.913-919. 
166. TUROVEROV, K.K., I.M. KUZNETSOVA and V.N. UVERSKY. The protein kingdom 
extended: Ordered and intrinsically disordered proteins, their folding, 
supramolecular complex formation, and aggregation. Prog.Biophys. Mol. Biol., 
2010, 102(2-3), pp.73-84. 
167. MCGLINCHEY, R.P., T.L. YAP and J.C. LEE. The yin and yang of amyloid: insights 
from alpha-synuclein and repeat domain of Pmel17. Phys. Chem. Chem. Phys., 
2011, 13(45), pp.20066-75. 
168. BORYSIK, A.J., S.E. RADFORD and A.E. ASHCROFT. Co-populated conformational 
ensembles of beta2-microglobulin uncovered quantitatively by electrospray 
ionization mass spectrometry. J. Biol. Chem., 2004, 279(26), pp.27069-77. 
169. STEFANIS, L. alpha-Synuclein in Parkinson's Disease. Cold Spring Harb. Perspect. 
Med., 2012, 2(2). 
170. FLOEGE, J. and G. EHLERDING. Beta-2-microglobulin-associated amyloidosis. 
Nephron, 1996, 72(1), pp.9-26. 
171. VLAD, C., K. LINDNER, C. KARREMAN, S. SCHILDKNECHT, M. LEIST, N. TOMCZYK, 
J. RONTREE, J. LANGRIDGE, K. DANZER, T. CIOSSEK, A. PETRE, M.L. GROSS, B. 
HENGERER and M. PRZYBYLSKI. Autoproteolytic fragments are intermediates in 
the oligomerization/aggregation of the Parkinson's disease protein alpha-
synuclein as revealed by ion mobility mass spectrometry. ChemBioChem, 2011, 
12(18), pp.2740-4. 
172. SMITH, D.P., K. GILES, R.H. BATEMAN, S.E. RADFORD and A.E. ASHCROFT. 
Monitoring copopulated conformational states during protein folding events 
using electrospray ionization-ion mobility spectrometry-mass spectrometry. J. 
Am. Soc. Mass Spectrom., 2007, 18(12), pp.2180-90. 
173. LUCA, S., W.M. YAU, R. LEAPMAN and R. TYCKO. Peptide conformation and 
supramolecular organization in amylin fibrils: constraints from solid-state NMR. 
Biochem., 2007, 46(47), pp.13505-22. 
174. HILTON, G.R. and J.L.P. BENESCH. Two decades of studying non-covalent 
biomolecular assemblies by means of electrospray ionization mass 
spectrometry. J. R. Soc. Interface, 2012, 9(70), pp.801-816. 
175. RUOTOLO, B.T. and C.V. ROBINSON. Aspects of native proteins are retained in 
vacuum. Curr Opin Chem Biol, 2006, 10(5), pp.402-408. 
176. RUOTOLO, B.T., K. GILES, I. CAMPUZANO, A.M. SANDERCOCK, R.H. BATEMAN 
and C.V. ROBINSON. Evidence for Macromolecular Protein Rings in the Absence 
of Bulk Water. Science, 2005, 310(5754), pp.1658-1661. 
177. BUSH, M.F., Z. HALL, K. GILES, J. HOYES, C.V. ROBINSON and B.T. RUOTOLO. 
Collision cross sections of proteins and their complexes: a calibration 
framework and database for gas-phase structural biology. Anal. Chem., 2010, 
82(22), pp.9557-65. 
 REFERENCES 
 
178 
 
178. SMITH, D.P., S.E. RADFORD and A.E. ASHCROFT. Elongated oligomers in β2-
microglobulin amyloid assembly revealed by ion mobility spectrometry-mass 
spectrometry. Proc. Natl. Acad. Sci., 2010, 107(15), pp.6794-6798. 
179. SMITH, D.P., K. GILES, R.H. BATEMAN, S.E. RADFORD and A.E. ASHCROFT. 
Monitoring Copopulated Conformational States During Protein Folding Events 
Using Electrospray Ionization-Ion Mobility Spectrometry-Mass Spectrometry. J 
Am Soc Mass Spectrom, 2007, 18(12), pp.2180-2190. 
180. SMITH, D.P., L.A. WOODS, S.E. RADFORD and A.E. ASHCROFT. Structure and 
Dynamics of Oligomeric Intermediates in β2-Microglobulin Self-Assembly. 
Biophys. J., 2011, 101(5), pp.1238-1247. 
181. HYUNG, S.J., A.S. DETOMA, J.R. BRENDER, S. LEE, S. VIVEKANANDAN, A. KOCHI, 
J.S. CHOI, A. RAMAMOORTHY, B.T. RUOTOLO and M.H. LIM. Insights into 
antiamyloidogenic properties of the green tea extract (-)-epigallocatechin-3-
gallate toward metal-associated amyloid-β species. Proc. Natl. Acad. Sci., 2013, 
110(10), pp.3743-8. 
182. YOUNG, L.M., J.C. SAUNDERS, R.A. MAHOOD, C.H. REVILL, R.J. FOSTER, L.H. TU, 
D.P. RALEIGH, S.E. RADFORD and A.E. ASHCROFT. Screening and classifying 
small-molecule inhibitors of amyloid formation using ion mobility 
spectrometry-mass spectrometry. Nat. Chem., 2015, 7(1), pp.73-81. 
183. LIU, Y.Q., L.H. HO, J.A. CARVER and T.L. PUKALA. Ion Mobility Mass 
Spectrometry Studies of the Inhibition of Alpha Synuclein Amyloid Fibril 
Formation by (-)-Epigallocatechin-3-Gallate. Aust. J Chem., 2011, 64(1), pp.36-
40. 
184. GRABENAUER, M., S.L. BERNSTEIN, J.C. LEE, T. WYTTENBACH, N.F. DUPUIS, H.B. 
GRAY, J.R. WINKLER and M.T. BOWERS. Spermine binding to Parkinson's 
protein alpha-synuclein and its disease-related A30P and A53T mutants. J. Phys. 
Chem. B, 2008, 112(35), pp.11147-54. 
185. NILSSON, M.R., M. DRISCOLL and D.P. RALEIGH. Low levels of asparagine 
deamidation can have a dramatic effect on aggregation of amyloidogenic 
peptides: Implications for the study of amyloid formation. Protein Sci., 2002, 
11(2), pp.342-349. 
186. DUNKELBERGER, E.B., L.E. BUCHANAN, P. MAREK, P. CAO, D.P. RALEIGH and 
M.T. ZANNI. Deamidation accelerates amyloid formation and alters amylin fiber 
structure. J. Am. Chem. Soc., 2012, 134(30), pp.12658-12667. 
187. WALSH, D.M., E. THULIN, A.M. MINOGUE, N. GUSTAVSSON, E. PANG, D.B. 
TEPLOW and S. LINSE. A facile method for expression and purification of the 
Alzheimer’s disease-associated amyloid β-peptide. FEBS J., 2009, 276(5), 
pp.1266-1281. 
188. VALENTINE, S.J., A.E. COUNTERMAN and D.E. CLEMMER. A database of 660 
peptide ion cross sections: use of intrinsic size parameters for bona fide 
predictions of cross sections. J. Am. Soc. Mass Spectrom., 1999, 10(11), 
pp.1188-211. 
189. MACKE, T.J. and D.A. CASE. Modeling unusual nucleic acid structures. In: N. 
LEONTES and J. SANTALUCIA, eds. Molecular Modeling of Nucleic Acids.  
Washington, DC: American Chemical Society, 1998, pp.379-393. 
 REFERENCES 
 
179 
 
190. CASE, D.A., T.E. CHEATHAM, 3RD, T. DARDEN, H. GOHLKE, R. LUO, K.M. MERZ, 
JR., A. ONUFRIEV, C. SIMMERLING, B. WANG and R.J. WOODS. The Amber 
biomolecular simulation programs. J Comput. Chem., 2005, 26(16), pp.1668-88. 
191. PHILLIPS, J.C., R. BRAUN, W. WANG, J. GUMBART, E. TAJKHORSHID, E. VILLA, C. 
CHIPOT, R.D. SKEEL, L. KALE and K. SCHULTEN. Scalable molecular dynamics 
with NAMD. J Comput. Chem., 2005, 26(16), pp.1781-802. 
192. HORNAK, V., R. ABEL, A. OKUR, B. STROCKBINE, A. ROITBERG and C. 
SIMMERLING. Comparison of multiple Amber force fields and development of 
improved protein backbone parameters. Proteins, 2006, 65(3), pp.712-25. 
193. Maestro [CD-ROM]. LLC, NY, USA: Schrödinger, 2014-2. 
194. Rapid Overlay of Chemical Structures (ROCS) [CD-ROM]. Santa Fe, NM, USA: 
OpenEye, Scientific Software. 
195. ROEPSTORFF, P. and J. FOHLMAN. Proposal for a common nomenclature for 
sequence ions in mass spectra of peptides. Biomed. Mass Spectrom., 1984, 
11(11), p.601. 
196. KALETA, D.T. and M.F. JARROLD. Peptide pinwheels. J Am. Chem. Soc., 2002, 
124(7), pp.1154-5. 
197. JIN, L., P.E. BARRAN, J.A. DEAKIN, M. LYON and D. UHRIN. Conformation of 
glycosaminoglycans by ion mobility mass spectrometry and molecular 
modelling. Phys. Chem. Chem. Phys., 2005, 7(19), pp.3464-71. 
198. THALASSINOS, K., M. GRABENAUER, S.E. SLADE, G.R. HILTON, M.T. BOWERS 
and J.H. SCRIVENS. Characterization of phosphorylated peptides using traveling 
wave-based and drift cell ion mobility mass spectrometry. Anal. Chem., 2009, 
81(1), pp.248-54. 
199. TENIDIS, K., M. WALDNER, J. BERNHAGEN, W. FISCHLE, M. BERGMANN, M. 
WEBER, M.L. MERKLE, W. VOELTER, H. BRUNNER and A. KAPURNIOTU. 
Identification of a penta- and hexapeptide of islet amyloid polypeptide (IAPP) 
with amyloidogenic and cytotoxic properties. J Mol. Biol., 2000, 295(4), 
pp.1055-71. 
200. WESTERMARK, P., U. ENGSTRÖM, K.H. JOHNSON, G.T. WESTERMARK and C. 
BETSHOLTZ. Islet amyloid polypeptide: pinpointing amino acid residues linked 
to amyloid fibril formation. Proc. Nat. Acad. Sci., 1990, 87(13), pp.5036-40. 
201. ZHAO, J., X. YU, G. LIANG and J. ZHENG. Structural polymorphism of human islet 
amyloid polypeptide (hIAPP) oligomers highlights the importance of interfacial 
residue interactions. Biomacromolecules, 2011, 12(1), pp.210-20. 
202. ABEDINI, A., G. SINGH and D.P. RALEIGH. Recovery and purification of highly 
aggregation-prone disulfide-containing peptides: application to islet amyloid 
polypeptide. Anal. Biochem., 2006, 351(2), pp.181-6. 
203. WILTZIUS, J.J., S.A. SIEVERS, M.R. SAWAYA, D. CASCIO, D. POPOV, C. RIEKEL and 
D. EISENBERG. Atomic structure of the cross-beta spine of islet amyloid 
polypeptide (amylin). Protein Sci., 2008, 17(9), pp.1467-74. 
204. NIELSEN, J.T., M. BJERRING, M.D. JEPPESEN, R.O. PEDERSEN, J.M. PEDERSEN, 
K.L. HEIN, T. VOSEGAARD, T. SKRYDSTRUP, D.E. OTZEN and N.C. NIELSEN. 
Unique identification of supramolecular structures in amyloid fibrils by solid-
state NMR spectroscopy. Angew. Chem. Int. Ed., 2009, 48(12), pp.2118-21. 
 REFERENCES 
 
180 
 
205. KUMAR, S. and A.D. MIRANKER. A foldamer approach to targeting membrane 
bound helical states of islet amyloid polypeptide. Chem. Commun., 2013, 
49(42), pp.4749-51. 
206. WILLIAMSON, J.A. and A.D. MIRANKER. Direct detection of transient alpha-
helical states in islet amyloid polypeptide. Protein Sci., 2007, 16(1), pp.110-7. 
207. ABEDINI, A., G. SINGH and D.P. RALEIGH. Recovery and purification of highly 
aggregation-prone disulfide-containing peptides: application to islet amyloid 
polypeptide. Anal Biochem, 2006, 351(2), pp.181-6. 
208. HEBDA, J.A., I. SARAOGI, M. MAGZOUB, A.D. HAMILTON and A.D. MIRANKER. A 
peptidomimetic approach to targeting pre-amyloidogenic states in type II 
diabetes. Chem. Biol., 2009, 16(9), pp.943-50. 
209. LARSON, J.L., E. KO and A.D. MIRANKER. Direct measurement of islet amyloid 
polypeptide fibrillogenesis by mass spectrometry. Protein Sci., 2000, 9(2), 
pp.427-31. 
210. MAREK, P.J., V. PATSALO, D.F. GREEN and D.P. RALEIGH. Ionic strength effects 
on amyloid formation by amylin are a complicated interplay among Debye 
screening, ion selectivity, and Hofmeister effects. Biochem., 2012, 51(43), 
pp.8478-90. 
211. JAIN, S. and J.B. UDGAONKAR. Salt-induced modulation of the pathway of 
amyloid fibril formation by the mouse prion protein. Biochem., 2010, 49(35), 
pp.7615-24. 
212. FUJIWARA, S., F. MATSUMOTO and Y. YONEZAWA. Effects of salt concentration 
on association of the amyloid protofilaments of hen egg white lysozyme 
studied by time-resolved neutron scattering. J Mol. Biol., 2003, 331(1), pp.21-8. 
213. CASTELLETTO, V., I.W. HAMLEY, C. CENKER and U. OLSSON. Influence of salt on 
the self-assembly of two model amyloid heptapeptides. J. Phys. Chem. B, 2010, 
114(23), pp.8002-8. 
214. BOSSIS, F. and L.L. PALESE. Amyloid beta(1-42) in aqueous environments: 
effects of ionic strength and E22Q (Dutch) mutation. Biochim. Biophys. Acta, 
2013, 1834(12), pp.2486-93. 
215. SMITH, D.P., S.E. RADFORD and A.E. ASHCROFT. Elongated oligomers in beta2-
microglobulin amyloid assembly revealed by ion mobility spectrometry-mass 
spectrometry. Proc Natl Acad Sci U S A, 2010, 107(15), pp.6794-8. 
216. COLE, H.L., J.M. KALAPOTHAKIS, G. BENNETT, P.E. BARRAN and C.E. MACPHEE. 
Characterizing early aggregates formed by an amyloidogenic peptide by mass 
spectrometry. Angew Chem Int Ed Engl, 2010, 49(49), pp.9448-51. 
217. WELLS, J.M. and S.A. MCLUCKEY. Collision-induced dissociation (CID) of 
peptides and proteins. Methods Enzymol., 2005, 402, pp.148-85. 
218. MENG, F., A. ABEDINI, A. PLESNER, C.B. VERCHERE and D.P. RALEIGH. The 
flavanol (-)-epigallocatechin 3-gallate inhibits amyloid formation by islet 
amyloid polypeptide, disaggregates amyloid fibrils, and protects cultured cells 
against IAPP-induced toxicity. Biochemistry, 2010, 49(37), pp.8127-33. 
219. CHENG, B., H. GONG, X. LI, Y. SUN, X. ZHANG, H. CHEN, X. LIU, L. ZHENG and K. 
HUANG. Silibinin inhibits the toxic aggregation of human islet amyloid 
polypeptide. Biochem. Biophys. Res. Commun., 2012, 419(3), pp.495-9. 
220. HUDSON, S.A., H. ECROYD, F.C. DEHLE, I.F. MUSGRAVE and J.A. CARVER. (-)-
epigallocatechin-3-gallate (EGCG) maintains kappa-casein in its pre-fibrillar 
 REFERENCES 
 
181 
 
state without redirecting its aggregation pathway. J Mol Biol, 2009, 392(3), 
pp.689-700. 
221. PALHANO, F.L., J. LEE, N.P. GRIMSTER and J.W. KELLY. Toward the Molecular 
Mechanism(s) by which EGCG Treatment Remodels Mature Amyloid Fibrils. J 
Am Chem Soc, 2013. 
222. YAN, L.M., M. TATAREK-NOSSOL, A. VELKOVA, A. KAZANTZIS and A. 
KAPURNIOTU. Design of a mimic of nonamyloidogenic and bioactive human 
islet amyloid polypeptide (IAPP) as nanomolar affinity inhibitor of IAPP 
cytotoxic fibrillogenesis. Proceedings of the National Academy of Sciences of 
the United States of America, 2006, 103(7), pp.2046-51. 
223. MENG, F., D.P. RALEIGH and A. ABEDINI. Combination of kinetically selected 
inhibitors in trans leads to highly effective inhibition of amyloid formation. J Am 
Chem Soc, 2010, 132(41), pp.14340-2. 
224. KAPURNIOTU, A., A. SCHMAUDER and K. TENIDIS. Structure-based design and 
study of non-amyloidogenic, double N-methylated IAPP amyloid core 
sequences as inhibitors of IAPP amyloid formation and cytotoxicity. J Mol Biol, 
2002, 315(3), pp.339-50. 
225. GILEAD, S. and E. GAZIT. Inhibition of amyloid fibril formation by peptide 
analogues modified with alpha-aminoisobutyric acid. Angew Chem Int Ed Engl, 
2004, 43(31), pp.4041-4. 
226. HOLLANDER, P.A., P. LEVY, M.S. FINEMAN, D.G. MAGGS, L.Z. SHEN, S.A. 
STROBEL, C. WEYER and O.G. KOLTERMAN. Pramlintide as an adjunct to insulin 
therapy improves long-term glycemic and weight control in patients with type 2 
diabetes: a 1-year randomized controlled trial. Diabetes Care, 2003, 26(3), 
pp.784-90. 
227. MIDDLETON, C.T., P. MAREK, P. CAO, C.C. CHIU, S. SINGH, A.M. WOYS, J.J. DE 
PABLO, D.P. RALEIGH and M.T. ZANNI. Two-dimensional infrared spectroscopy 
reveals the complex behaviour of an amyloid fibril inhibitor. Nat Chem, 2012, 
4(5), pp.355-60. 
228. DYACHENKO, A., M. GOLDFLAM, M. VILASECA and E. GIRALT. Molecular 
recognition at protein surface in solution and gas phase: Five VEGF peptidic 
ligands show inverse affinity when studied by NMR and CID-MS. Biopolymers, 
2010, 94(6), pp.689-700. 
229. YOUNG, L.M., J.C. SAUNDERS, R.A. MAHOOD, C.H. REVILL, R.J. FOSTER, A.E. 
ASHCROFT and S.E. RADFORD. ESI-IMS–MS: A method for rapid analysis of 
protein aggregation and its inhibition by small molecules. Methods, 2015, in 
press, http://dx.doi.org/10.1016/j.ymeth.2015.05.017. 
230. GRIMSTER, N.P., S. CONNELLY, A. BARANCZAK, J. DONG, L.B. KRASNOVA, K.B. 
SHARPLESS, E.T. POWERS, I.A. WILSON and J.W. KELLY. Aromatic sulfonyl 
fluorides covalently kinetically stabilize transthyretin to prevent 
amyloidogenesis while affording a fluorescent conjugate. J. Am. Chem. Soc., 
2013, 135(15), pp.5656-68. 
231. KLABUNDE, T., H.M. PETRASSI, V.B. OZA, P. RAMAN, J.W. KELLY and J.C. 
SACCHETTINI. Rational design of potent human transthyretin amyloid disease 
inhibitors. Nat. Struc. Mol. Biol., 2000, 7(4), pp.312-321. 
 REFERENCES 
 
182 
 
232. CONNELLY, S., S. CHOI, S.M. JOHNSON, J.W. KELLY and I.A. WILSON. Structure-
based design of kinetic stabilizers that ameliorate the transthyretin 
amyloidoses. Curr. Opin. Struct. Biol., 2010, 20(1), pp.54-62. 
233. HAMRANG, Z., N.J.W. RATTRAY and A. PLUEN. Proteins behaving badly: 
emerging technologies in profiling biopharmaceutical aggregation. Trends 
Biotechnol., 2013, 31(8), pp.448-458. 
234. MENG, F., P. MAREK, K.J. POTTER, C.B. VERCHERE and D.P. RALEIGH. Rifampicin 
does not prevent amyloid fibril formation by human islet amyloid polypeptide 
but does inhibit fibril thioflavin-T interactions: Implications for mechanistic 
studies of β-cell death. Biochem., 2008, 47(22), pp.6016-6024. 
235. BUELL, A.K., C.M. DOBSON, T.P. KNOWLES and M.E. WELLAND. Interactions 
between amyloidophilic dyes and their relevance to studies of amyloid 
inhibitors. Biophys. J., 2010, 99(10), pp.3492-7. 
236. FENG, B.Y., B.H. TOYAMA, H. WILLE, D.W. COLBY, S.R. COLLINS, B.C.H. MAY, S.B. 
PRUSINER, J. WEISSMAN and B.K. SHOICHET. Small-molecule aggregates inhibit 
amyloid polymerization. Nat. Chem. Biol., 2008, 4(3), pp.197-199. 
237. MENG, F. and D.P. RALEIGH. Inhibition of glycosaminoglycan-mediated amyloid 
formation by islet amyloid polypeptide and proIAPP processing intermediates. 
J. Mol. Biol., 2010, 406(3), pp.491-502. 
238. DAUBENFELD, T., A.P. BOUIN and G. VAN DER REST. A deconvolution method 
for the separation of specific versus nonspecific interactions in noncovalent 
protein-ligand complexes analyzed by ESI-FT-ICR mass spectrometry. J. Am. Soc. 
Mass Spectrom., 2006, 17(9), pp.1239-48. 
239. MENG, F., A. ABEDINI, A. PLESNER, C.T. MIDDLETON, K.J. POTTER, M.T. ZANNI, 
C.B. VERCHERE and D.P. RALEIGH. The sulfated triphenyl methane derivative 
acid fuchsin is a potent inhibitor of amyloid formation by human islet amyloid 
polypeptide and protects against the toxic effects of amyloid formation. J. Mol. 
Biol., 2010, 400(3), pp.555-66. 
240. KAMIHIRA-ISHIJIMA, M., H. NAKAZAWA, A. KIRA, A. NAITO and T. NAKAYAMA. 
Inhibitory mechanism of pancreatic amyloid fibril formation: Formation of the 
complex between tea catechins and the fragment of residues 22–27. Biochem., 
2012, 51(51), pp.10167-10174. 
241. ENGEL, M.F.M., C.C. VANDENAKKER, M. SCHLEEGER, K.P. VELIKOV, G.H. 
KOENDERINK and M. BONN. The polyphenol EGCG inhibits amyloid formation 
less efficiently at phospholipid interfaces than in bulk solution. J. Am. Chem. 
Soc., 2012, 134(36), pp.14781-14788. 
242. HUDSON, S.A., H. ECROYD, F.C. DEHLE, I.F. MUSGRAVE and J.A. CARVER. (-)-
epigallocatechin-3-gallate (EGCG) maintains kappa-casein in its pre-fibrillar 
state without redirecting its aggregation pathway. J. Mol. Biol., 2009, 392(3), 
pp.689-700. 
243. KHURANA, R., V.N. UVERSKY, L. NIELSEN and A.L. FINK. Is Congo red an amyloid-
specific dye? J. Biol. Chem., 2001, 276(25), pp.22715-22721. 
244. ROTERMAN, I., M. KRÓL, M. NOWAK, L. KONIECZNY, J. RYBARSKA, B. STOPA, B. 
PIEKARSKA and G. ZEMANEK. Why Congo red binding is specific for amyloid 
proteins - model studies and a computer analysis approach. Med. Sci. Monit., 
2001, 7(4), pp.771-784. 
 REFERENCES 
 
183 
 
245. NECULA, M., R. KAYED, S. MILTON and C.G. GLABE. Small molecule inhibitors of 
aggregation indicate that amyloid β oligomerization and fibrillization pathways 
are independent and distinct. J. Biol. Chem., 2007, 282(14), pp.10311-10324. 
246. LORENZO, A. and B.A. YANKNER. Beta-amyloid neurotoxicity requires fibril 
formation and is inhibited by congo red. Proc. Natl. Acad. Sci., 1994, 91(25), 
pp.12243-12247. 
247. POLLACK, S.J., I.I.J. SADLER, S.R. HAWTIN, V.J. TAILOR and M.S. SHEARMAN. 
Sulfonated dyes attenuate the toxic effects of β-amyloid in a structure-specific 
fashion. Neurosci. Lett., 1995, 197(3), pp.211-214. 
248. MALTSEV, A.S., A. GRISHAEV and A. BAX. Monomeric α-synuclein binds Congo 
red micelles in a disordered manner. Biochem., 2012, 51(2), pp.631-42. 
249. THOMAS, T., T.G. NADACKAL and K. THOMAS. Aspirin and non-steroidal anti-
inflammatory drugs inhibit amyloid-β aggregation. Neuroreport, 2001, 12(15), 
pp.3263-3267. 
250. LIM, G.P., F. YANG, T. CHU, P. CHEN, W. BEECH, B. TETER, T. TRAN, O. UBEDA, 
K.H. ASHE, S.A. FRAUTSCHY and G.M. COLE. Ibuprofen suppresses plaque 
pathology and inflammation in a mouse model for Alzheimer's disease. J. 
Neurosci., 2000, 20(15), pp.5709-5714. 
251. MCKEE, A.C., I. CARRERAS, L. HOSSAIN, H. RYU, W.L. KLEIN, S. ODDO, F.M. 
LAFERLA, B.G. JENKINS, N.W. KOWALL and A. DEDEOGLU. Ibuprofen reduces 
Aβ, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain 
Res., 2008, 1207(0), pp.225-236. 
252. SUN, N., J. SUN, E.N. KITOVA and J.S. KLASSEN. Identifying nonspecific ligand 
binding in electrospray ionization mass spectrometry using the reporter 
molecule method. J. Am. Soc. Mass Spectrom., 2009, 20(7), pp.1242-50. 
253. SUN, J., E.N. KITOVA, W. WANG and J.S. KLASSEN. Method for distinguishing 
specific from nonspecific protein-ligand complexes in nanoelectrospray 
ionization mass spectrometry. Anal. Chem., 2006, 78(9), pp.3010-8. 
254. WANG, W., E.N. KITOVA and J.S. KLASSEN. Influence of solution and gas phase 
processes on protein-carbohydrate binding affinities determined by 
nanoelectrospray Fourier transform ion cyclotron resonance mass 
spectrometry. Anal. Chem., 2003, 75(19), pp.4945-55. 
255. KIM, Y.S., T.W. RANDOLPH, M.C. MANNING, F.J. STEVENS and J.F. CARPENTER. 
Congo red populates partially unfolded states of an amyloidogenic protein to 
enhance aggregation and amyloid fibril formation. J. Biol. Chem., 2003, 278(12), 
pp.10842-50. 
256. THOMAS, T., G.T. NADACKAL and K. THOMAS. Aspirin and diabetes: inhibition 
of amylin aggregation by nonsteroidal anti-inflammatory drugs. Exp. Clin. 
Endocr. Diab., 2003, 111(1), pp.8-11. 
257. SIPE, J.D., M.D. BENSON, J.N. BUXBAUM, S. IKEDA, G. MERLINI, M.J. SARAIVA, P. 
WESTERMARK and N.C.O.T.I.S.O. AMYLOIDOSIS. Amyloid fibril protein 
nomenclature: 2012 recommendations from the Nomenclature Committee of 
the International Society of Amyloidosis. Amyloid, 2012, 19(4), pp.167-70. 
258. PETKOVA, A.T., Y. ISHII, J.J. BALBACH, O.N. ANTZUTKIN, R.D. LEAPMAN, F. 
DELAGLIO and R. TYCKO. A structural model for Alzheimer's β-amyloid fibrils 
based on experimental constraints from solid state NMR. Proc. Natl. Acad. Sci., 
2002, 99(26), pp.16742-16747. 
 REFERENCES 
 
184 
 
259. AISEN, P., S. GAUNTHIER, B. VELLAS, R. BRIAND, D. SAUMIER and J. LAURIN. 
Alzhemed: A potential treatment for Alzheimer's disease. Curr. Alzheimer Res., 
2007, 4, pp.473-478. 
260. GERVAIS, F., J. PAQUETTE, C. MORISSETTE, P. KRZYWKOWSKI, M. YU, M. AZZI, 
D. LACOMBE, X. KONG, A. AMAN, J. LAURIN, W.A. SZAREK and P. TREMBLAY. 
Targeting soluble Aβ peptide with Tramiprosate for the treatment of brain 
amyloidosis. Neurobiol. Aging, 2007, 28(4), pp.537-547. 
261. VALLER, M.J. and D. GREEN. Diversity screening versus focussed screening in 
drug discovery. Drug Discov. Today, 2000, 5(7), pp.286-293. 
262. DE FELICE, F.G., M.N.N. VIERA, L.M. SARAIVA, J.D. FIGUEROA-VILLAR, J. GARCIA-
ABREU, R. LIU, L. CHANG, W.L. KLEIN and S.T. FERREIRA. Targeting the 
neurotoxic species in Alzheimer’s disease: inhibitors of Aβ oligomerization. 
FASEB J., 2004, 18(12), pp.1366-1372. 
263. LADIWALA, A.R.A., J.C. LIN, S.S. BALE, A.M. MARCELINO-CRUZ, M. 
BHATTACHARYA, J.S. DORDICK and P.M. TESSIER. Resveratrol selectively 
remodels soluble oligomers and fibrils of amyloid Aβ into off-pathway 
conformers. J. Biol. Chem., 2010, 285(31), pp.24228-24237. 
264. YANG, F., G.P. LIM, A.N. BEGUM, O.J. UBEDA, M.R. SIMMONS, S.S. 
AMBEGAOKAR, P.P. CHEN, R. KAYED, C.G. GLABE, S.A. FRAUTSCHY and G.M. 
COLE. Curcumin inhibits formation of amyloid β oligomers and fibrils, binds 
plaques, and reduces amyloid in vivo. J. Biol. Chem., 2005, 280(7), pp.5892-
5901. 
265. SCHERZER-ATTALI, R., R. PELLARIN, M. CONVERTINO, A. FRYDMAN-MAROM, N. 
EGOZ-MATIA, S. PELED, M. LEVY-SAKIN, D.E. SHALEV, A. CAFLISCH, E. GAZIT and 
D. SEGAL. Complete phenotypic recovery of an Alzheimer's disease model by a 
quinone-tryptophan hybrid aggregation inhibitor. PLoS ONE, 2010, 5(6), 
p.e11101. 
266. YATES, D. and D.M. MCLOUGHLIN. The molecular pathology of Alzheimer’s 
disease. Psychiatry, 2008, 7(1), pp.1-5. 
267. KIM, H.-J., S.-C. CHAE, D.-K. LEE, B. CHROMY, S.C. LEE, Y.-C. PARK, W.L. KLEIN, 
G.A. KRAFFT and S.-T. HONG. Selective neuronal degeneration induced by 
soluble oligomeric amyloid beta protein. FASEB J., 2003, 17(1), pp.118-120. 
268. LAST, N.B., E. RHOADES and A.D. MIRANKER. Islet amyloid polypeptide 
demonstrates a persistent capacity to disrupt membrane integrity. Proc. Natl. 
Acad. Sci. U. S. A., 2011, 108(23), pp.9460–9465. 
269. KROTH, H., A. ANSALONI, Y. VARISCO, A. JAN, N. SREENIVASACHARY, N. REZAEI-
GHALEH, V. GIRIENS, S. LOHMANN, M.P. LOPEZ-DEBER, O. ADOLFSSON, M. 
PIHLGREN, P. PAGANETTI, W. FROESTL, L. NAGEL-STEGER, D. WILLBOLD, T. 
SCHRADER, M. ZWECKSTETTER, A. PFEIFER, H.A. LASHUEL and A. MUHS. 
Discovery and structure activity relationship of small molecule inhibitors of 
toxic β-amyloid-42 fibril formation. J. Biol. Chem., 2012, 287(41), pp.34786-
34800. 
270. NIE, Q., X.-G. DU and M.-Y. GENG. Small molecule inhibitors of amyloid β 
peptide aggregation as a potential therapeutic strategy for Alzheimer's disease. 
Acta Pharma. Sin., 2011, 32(5), pp.545-551. 
271. WEI, L., P. JIANG, W. XU, H. LI, H. ZHANG, L. YAN, M.B. CHAN-PARK, X.-W. LIU, 
K. TANG, Y. MU and K. PERVUSHIN. The molecular basis of distinct aggregation 
 REFERENCES 
 
185 
 
pathways of islet amyloid polypeptide. J. Biol. Chem., 2011, 286(8), pp.6291-
6300. 
272. BULAWA, C.E., S. CONNELLY, M. DEVIT, L. WANG, C. WEIGEL, J.A. FLEMING, J. 
PACKMAN, E.T. POWERS, R.L. WISEMAN, T.R. FOSS, I.A. WILSON, J.W. KELLY 
and R. LABAUDINIÈRE. Tafamidis, a potent and selective transthyretin kinetic 
stabilizer that inhibits the amyloid cascade. Proc. Natl. Acad. Sci. U. S. A., 2012, 
109, pp.9629-9634. 
273. AITKEN, J.F., K.M. LOOMES, B. KONARKOWSKA and G.J.S. COOPER. Suppression 
by polycyclic compounds of the conversion of human amylin into insoluble 
amyloid. Biochem. J., 2003, 374(3), pp.779-784. 
274. WU, C., H. LEI, Z. WANG, W. ZHANG and Y. DUAN. Phenol red interacts with the 
protofibril-like oligomers of an amyloidogenic hexapeptide NFGAIL through 
both hydrophobic and aromatic contacts. Biophys. J., 2006, 91(10), pp.3664-
3672. 
275. PORAT, Y., Y. MAZOR, S. EFRAT and E. GAZIT. Inhibition of islet amyloid 
polypeptide fibril formation: a potential role for heteroaromatic interactions. . 
Biochem., 2004, 43(45), pp.14454-14462. 
276. JOHNSON, S.M., S. CONNELLY, C. FEARNS, E.T. POWERS and J.W. KELLY. The 
transthyretin amyloidoses: from delineating the molecular mechanism of 
aggregation linked to pathology to a regulatory-agency-approved drug. J. Mol. 
Biol., 2012, 421(2–3), pp.185-203. 
277. RAZAVI, H., S.K. PALANINATHAN, E.T. POWERS, R.L. WISEMAN, H.E. PURKEY, 
N.N. MOHAMEDMOHAIDEEN, S. DEECHONGKIT, K.P. CHIANG, M.T.A. DENDLE, 
J.C. SACCHETTINI and J.W. KELLY. Benzoxazoles as transthyretin amyloid fibril 
inhibitors: synthesis, evaluation, and mechanism of action. Angew. Chem. Int. 
Ed., 2003, 42(24), pp.2758-2761. 
278. HAMMARSTRÖM, P., R.L. WISEMAN, E.T. POWERS and J.W. KELLY. Prevention 
of transthyretin amyloid disease by changing protein misfolding energetics. 
Science, 2003, 299(5607), pp.713-716. 
279. MILLER, G. Stopping Alzheimer's before it starts. Science, 2012, 337(6096), 
pp.790-792. 
 
 
